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ABSTRACT 
 
Objectives.  Autoantibodies to the 65kDa isoform of glutamic acid decarboxylase 
(GAD65Abs) are accepted markers for type 1 diabetes and, together with 
autoantibodies to insulin (IAA) and a protein tyrosine phosphatase-like islet cell 
antigen (IA-2), predict the disease.  IAA are often the first autoantibodies detected 
in type 1 diabetics and can be present before the onset of clinical diabetes.  These 
autoantibodies and their epitopes are however not well characterized.  We 
explored the use of monoclonal antibodies and their recombinant Fab (rFab) as 
reagents for epitope analysis. 
Methods and Results.  Four rFab specific for insulin were cloned from murine 
monoclonal antibodies (mAbs) 1E2, HB-126, HB-123, HB-127, and one rFab 
specific for GAD65 was cloned from human mAb IgG antibody DP-D (derived from 
autoimmune disease patients), to characterise insulin and GAD65 autoantibodies 
present in the sera of patients with type 1 diabetes.  Only rFab 126 and DP-D 
showed insulin and GAD65 specific binding, respectively in radiobinding assays.  
In competition experiments with sera positive for autoantibodies to insulin the rFab 
126 significantly reduced the binding to 125I-insulin by sera of type 1 (n=35) and 
type 1.5 diabetes (or LADA) (n=14) patients (p<0.0001).  There was no difference 
in the competition pattern in IAA positive type 1 diabetes patients (n=35) and IAA 
positive type 1.5 diabetes patients (n=14).  The insulin epitope that the rFab binds 
to was mapped using competitive radiobinding assays with two monoclonal 
antibodies (mAb 1 and mAb 125) whose epitopes are on the B chain and A chain 
loop of insulin, respectively.  We found the epitope of this recombinant antibody to 
be located on the A chain loop of the insulin molecule.  The 3-dimensional 
structure of rFab 123, 126 and DP-D were determined using an automated 
homology modelling programme.  Using the computer programme ‘PatchDock’ we 
attempted to further map the epitope that rFab 126 binds to on insulin.  Of the 
three models generated, only one supported our findings that rFab 126 binds to 
the A chain loop of insulin. 
The binding of GAD65Ab in 61 type 1 diabetes patients to GAD65 was analyzed 
by competitive radioimmunoassays with rFab DP-D to ascertain disease-specific 
GAD65Ab binding specificities.  The median binding was reduced significantly by 
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rFab DP-D (80%) (p<0.0001).  The competition pattern in type 1 diabetes patients 
was different from that in GAD65Ab-positive type 1.5 diabetes patients (n=44), first 
degree relatives (n=38), and healthy individuals (n=14) (Padoa et al., 2003). 
Conclusions.  We have shown that rFab specific for insulin and GAD65 can be 
generated using PCR technology and that such agents can be used to determine 
the insulin/GAD65 epitopes recognized by autoantibodies from type 1 and 1.5 
diabetics.  These novel findings with GAD65- and insulin-specific rFab support the 
view that type 1 diabetes is associated with disease- and epitope-specific GAD65- 
and insulin-autoantibodies and supports the notion that the middle epitope of 
GAD65 is disease-specific.  These GAD65-specific rFab should prove useful in 
predicting type 1 diabetes.  Furthermore, rFabs may be a novel method for 
blocking autoimmune responses against β cell autoantigens in type 1 diabetics. 
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CHAPTER 1 
 
1.  INTRODUCTION 
 
Towards the end of the 19th century von Behring and Kitasato (1890) showed that 
immunity to diphtheria and tetanus was associated with antibodies and could be 
transferred by immune serum.  This discovery was the catalyst that, over the next 
century, highlighted the importance of the antibody molecule in immune defence 
and lead to many of the questions surrounding the structure, function, and 
genetics of the antibody molecule being answered. 
 
1.1.  THE STRUCTURE AND FUNCTION OF ANTIBODIES 
 
Antibodies are large glycoprotein molecules produced by B lymphocytes of the 
immune system in higher organisms.  Their primary function is to recognise and 
attach matter harmful to the organism, thereby marking it for destruction by other 
components of the immune system. 
 
Antibodies are symmetrical molecules made up of four polypeptide chains: two 
identical glycosylated heavy chains of molecular weight (Mr) 50 to 75 kDa, and a 
pair of identical nonglycosylated light chains, approximately 25 kDa in size 
(Edelman and Benacerraf, 1962).  The heavy chains determine all the effector 
functions of antibodies (e.g. complement fixation and transport across 
membranes), while the light chains play an important part in determining the 
specificity of antibodies.  Disulphide bonds join the heavy chains together, and 
each light chain is disulphide bonded to one heavy chain; resulting in a ‘Y’ shaped 
antibody molecule (Figure 1.1).  Each light and heavy chain is made up of a series 
of homology units of approximately 110 amino acids (Figure 1.1).  Each homology 
unit is folded into a compact, globular structure (a domain) containing large 
amounts of β-pleated sheets (Poljak et al., 1972).  Individual domains are relatively 
resistant to proteolytic attack.  In contrast, the short linking sequences joining 
individual domains are often susceptible to proteolysis (Koch et al., 1973). 
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Figure 1.1:  Structure of an IgG molecule (Goding, 1983). 
(      = disulphide bridges). 
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Each heavy chain is encoded for by variable (VH), diversity (D), joining (JH), and 
constant (CH) segment genes; while each light chain is encoded for by VL, JL, and 
CL segment genes (Figure 1.2) (reviewed by Milstein, 1982; reviewed by Azzazy 
and Highsmith, 2002).  Each heavy chain is segmented into four regions: a 
variable domain plus three constant (CH1, CH2, CH3) domains and the light chain 
consists of a variable domain and a single constant domain (CL) (Kehry et al., 
1979).  The DNA and amino acid sequences of the constant region are relatively 
conserved within a given species.  Within each variable region lie three hyper-
variable segments or complementarity-determining regions (CDRs) which exhibit 
great sequence diversity.  The VH and VL domains are folded in such a way that 
brings the hypervariable regions together to create an antigen-combining site 
(paratope), the specificity of which is determined by both heavy and light chains 
(Wu and Kabat, 1970; Kabat and Wu, 1971).  Each antibody molecule has two 
identical antigen combining sites, except for polymeric IgM, which has ten. 
 
An immunoglobulin molecule can be broken down into two regions, the Fc and the 
Fab (Figure 1.1) (Porter, 1959).  The Fc portion, so called because it is the 
fragment of the antibody molecule that most readily crystallizes, is involved in 
effecting the physiological roles the antibody must play.  These include antibody 
dependent cell-mediated cytotoxicity and initiation of the complement system.  The 
Fc portion of the antibody also provides for the long half-life of antibodies in the 
blood.  Two identical Fab fragments are present at the top ends of the ‘Y’ in every 
immunoglobulin structure.  The Fab region is named as such because it is the 
fragment that contains the antibody binding site.  The region between the Fab and 
the Fc fragment is called the hinge.  This segment allows lateral and rotational 
movement of the two antigen binding domains. 
 
1.1.1.  Proteolytic fragmentation of immunoglobulins 
 
Proteolytic attack of immunoglobulin G (IgG) by papain at neutral pH cleaves at 
the hinge (Smyth and Utsumi, 1967), generating two identical Fab fragments, each 
containing one intact light chain disulphide bonded to the Fd fragment (VH and CH1 
domains) of the heavy chain (Figure 1.1).  Pepsin also cleaves IgG at the hinge 
(pH ~4), but the pepsin cleavage site lies on the carboxy side of the inter-heavy 
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chain disulphide bond(s) (Figure 1.1).  The divalent antigen-binding fragment 
produced is known as F(ab’)2.  The heavy chain fragment in F(ab’)2 is slightly 
longer than the papain Fd fragment, and is known as Fd’.  It is possible to 
generate an even smaller antigen-binding fragment (Fv) by proteolysis (Figure 
1.1).  The Fv fragment contains only the noncovalently associated VH and VL 
domains (Inbar et al., 1972; Kakimoto and Onoue, 1974). 
 
1.1.2.  Properties of the different immunoglobulin classes 
 
There are five main classes of immunoglobulins: IgM, IgD, IgG, IgE, and IgA.  
They differ not only in their physiological roles but also in their structures (Table 
1.1).  The class of an immunoglobulin molecule is distinguished by its heavy chain.  
Thus, IgM, IgD, IgG, IgE, and IgA possess µ, δ, γ, ε, and α heavy chains 
respectively (Shimizu et al., 1982).  The differences in the heavy chain 
polypeptides allow these proteins to function in different types of immune 
responses and at particular stages of the maturation of the immune response.  
The protein sequences responsible for these differences are found primarily in the 
Fc fragment.  Different classes of antibodies may also vary in the number of Y-like 
units that join to form the complete protein.  IgM antibodies, for example, have five 
Y-shaped units. 
 
While there are five different types of heavy chains, there are only two types of 
light chains, κ or λ.  One light chain always associates with one heavy chain, so 
the ratio of heavy to light chains is always 1:1.  Any one antibody molecule will 
have only one type of light chain and one type of heavy chain.  There are no 
restrictions on which types of heavy or light chains can form antibodies, so 
antibodies of all classes can contain either κ or λ light chains. 
 
In the mouse and rat, over 95% of light chains are κ.  In the mouse, there is only 
one κ light chain class, but paradoxically there are four λ chain subclasses (λ1 – 
λ4).  In humans the κ:λ ratio is about 60:40, but the exact number of subclasses is 
unknown.  Both κ and λ light chains appear to be able to take part in all biological 
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(DH) 
functions of antibodies although in some special circumstances one light chain 
may predominate (reviewed by Blomberg and Tonegawa, 1982). 
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Figure 1.2:  A schematic representation of the genes coding for antibodies  
(Milstein, 1982). 
In the mouse, the κ, λ, and heavy chain genes are on chromosomes 6, 
16, and 12, respectively (Swan et al., 1979; D’Eustachio et al., 1980; 
Francke et al., 1982).  Human κ, λ, and heavy chain genes are located 
on chromosome 2, 22, and 14, respectively (Shander et al., 1980; 
Erikson et al., 1981; Malcolm et al., 1982).  The V regions are coded 
by V, D, and J fragments of DNA which occur many thousands of 
bases apart.  The number and detailed arrangements of genes in each 
case vary in different species.  For the expression of an antibody, 
individual V, J, and C fragments are associated combinatorially within 
a horizontal array (see Figure 1.3). 
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Table 1.1:  Properties of immunoglobulin classes. 
Characteristics IgG IgM IgA IgE IgD 
Mr (kDa) 160 900 170 - 500 190 180 
Heavy chain γ µ α ε δ 
Light chain κ or λ κ or λ κ or λ κ or λ κ or λ 
Molecular 
formula 
γ2κ2 or γ2λ2 (µ2κ2)5 or (µ2λ2)5 (α2κ2)n or (α2λ2)n ε2κ2 or ε2λ2 δ2κ2 or δ2λ2 
Valency 2 10 2, 4, or 6 2 2 
Subclasses 4 1 1 1 1 
Concentration 
in serum 
8-16 mg/ml 0.5-2 mg/ml 1-4 mg/ml 10-400 ng/ml 0-0.4 mg/ml 
Serum half-life G1, G2a, G3 4 days 
G2b 2 days 
1 day 1 day Short (probably less 
than 1 day) 
Short (probably less 
than 1 day) 
Special 
properties 
Major class in serum.  
IgG-bearing 
lymphocytes are rare 
First antibody in most 
responses 
Major class in 
secretions (e.g. tears, 
saliva, bile, and gut) 
Minor class in serum.  
Binds to mast cells.  
Responsible for 
allergic reactions, 
histamine and 
serotonin release 
Major class on 
lymphocyte surface.  
Minor class in serum. 
Function Secondary response Primary response Protects mucous 
membranes 
Protects against 
parasites (?) 
? 
Table reproduced from Goding, 1983; Harlow and Lane, 1989.
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1.1.3.  Antibody specificity 
 
The immune system encounters an immense variety of foreign substances on a 
daily basis.  To perform their crucial role as the first line of defence against any 
invading agent, antibodies must be extremely diverse to combat a large number of 
unexpected and unknown antigens.  Through a complex process of gene splicing, 
B cells have been estimated to produce between 1 x 108 to 1 x 1010 IgG antibodies 
that differ in the composition of their binding sites (French et al., 1989).  These 
binding sites also take advantage of the different chemical properties of the 20 
amino acids.  The immune system is thus able to generate a number of antibody 
binding sites that can accommodate the shape, charge, and hydrophobicity of any 
given antigen. 
 
1.1.4.  Genetic diversity of immunoglobulin molecules 
 
1.1.4.1.  Mechanisms responsible for diversity of antigen-binding sites 
Several mechanisms are responsible for the diversity of paratopes: 
i. Recombinatorial diversity: created by random selection of one heavy chain V, 
D, and J gene, or one light chain V J gene segment out of a pool, to constitute 
the VH and VL domains, respectively. 
ii. Junctional diversity: formed by the imprecise joining mechanisms and by 
deletion or addition of random nucleotides at the borders of the recombining 
VH-D-JH minigenes. 
iii. Combinatorial diversity: generated by the assembly of the VH and VL domains. 
Other mechanisms include alteration of the structural shape of the paratope and 
specific maturation of the paratope caused by a somatic hypermutation that 
improves the shape complementarity of the antibody with the antigen.  The 
cumulative effects of these mechanisms determine the antigenic affinity and 
specificity of an antibody (Davis et al., 1980; reviewed by Azzazy and Highsmith, 
2002). 
 
1.1.4.2.  Formation of a functional κ gene 
In germline and non-B cell DNA, the coding sequences for the V and C regions of 
the κ light chain are separated by several hundred kilobase pairs.  The gene is 
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silent in these cells.  There are approximately 200 different κ V regions and only 
one C region (Cory et al., 1981; Fitzsimmons et al., 1998).  During the maturation 
of B cells, recombination brings one of the V regions and the C region together to 
produce a functional gene. 
 
Studies showed that simple joining of the V and C regions did not account for all 
the variation that was detected.  This led to the discovery of a third segment 
between the V and C regions called the J (joining) region.  Recombination brings 
the V region just upstream of one of five J regions, producing a V-J-C region 
alignment (Weigert et al., 1978).  This alignment yields a functional κ gene.  The 
recombination events do not always occur at exactly the same nucleotides, and 
this allows for some variation in the amino acids found at the V-J junction. 
 
Four of the five different J regions (Sakano et al., 1979) for the κ chains, found in 
genomic DNA sequences, can be used to synthesise functional polypeptides.  J3 
has a mutated donor splice site and cannot produce a functional mRNA.  
Therefore, in the maturation of a functional κ light chain gene, recombination must 
occur between one of the approximately 200 V regions and one of the four 
functional J regions, yielding approximately 800 different κ chain polypeptides for 
homozygous mice.  In humans, the κ genes contain 40 V regions and 5 J 
segments producing 200 possible κ light chains. 
 
1.1.4.3.  Formation of a functional λ gene 
Similar types of recombination events are required to produce a functional λ light 
chain polypeptide.  In the germ-line DNA, there are two V regions and four C 
regions in the λ coding region (Brack et al., 1978).  Each C region is paired with a 
single J region, and recombination occurs between the V and J regions.  However, 
the two V regions are not found upstream of the C regions as in the κ gene.  Each 
V region is paired with two J-C regions.  Analysis of the DNA sequences around 
the J4 region has shown that it carries several mutations that block the successful 
production of mRNA.  Also, no recombination events have ever been reported that 
join a downstream V region to an upstream C region.  This arrangement only 
allows the production of five possible λ light chains.  In contrast, humans can 
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produce 120 λ light chains (30 V segments and 4 J segments).  Humans can thus 
produce a total of 320 light chain specificities. 
 
1.1.4.4.  Formation of a functional heavy chain gene 
In addition to the V, J, and C regions, heavy chains contain a fourth coding region 
referred to as the D region.  The D region is located between the V regions and 
the J-C region.  The production of a functional heavy chain requires two 
recombination events, one joining a D region to a J-C region, and another joining a 
V region to the D region (Figure 1.3) (Davis et al., 1980).  There are approximately 
50 to 100 V, 12 D, and 4 J chain regions that form the heavy chain gene cluster on 
chromosome 12 in the mouse.  The D regions produce functional proteins in all 
three reading frames, therefore, because the recombination events are not 
precise, the D regions can code for 36 different sequences.  Having multiple 
regions helps to generate a large number of heavy chains, with at least 7 200 
different possibilities for homozygous mice.  Human heavy chain genes contain 65 
V, 27 D, and 6 J regions producing 11 000 possible heavy chain V domains. 
 
1.1.4.5.  Creation of diverse antigen binding sites 
Recombination between the V, D, and J regions produces a large number of 
different heavy and light chain polypeptide sequences.  The V regions contain the 
coding sequences for CDR 1 and CDR 2 of the heavy and light chains.  The third 
CDR is the product of the V-D-J recombination (heavy chain) or V-J joining (light 
chain).  Because recombination is not always precise, the greatest sequence 
diversity is present in the third CDR. 
 
For the mouse, there are at least 800 potential κ chains, five λ chains, and 7 200 
heavy chains.  If all light chains have a chance to pair with all heavy chains in the 
production of the antigen binding site, there are potentially 5.8 x 106 binding 
domains ([800 + 5] x 7 200).  Similarly, the total diversity possible in a human who 
is homozygous for all of their antibody genes is 3.5 x 106.  Diversity at the 
recombination junctions increases the number of possible combinations.  
Recombination and random assortment of the light and heavy chains create the 
lower limit for the number of different antigen binding sites. 
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Germline DNA V1    V2     Vn    D1     Dn    J1    Jn    Cµ    Cµs    Cµm    Cδ  
 
 
 
B cell       VDJ    Cµ    Cµs    Cµm    Cδ 
 
 
 
 
B cell mRNA    VDJCµCµs     VDJCµCµm      VDJCδ 
 
 
 
 
Cell expression        IgMs   IgMm   IgD 
 
 
 
 
 
Figure 1.3:  Heavy chain gene rearrangement and alternative forms of splicing of  
precursor RNA (Milstein, 1982). 
Large deletions of germ line DNA are involved in the commitment of 
differentiated lymphocytes to the production of a single antibody.  
Alternative forms of splicing allow a single V gene to be expressed in 
conjunction with multiple C genes.  IgMs and IgMm are the secreted 
and membrane bound forms. 
 
 
DNA 
HnRNA 
Processing 
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Greater than half of the heavy or light chain V regions carry point mutations in the 
antigen binding regions.  Although the mechanisms that generate these mutations 
are not known, they appear to provide a system that fine-tunes the binding site, 
thus creating a better fit for the antigen-antibody interaction.  This process is 
known as affinity maturation. 
 
1.1.5.  Allelic exclusion 
 
The recombination events that produce different heavy and light chains do not 
always lead to a functional gene.  During B cell differentiation, light chain 
rearrangements begin with the κ region, and, if the first rearrangement of one of 
the diploid genes results in a non-functional allele, the other copy undergoes 
recombination.  If both recombination events lead to non-functional genes, then 
recombination begins at the λ locus.  Similar mechanisms lead to the generation of 
a functional heavy chain gene.  Once recombination yields a functional antibody, 
an unknown mechanism prevents further recombination, fixing the antigen binding 
site for the life of the cell.  This mechanism is called allelic exclusion and explains 
why B lymphocytes secrete antibodies with only one type of antigen binding site 
and why antibodies have only one type of light chain (Perry et al., 1980). 
 
1.1.6.  Generation of the different classes and subclasses of antibodies 
 
A second set of recombination events that involve the heavy chain C region were 
later discovered.  These rearrangements do not affect the V region and do not 
alter the antigen binding domain.  They do not contribute to the diversity of binding 
sites, but instead allow the replacement of one heavy chain C region with another.  
The rearrangement occurs downstream of the J region.  Aligned here in germline 
DNA is a tandem array of the heavy chain C region genes: µ-chain (IgM), δ-chain 
(IgD), γ3-chain (IgG3), γ1-chain (IgG1), γ2b-chain (IgG2b), γ2a-chain (IgG2a), ε-chain 
(IgE), and α-chain (IgA).  These rearrangements move the same antigen binding 
site onto different antibody classes and subclasses.  This process is known as 
class switching and is one of the characteristic events of the maturation of the 
antibody response.  The different classes and subclasses determine many of the 
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functional properties of antibodies.  Class switching, therefore, creates an 
important mechanism for controlling where and how the antigen binding site will be 
used (Burrows et al., 1980). 
 
1.2.  THE DEVELOPMENT OF HYBRIDOMA TECHNOLOGY 
 
Genetic engineering has come to the fore in the last twenty years.  It is now 
possible to study, control, and manipulate genes in ways that were inconceivable a 
few years ago.  The revolution which occurred in the field of immunology was 
triggered in 1975 when Köhler and Milstein developed a technique for the 
production of monoclonal antibodies (mAbs) by fusing the nuclei of normal 
antibody-forming cells with those of malignant cells.  It is important to acknowledge 
the numerous discoveries (Table 1.2) which culminated in Köhler and Milstein’s 
achievement.  Those deserving special mention were the proof of the clonal 
selection theory (Nossal and Lederberg, 1958), the development of cell fusion 
techniques (Okada, 1962; Littlefield, 1964), the artificial induction of 
plasmacytomas (Potter and Boyce, 1962), their adaptation to tissue culture 
(Horibata and Harris, 1970), and the fusion of two different plasma cell tumour 
lines with both antibody products being retained (Cotton and Milstein, 1973). 
 
Table 1.2:  Landmarks in the history of antibody research. 
1847 Urinary protein in myeloma Bence Jones 
1890 Discovery of antibodies von Behring and Kitazato 
1900 ‘Side-chain’ theory formulated 
Discovery of ABO blood groups 
Ehrlich 
Landsteiner 
1955-6 Allotypes Grubb, Oudin 
1956 Classification of Bence-Jones proteins into 
two groups (now called κ and λ in honour of 
their discoverers) 
Korngold and Lipari 
1957 Clonal selection theory Burnet 
1958 One cell; one antibody 
Cell fusion by Sendai virus 
Nossal and Lederberg 
Okada 
1959 Elucidation of disulphide-bonded chain Edelman 
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structure of antibodies 
1960 Discovery of spontaneous cell fusion Barski 
1962 Demonstration that Bence-Jones proteins are 
antibody light chains 
Induction of plasmacytomas by mineral oil 
Edelman and Gally 
 
Potter and Boyce 
1962-3 Controlled proteolytic cleavage of IgG, 
identification of Fab and Fc; topographic 
relationship between light and heavy chains 
Porter, Fleischman, Pain 
and Press 
1964 Use of mutant cells and selective media to 
isolate hybrids 
Littlefield 
1965 Amino acid sequencing reveals that N-
terminal half of light chains is variable; C-
terminal constant 
Postulate of two genes; one polypeptide 
Hilschmann and Craig 
 
 
Dreyer and Bennett 
1969 First complete amino acid sequence of an 
immunoglobulin; concept of domains 
Edelman and colleagues 
1970 Hypervariable regions 
Growth of plasmacytomas in continuous 
culture 
Wu and Kabat 
Horibata and Harris 
1973 Fusion of mouse and rat myeloma cells with 
preservation of secretion of both 
immunoglobulins sets the stage for 
production of monoclonal antibodies 
Cotton and Milstein 
1975 Construction of hybridomas secreting 
antibody of predefined specificity 
Köhler and Milstein 
1976 Demonstration of DNA rearrangements in 
antibody-forming cells 
Use of polyethylene glycol for cell fusion 
Tonegawa and colleagues 
 
Pontecorvo 
1977 Cloning and sequencing λ genes; J segments Tonegawa and colleagues 
1977-80 Multiple germ-line genes for V regions 
Discovery of D segments 
Many authors 
Group of L Hood 
1980 Mechanisms of insertion of membrane IgG Groups led by L Hood and 
R Wall 
Table reproduced from Goding, 1983. 
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In an attempt to produce a general way of constructing continuous cell lines 
secreting antibody of known specificity, Köhler and Milstein (1975) expanded on 
previous experiments and fused a hypoxanthine, aminopterin, and thymidine 
(HAT)-sensitive variant of MOPC-21 myeloma cells with spleen cells from mice 
immunised with sheep red cells.  The fusion was mediated by Sendai virus, and 
hybrids were selected by growth in HAT medium.  Normal spleen cells can only 
survive a few days in culture and the myeloma cells are defective in the enzyme 
hypoxanthine guanine phosphoribosyl transferase (HGPRT), an enzyme which 
enables cells to synthesise purines using an extra-cellular source of hypoxanthine 
as precursor.  This enzyme deficiency is not normally a problem as there are a 
number of alternate pathways from which the cells can synthesise purines.  
However, in the presence of aminopterin, cells are unable to use these alternate 
pathways and are dependent on the HGPRT enzyme for survival.  It was hoped 
that the two cell lines would ‘complement’ one another: the spleen cells providing 
the missing HGPRT enzyme and the myeloma cells providing the ‘immortality’ 
needed for continuous growth in culture (Figure 1.4). 
 
The experiment was a success: a number of cloned hybrid lines secreting anti-
sheep erythrocyte antibodies were produced.  These mAbs can be obtained in 
unlimited quantities either in tissue culture or by injecting the hybridoma cells into 
the peritoneal cavity of mice.  The injected neoplastic cells proliferate and secrete 
large amounts of antibody resulting in antibody-rich ascites.  With the successful 
production of hybridomas, it now became possible to produce antibodies that are 
not only specific to a single antigenic site but are also a homogeneous population 
of molecules and, therefore, represent a chemically pure reagent. 
 
1.2.1.  Stages of hybridoma/monoclonal antibody production 
 
1.2.1.1.  Immunisation of mice 
Animals are injected with an antigen preparation, and once a good humoral 
response has appeared, an appropriate screening procedure is developed.  The 
sera from test bleeds are used to develop and validate the screening procedure.  
Animals are killed four to five days after boosting, the spleen removed, and 
antibody-secreting cells fused with myeloma cells. 
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                    Immune mouse 
 
 
 
     spleen 
 
           
      normal antibody-forming cells 
 
 
       plasmacytoma cells 
 
      unfused              unfused 
        plasmacytoma cells  heterokaryons  spleen cells 
 
 
 
       Die in HAT medium     Hybrids   Die in culture 
 
 
 
 
 
 
            Clone 1   Clone 2 Clone 3   Clone 4 
 
Figure 1.4:  Production of hybridomas (Goding, 1983). 
Spleen cells from immune mice are fused with HGPRT- myeloma 
(plasmacytoma) cells using polyethylene glycol.  The binucleate fusion 
products are known as heterokaryons.  At the next division, the nuclei 
fuse, generating hybrid cells, which grow in HAT medium.  Unfused 
myeloma cells die in HAT medium and unfused spleen cells can only 
survive a few days in culture.  Hybrids are tested for production of 
antibody of the desired specificity, and cloned by limiting dilution. 
Polyethylene glycol 
HAT medium 
Clone by limiting dilution 
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1.2.1.2.  Fusion partners 
Myelomas can be induced in a few strains of mice by injecting mineral oil into the 
peritoneum.  Many of the first examples of these myelomas were isolated from 
BALB/c mice by Potter (1972), and these cells are referred to by the abbreviation 
MOPC (mineral oil plasmacytoma).  Derivatives of BALB/c myelomas have 
become the most commonly used partners for fusions (Figure 1.5).  Myelomas 
have all the cellular machinery necessary for the secretion of antibodies, and 
many secrete these proteins.  To avoid the production of hybridomas that secrete 
more than one type of antibody, myelomas that are used for fusions have been 
selected for the lack of functional antibody production. 
 
Hybridomas can be prepared by fusing myelomas and antibody-secreting cells 
isolated from different species, but the number of viable hybridomas increases 
dramatically when closely related species are used. 
 
1.2.1.3.  Fusion agents 
In theory, the fusion between the myeloma cell and the antibody-secreting cell can 
be effected by any fusogen.  In practice, hybridoma fusions became routine after 
the introduction of polyethylene glycol (PEG) (Pontecorvo, 1976).  PEG fuses the 
plasma membranes of adjacent myeloma and/or antibody-secreting cells, forming 
a single cell with two or more nuclei (called heterokaryons).  During mitosis and 
further rounds of division, the individual chromosomes are segregated into 
daughter cells.  Because of the abnormal number of chromosomes, segregation 
does not always deliver identical sets of chromosomes to daughter cells, and 
chromosomes may be lost.  There is usually a preferential loss of chromosomes 
from one or other cell (Tucker et al., 1981).  If one of the chromosomes that carry 
a functional, rearranged immunoglobulin heavy or light chain gene is lost, 
production of the antibody will stop.  This will result in a decrease in antibody titre 
and in unstable lines (Nowak, 1985).  If the chromosome that is lost contains a 
gene used in drug selection, then the growth of the hybridoma will be unstable, 
and cells will continue to die during selection. 
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      BALB/c MOUSE 
 
 
       Mineral oil injection1 
 
 
      MOPC 21  (carried as tumour) 
 
 
       Established as cell line2 
 
 
          P3K 
      Select for     Select for nonsecretion 
      HPRT(-)3     and HPRT(-)8 
 
        P3-X63Ag8      NSI/1-Ag4-1 
Select for      Fuse to   Select for       Select for 
nonexpression4    spleen cells5  APRT(-)9  non- 
   expression10 
         Subclone6 
   X63-Ag8.653    Sp2/O-Ag14       FOX-NY     NSO/1 
 
          Fuse with self7 
 
     FO 
 
Figure 1.5:  Myeloma family tree (Harlow and Lane, 1989). 
1Potter, 1972; 2Horibata and Harris, 1970; 3Köhler and Milstein, 1975; 
4Kearney et al., 1979; 5Köhler and Milstein, 1975; 6Shulman et al., 
1978; 7de St. Groth and Scheidegger, 1980; 8Köhler et al., 1976; 
9Taggart and Samloff, 1983; 10Galfre and Milstein, 1981. 
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1.2.1.4.  Selection procedures for hybrid cells 
Even in the most efficient hybridoma fusions, only about 1% of the starting cells 
are fused and of these about 1 in 105 form viable hybrids.  This leaves a large 
number of unfused cells still in the culture necessitating a selection procedure to 
recover only fused cells.  Since antibody-forming cells die quickly, it is only 
necessary to separate the myeloma cells.  This is usually achieved by drug 
selection (Littlefield, 1964).  Littlefield’s procedure depends on the fact that when 
the main biosynthetic pathway for guanosine is blocked, by the folic acid 
antagonist aminopterin, there is an alternative ‘salvage’ pathway in which the 
nucleotide metabolites hypoxanthine or guanine are converted to guanosine 
monophosphate via the enzyme hypoxanthine guanine phosphoribosyl transferase 
(HGPRT or HPRT; Figure 1.6).  Mutant myeloma cell lines deficient in HGPRT 
were used as fusion partners (Littlefield, 1964).  In the absence of this enzyme the 
cells die in HAT medium because both the main and the salvage pathways are 
blocked.  Thus, only hybrids which have the wild-type enzyme from the normal 
antibody-forming cells can actively multiply in HAT medium (Figure 1.6). 
 
1.2.1.5.  Cloning 
To ensure that the antibodies are indeed monoclonal, it is essential to clone the 
hybrid cell lines.  Köhler and Milstein (1975) used soft agar cultures to grow 
isolated colonies, and detected clones secreting anti-erythrocyte antibodies by 
overlaying with sheep red cells and complement.  A zone of haemolysis 
surrounded colonies secreting anti-erythrocyte antibodies.  Nowadays researchers 
prefer to clone by limiting dilution.  Hybridoma lines should be cloned at least twice 
to make absolutely certain that each is a true clone, and also because of the 
relatively high probability of growth of nonproducer variants due to chromosome 
loss (Goding, 1983). 
 
1.3.  ANTIBODY ENGINEERING 
 
The advent of hybridoma technology made possible the generation of a large 
number of antibodies that bind with high specificity and high affinity to a target 
molecule.  The availability of mAbs has created an explosion of knowledge about 
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thymidylate 
synthetase 
the antibody molecule, and with it widespread use in biomedical research, 
diagnostics, and more recently in therapeutic applications. 
 
 
           5-amino imidazole- 
        4-carboxy ribonucleotide 
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           4-carboxamide 
ribonucleotide 
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hypoxanthine     inosine monophosphate 
           hypoxanthine guanine 
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      RNA   GTP  dGTP 
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UDP  dUDP  dUMP     dCTP     dATP 
 
 
Figure 1.6:  Metabolic pathways relevant to hybrid selection in medium containing  
HAT (Goding, 1983). 
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However, despite their usefulness in scientific research and as diagnostic tools, 
mAbs are subject to the constraints of the immune system.  A few of the 
shortcomings of hybridoma technology include the size of mAbs, their affinity for 
target antigen; their effectiveness at recruiting the other cells of the human 
immune system; separate immunisations for each antigen, and laborious and 
inefficient cell fusion processes.  The major hurdle, however, has proven to be 
similar to that of serum therapy.  When the rodent mAbs are administered in 
multiple doses, the patient invariably raises an immune response to the mAbs.  
This Human Anti-Mouse Antibody (HAMA) response can occur within two weeks 
of the initiation of treatment and prevents long-term therapy.  This greatly reduces 
the therapeutic potential of these mAbs (Vaughan et al., 1996). 
 
Prior to the advent of molecular biology techniques, antibody fragments (Fab or 
F(ab1)2) could only be obtained by proteolytic digestion of a whole immunoglobulin.  
Since the first description of the polymerase chain reaction (PCR) over 20 years 
ago, numerous discoveries have been made and new techniques developed which 
have transformed immunology and antibody production methods.  PCR provided a 
simple method to amplify and rapidly clone the relevant heavy and light chain 
genes of an immunoglobulin into bacterial expression systems to obtain different 
types of fragments in fully functional form.  Although the effects of designed 
mutations could be analysed in this system, not all proteins folded correctly in the 
cytoplasm.  This led to the development of phage display which allowed the 
correct association of the engineered antibody fragments.  This method bypasses 
hybridoma technology as well as immunisation.  Phage display allows the creation 
of large repertoires of antibody fragments from antibody variable genes, thus 
making it possible to obtain ‘human’ antibody fragments without the laborious and 
often ineffective humanisation procedures applied to murine mAbs. 
 
1.3.1.  Antibody fragments 
 
In order to address the limitations of large IgG molecules, smaller engineered 
mAb-based molecules were developed; namely, the antigen binding fragment 
(Fab) and the variable domain (Fv) fragment (Figure 1.7).  These fragments can 
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be produced by proteolytic cleavage of antibodies or via cloning and expression of 
the amplified immunoglobulin genes in bacteria. 
 
1.3.1.1.  Fv and Fab antibody fragments 
The 25 kDa Fv consists of a heterodimer of the VH and VL domains (Huston et al., 
1988) and is the smallest antigen binding fragment of an antibody that contains a 
complete binding site.  Fab fragments consist of the intact light chain (VLCL) and 
the Fd fragment of the heavy chain (VHCH1).  A disulphide bond covalently links 
the chains together.  These antibody fragments have advantages over whole 
antibodies for many therapeutic uses because of their smaller size and better 
tissue penetration and clearance.  Their smaller size also makes them more 
suitable for structural studies like nuclear magnetic resonance spectroscopy 
(reviewed by Riechmann and Muyldermans, 1999). 
 
Specific primers are used for the amplification of VH and VL domains.  The 5’ 
primer is constructed from available data on the N-terminal conserved sequences 
of the leader and first framework regions of the antibody and the 3’ primer is based 
on conserved constant region sequences (Larrick et al., 1989).  When N-terminal 
amino acid sequences of VH or VL are not available, 5’ primers can be designed 
according to family specific degenerate primer sets available from various 
databases, such as the Kabat database (www.kabatdatabase.com).  For 
construction of Fab fragments, the VHCH1 fragment is amplified with primers 
representing the leader sequence 5 to 8 amino acids 5' of the VH framework 1 
region and amino acids 205 to 220 of the CH1 region. The VLCL construct is 
created with primers representing the leader sequence 5 to 8 amino acids 5' of the 
VL framework 1 region and amino acids 205 to 220 of the CL region (Padoa et al., 
2003). 
 
Other characteristics to bear in mind when designing primers for cloning of 
antibody fragments include restriction enzyme sites, detection and purification 
tags, expression strategies, and the vector being used for cloning experiments 
(reviewed by Gavilondo and Larrick, 2000). 
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Figure 1.7:  Schematic representation of recombinant antibody constructs  
(Hudson, 1999). 
(a)  Intact IgG (bivalent).  (b)  Monovalent immunoglobulin fragments 
(Fab, Fv, scFv, and a V-domain).  Also shown are scFv multimers: (c) 
diabodies; (d) triabodies; (e) tetrabodies.  V domains and C domains 
are represented by ovals (VH domains are shaded grey with amino-
terminal dots, VL domains are black and C domains are white) and 
linkers are represented as black lines.  Fv molecules are shown with 
the different target (antigen)-binding regions (TBRs)-A, -B, -C or –D 
and with different shading within the VH domains representing different 
target specificity.  For size comparison, also shown are (f) a domain 
conjugated dimeric Fab and (g) a chemically conjugated Fab trimer 
(using the maleiimide cross-linking reagent, TFM).  Only one V domain 
arrangement is shown for each structure; there are obviously 
alternative orientations of V domains and linker polypeptides. 
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1.3.1.2.  scFv fragments 
The variable domains of Fv fragments are not associated by covalent bonds, and 
dissociation of the bonds at low protein concentrations has been observed 
(Glockshuber et al., 1990).  Many different approaches have been used to improve 
the domain association of Fv fragments.  One is the construction of single chain 
antibodies (scFv; Figure 1.7) in which the two variable domains are linked into a 
single polypeptide using a short (10 to 20 residues), hydrophilic linker (Bird et al., 
1988; Huston et al., 1988).  The peptide linker should be flexible and long enough 
to allow pairing of the two domains to form an intact antigen binding site.  The 
amino acid composition also has a crucial role in the design of a viable linker.  
Many commonly used linker peptides are rich in the small, polar glycine and serine 
residues (Gly4Ser)3.  These residues are optimal for the linker peptides since 
hydrophilic amino acids allow hydrogen bonding to the solvent and glycines 
provide the necessary flexibility.  These properties prevent the penetration of the 
linker peptide into the hydrophobic interface formed in the association of the VH-VL 
domains. 
 
1.3.1.2.1.  Expression of scFv and Fab fragments in bacteria 
scFv and Fab fragments are produced in E. coli and secreted as soluble and 
active recombinant antibody fragments into the periplasmic space (Glockshuber et 
al., 1990; Anand et al., 1991) or they can be harvested from the bacterial culture 
medium (Takkinen et al., 1991).  These antibody fragments, derived from genes 
isolated from murine hybridoma cell lines, are capable of specifically binding to 
their target antigens with affinities ranging up to those of their parent mAbs 
(Denzin and Voss, 1992; Malby et al., 1993).  The Fab cDNA genes can be 
modified relatively easily before expression in bacteria.  For example, 
modifications of the primary structure of either the Fd and/or κ chain that are useful 
for subsequent conjugation of imaging or therapeutic agents, or fusion to other 
peptides, can be introduced by site-directed mutagenesis techniques (Better et al., 
1988). 
 
Gene expression of antibody fragments is controlled by inducible promoters while 
prokaryotic leader sequences are used to direct export of the scFv/Fab into the 
periplasmic space of E. coli.  After removal of the leader peptide, the oxidising 
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environment in the periplasm allows correct disulphide bond formation.  If the 
antibody fragments are expressed in the bacterial cytoplasm, inactive antibody 
fragment chains are produced; either in soluble form or in aggregates (inclusion 
bodies) that need to be refolded in vitro after extraction (Lilley et al., 1994).  scFvs 
are easier to express compared with recombinant Fab, where two separate 
proteins must be expressed and then fold together correctly to form the antigen 
binding pocket. 
 
Several conventional chromatography methods have been used to purify 
bacterially produced antibody fragments.  Immobilised metal ion affinity 
chromatography (IMAC) is the most widely accepted as a result of its simplicity, 
speed, low cost, and performance.  IMAC is based on the binding affinity of metal 
ions such as Ni2+, Cu2+ or Zn2+, chelated to a chromatography matrix, for multiple 
histidine residues genetically linked to the N- or C-terminus of a scFv or one of the 
Fab chains (Goel et al., 2000; Xiang et al., 2002). 
 
1.3.1.3.  Valence of engineered antibodies 
A major limitation of scFv molecules is their monovalent interaction with target 
antigen.  The binding of a scFv to its target antigen can be improved by increasing 
its functional affinity through the creation of a multimer.  A number of multivalent 
scFv-based structures (Figure 1.7) have been engineered, including 
miniantibodies (Pack and Plückthun, 1992), dimeric miniantibodies (Müller et al., 
1998), minibodies (Hu et al., 1996), (scFv)2 (Adams et al., 1993), diabodies 
(Holliger et al., 1993), and triabodies (Iliades et al., 19978).  These molecules span 
a range of valence (two to four binding sites), size (50 to 120kDa), flexibility, and 
ease of production. 
 
Among the easiest constructs to engineer are the noncovalent diabody and 
triabody molecules.  These are produced by shortening the peptide linker that 
connects the VH and VL chains of a single scFv molecule from 15 amino acids to 
five amino acids (diabody) or zero to three amino acids (triabody).  A variety of 
miniantibodies have been produced by Pack and Plückthun (1992).  These scFv 
dimers are joined by amphipathic helices that offer a high degree of flexibility.  
Müller et al. (1998) modified the miniantibody structure to create a dimeric 
  
25
bispecific (DiBi) miniantibody that contains two miniantibodies (four scFv 
molecules) connected via a double helix (Figure 1.7). 
 
1.3.2.  Humanisation of recombinant antibodies 
 
The most prominent aspect of antibody engineering has been the focus on the 
xenogeneic nature of murine mAbs.  Attempts to improve the efficacy and safety of 
these mAbs for therapeutic applications have led to the development of a number 
of technologies for reducing immunogenicity of murine mAbs.  An optimal 
technology for generation of mAbs lacking immunogenicity in humans should 
produce mAbs that are fully human in sequence, lacking any murine amino acid 
components.  It should be able to generate mAbs against human antigens with the 
desired effector function.  These mAbs should be of high affinity and specificity.  
The technology should be easy to use so that many researchers can generate 
mAbs without the need for sophisticated molecular biology techniques. 
 
Some of the early attempts at generating human mAbs involved immortalisation of 
human B lymphocytes by hybridoma technology, however, numerous difficulties, 
including the instability of human hybridomas and a preponderance of low affinity 
IgM mAbs resulted in this technology seldom being used (James and Bell, 1987; 
Winter and Milstein, 1991).  A novel technique was later described that involved 
infecting the human B lymphocyte with Epstein-Barr virus, thus immortalising 
these cells (Kudo et al., 1993).  However, due to the difficulties in obtaining B 
lymphocytes producing efficient human mAbs and ethical problems finding 
humans immunised against target antigens, this technique was not very 
successful.  In an attempt to overcome the problem of low efficiency, severe 
combined immunodeficient (SCID) mice were injected with human peripheral 
blood lymphocytes (Abiko et al., 1997).  These mice show spontaneous secretion 
of human immunoglobulin such that a specific human antibody response is 
inducible following immunisation with a specific antigen. 
 
In an effort to realise Erhlich's dream of a magic bullet with high binding affinity, 
reduced immunogenicity, increased half-life in the body, and adequate recruitment 
of effector functions, scientists have used techniques from molecular biology to 
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design, engineer, and express mAbs from hybridoma technology to produce 
humanised mAbs. 
 
1.3.2.1.  Chimeric antibodies 
One approach used to reduce the immunogenicity of murine antibodies was to link 
the xenogeneic variable region to the corresponding human gamma and kappa (or 
lambda) constant regions (Morrison et al., 1984), thus generating human-mouse 
chimeric antibodies (Figure 1.8). 
 
a.        b.         c.            d. 
 
 
 
Figure 1.8:  Humanised antibodies a) murine, b) chimeric c) humanised, d) human  
(http://www.path.cam.ac.uk/~mrc7/humanisation/index.html). 
 
Such chimeric antibodies show the same specificity and affinity of parental murine 
antibodies and are capable of efficiently mediating antibody-dependent cell-
mediated cytotoxicity (ADCC), antibody-dependent macrophage cytotoxicity 
(ADMC), and complement fixation in the human context.  In general, substitution of 
the murine constant regions by human ones increases the biological half-life in 
vivo.  When these antibodies were used therapeutically in clinical trial studies in 
humans, some still caused a human anti-chimeric antibody (HACA) response 
directed against the murine antibody variable regions (reviewed in Adair, 1992). 
 
1.3.2.2.  Humanised antibodies 
To overcome this HACA response, scientists endeavoured to make the chimeric 
antibody more ‘human’.  This was achieved by the development of the technique 
of antibody ‘humanisation’.  This process, also known as CDR grafting (Jones et 
al., 1986; Verhoeyen et al., 1988), and reshaping (Riechmann et al., 1988), 
involves the redesign of the variable region domain.  Only the amino acids 
constituting the mouse CDRs are transplanted into the human antibody framework 
variable regions (Figure 1.8).  Antibodies made this way are called humanised, 
reshaped, or CDR-grafted.  An optimal humanised antibody is one that contains 
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the fewest number of mouse amino acids shifted into the human CDRs but retains 
the binding affinity and specificity of the original mouse antibody.  Simple grafting 
of the rodent CDRs into human frameworks does not always reconstitute the 
binding affinity and specificity of the original mAb.  This technology usually 
requires individual tailoring for each antibody, including extensive molecular 
modelling and manipulation of the DNA encoding the mAb.  The xenogeneic CDRs 
of the humanized antibodies may, however, evoke an anti-idiotypic response in 
patients.  To minimize this response, only the specificity determining residues 
(SDRs), the CDR residues that are most crucial in the antibody-ligand interaction, 
are grafted onto the human frameworks (Kashmiri et al., 2005). 
 
Human hybridoma technology has always been hampered by the fact that 
immunological specificity could in most cases, due to ethical reasons, not be 
generated by immunising human individuals.  Several in vitro immunisation 
approaches have been developed that circumvent the ethical problems 
(Borrebaeck et al., 1988; Guzman et al., 1995), although immunisation of naïve 
human B cells in vitro has only generated primary immune responses.  Thus, 
human mAbs generated by this approach are normally low-intermediate affinity 
IgM antibodies (Ohlin et al., 1989) and not directly applicable in a clinical situation.  
The introduction of phage display technology (Smith, 1985), in conjunction with 
methods of generating antibody libraries, allowed one to bypass in vivo 
immunisations of animals or humans to produce human antibodies that can be 
used for therapeutic purposes.  The advantage of phage display systems is that it 
provides a faster and more efficient selection method than traditional bacterial 
screening. 
 
1.3.2.3.  Phage display technology 
The possibility to clone antibody genes and display the antibody fragments on the 
surface of filamentous bacteriophage (McCafferty et al., 1990) provides a powerful 
tool to select specific binders from combinatorial libraries of VH and VL genes 
(panning) (Parmley and Smith, 1988; Hawkins and Winter, 1992).  The phage 
display process involves the following steps: (1) genetically engineering phage 
display libraries to ‘display’ human scFv antibodies on the surface of the 
recombinant phage, (2) selecting antibodies with high affinity and specificity to any 
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given target by screening the antibody phage display libraries, and (3) producing 
and characterizing the selected antibodies (Figure 1.9). 
 
 
 
 
 
 
 
Figure 1.9:  Generation of antibodies by the immune system and phage  
technology (Marks et al., 1992). 
Steps: (1) rearrangement or assembly of germline V genes; (2) 
surface display of antibody (fragment); (3) antigen-driven or affinity 
selection; (4) affinity maturation; (5) production of soluble antibody 
(fragment). 
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A pool of phage displaying a collection of diverse antibodies is called an antibody 
phage display library.  A number of different types of phage-display libraries have 
been constructed.  The amplification of V genes isolated from IgG-secreting 
plasma cells from animals or individuals immunized with antigen (Persson et al., 
1991), exposed to infectious agents (Burton et al., 1991), with autoimmune 
diseases (Graus et al., 1997), or with cancer (Cai and Garen, 1995) gives rise to 
immune libraries (Clackson et al., 1991).  A second category, termed the single-
pot library, consists of naive, semi-synthetic, and synthetic libraries.  These 
libraries are designed to isolate antibody fragments that bind to every possible 
antigen.  Naive libraries are constructed from rearranged V genes from B cells 
(IgM) of non-immunized donors (de Haard et al., 1999).  Semisynthetic libraries 
are derived from unrearranged V genes from germline cells or from a single 
antibody framework with genetically randomized CDR3 regions (Pini et al., 1998).  
The fully synthetic libraries have a human framework with randomly integrated 
CDR cassettes (Hayashi et al., 1994).  cDNA libraries are generated from RNAs 
derived from human bone marrow, splenic lymphocytes from splenectomized 
individuals, or peripheral blood lymphocytes (de Carvalho Nicacio et al., 2002).  
The large non-immune or naïve human scFv (or Fab) libraries offer a rich source 
for isolation of antibodies of human origin to virtually any antigen, including self-
antigens. 
 
1.3.2.3.1.  Construction of human scFv antibody phage display libraries 
Libraries of antibody fragments are first constructed for the light and heavy chains 
by PCR using degenerate primers (Larrick et al., 1989).  These are combined into 
the phage display vector where the chains are randomly paired and can, thus, 
provide an additional source of variation for antibody specificity and affinity 
(Zebedee et al., 1992).  This strategy requires no immunisation, the antibody 
genes are cloned, and the antibody fragments express well in E. coli (Figure 1.9).  
The number and affinity of the antibodies generated to a particular antigen is a 
function of library size and diversity, with larger libraries yielding a greater number 
of high-affinity antibodies (Sheets et al., 1998). 
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1.3.2.3.2.  Display of human scFv and Fab antibodies on the surface of phage 
Two methods for the display of antibody fragments on the surface of phage exist.  
Recombinant DNA techniques allow the pairing of the antibody fragment to one of 
two coat proteins of the bacteriophage, either the major coat protein encoded for 
by gene VIII or the minor coat protein encoded for by gene III.  A system based on 
gene VIII will display several copies of the antibody fragment, theoretically over     
2 000 copies/phage particle, leading to a multivalent selection system (Kang et al., 
1991).  In this case, the avidity will mask the single specificity of a specific 
displayed fragment, thus giving good avidity as a multicopy product on the phage 
surface, even though the single antibody fragment might exhibit a low affinity 
constant.  The gene III product is located at the tip of the bacteriophage particle in 
approximately four copies/phage (McCafferty et al., 1990).  In this system, each 
phage expresses a single, functional antibody with specificity to a particular 
antigen on its surface and the gene encoding the protein incorporated into its 
genome.  It is by the gene III product that phage particles attach to the F pili of the 
bacteria and consequently an infectious phage must have at least one native gene 
III product.  The system based on the gene III product is the most attractive to use 
in antibody engineering since it allows selection based on affinity rather than 
avidity (Barbas et al., 1991). 
 
1.3.2.3.3.  Selection of human scFv and Fab antibodies 
In addition to circumventing the limitations of human hybridoma technology, 
phage-expressed scFvs (or Fabs) are amenable to screening methods such as 
affinity enrichment that are more efficient than screening hybridoma culture 
supernatants by enzyme-linked immunosorbent assays (ELISA).  Affinity selection 
methodologies typically use purified, abundant, soluble targets that can be 
immobilised to enrich reactive phage from large antibody display libraries.  The 
target molecules can be purified proteins that are immobilized onto a solid surface, 
or blotted on nitrocellulose membranes (Skerra et al., 1991; Griffiths et al., 1994).  
Employing solid supports for an antigen target can alter the conformation of the 
antigen and lead to the isolation of antibodies that recognise only unnatural or 
denatured forms of the antigen.  This concern can be addressed by using 
biotinylated antigen and recovering specific binders with streptavidin-conjugated 
magnetic beads (Hawkins et al., 1992). 
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Upon incubation, the antigen specific phage antibodies will interact with the target 
molecule and remain attached.  The remaining unbound billions of phages are 
washed away (Figure 1.10).  The selected antigen specific phage are used to 
infect bacteria, one single phage per bacterium.  Each infected bacterial cell grows 
into a single colony once spread onto agar plates.  Each clone thus produces a 
single type of mAb.  Isolated clones are then pooled and further amplified to 
produce the phage antibodies for the next round of screening (panning).  Selection 
of those scFv antibodies with the strongest affinity and specificity can be achieved 
through multiple rounds of panning (Figure 1.10) of antibody-expressing phage 
particles against antigens of interest by altering selection conditions.  Good 
candidate antibodies will go through additional testing such as ELISA and 
sequence analysis. 
 
While affinity selection of phage-displayed antibodies provides a powerful method 
for enriching antigen-reactive scFvs (or Fabs) from large libraries, it requires 
multiple steps to isolate a single clone.  An alternative method for rapidly 
screening large numbers of phage-expressed antibodies, which circumvents many 
of these limitations, is the plaque lift assay in which nitrocellulose is overlaid on a 
solid agar lawn containing bacteria infected with phage.  Phage-expressed scFvs 
(or Fabs) are bound by the nitrocellulose, and subsequently the filter can be 
probed with soluble, labelled antigen to identify plaques expressing reactive 
antibodies (Watkins et al., 1998).  The plaque lift assay is complementary to 
affinity enrichment approaches in that it permits isolation of clones in a single step 
as well as the rapid characterisation of soluble scFv (or Fab) produced by phage 
expression systems.  Finally, because plaques arise from infection by a single 
phage, every clone present in a library can be screened, permitting the 
identification and isolation of rare, nonabundant scFv (or Fab) specificities 
(Watkins et al., 1998). 
 
The whole phage display and selection process takes about three to four weeks to 
complete, with the initial identification and isolation of antibodies usually within 10 
to 14 days and the genetic characterization of the antibodies within an additional 1 
to 2 weeks.  As in the immune system, the V genes can be subjected to random 
mutation, and mutants with high binding affinities may be selected. 
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Figure 1.10:  Bio-panning of phage display library (Azzazy and Highsmith, 2002). 
The library is screened in four steps: (1) binding of phages to the 
target antigen (in this case antigen immobilised on a solid support), 
(2) washing to remove unbound phage, (3) dissociation to recover 
antigen-specific phage, and (4) amplification of the antigen-specific 
phage by infection of E. coli.  Caution must be exercised during the 
binding and washing steps to avoid low-ionic strength or other 
conditions that may favour adsorption of phage directly onto plastic 
or other matrix. 
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1.3.2.3.4.  Affinity maturation by chain shuffling 
In chain shuffling, the scFv molecule is subjected to cycles of manipulations in 
which the gene for one chain (e.g., VH) is cloned into a repertoire for the second 
chain (e.g., VL) (Marks et al., 1992).  The resulting library, that contains scFv-
phage with VH chains specific for the antigen and random VL chains, is panned 
against the target antigen to identify clones with improved binding characteristics.  
The cycle is repeated, this time shuffling the new VL gene into a VH repertoire.  
This method provides additional diversity, particularly in the framework regions of 
the antibody fragments and hence, the potential for significant increases in affinity.  
A potential drawback associated with chain shuffling is that it can result in changes 
to the antigenic specificity of the scFv (Ward, 1995). 
 
1.3.2.3.5.  Affinity maturation by site-directed mutagenesis 
In this method, amino acids of one or more of the CDRs are substituted, and 
subsequent clones with higher affinity for the antigen selected.  A refinement of the 
above technique, termed ‘parsimonious mutagenesis’ (Balint and Larrick, 1993), 
involves screening the entire CDR sequence of an antibody fragment to identify 
amino acids that are actively involved in binding to the antigen.  Two methods are 
used to improve the efficiency of the selection process.  First, the number of 
codons introduced is limited such that each amino acid is only coded for by a 
single codon.  Second, the amino acids at each position are manipulated to favour 
parental sequences, conservative changes, and those that more commonly 
appear in antibody CDRs (reviewed by Adams and Schier, 1999). 
 
Protein display on filamentous phage has a broad range of applications, which 
include drug and target discovery, protein evolution and rational drug design.  
While phage display represents considerable progress over hybridoma 
technology, deficiencies still do exist: the size of the library is limited to 
approximately 1010, variants may be selected against in the host environment due 
to toxicity to E. coli, and difficulties eluting phage carrying antibodies with high 
affinities can be encountered (Schier and Marks, 1996).  Many of these limitations 
are circumvented by utilising a cell-free transcription, translation, and selection 
system in ribosome display (Schaffitzel et al., 1999). 
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1.3.2.4.  Ribosome display 
Ribosome display (Hanes and Plückthun, 1997) aims for simultaneous selection 
and evolution of proteins from diverse libraries without any bacterial 
transformation.  DNA (which encodes a protein library) is transcribed to mRNA 
which is purified and used for in vitro translation.  The mRNA, ribosomes, and 
translated peptide are prevented from dissociating and this complex is then used 
for affinity selection on an immobilised target.  Complexes that do not encode a 
binding peptide that specifically recognise the target antigen are removed by 
washing.  mRNA that encodes a polypeptide similar to the target antigen 
dissociates from the complex and is reverse transcribed into cDNA.  The cDNA is 
amplified and used for the following cycle of enrichment and PCR.  This process 
involves no transformation and large libraries can, therefore, be constructed and 
used for selection.  Additionally, library diversification is introduced via DNA 
shuffling (Stemmer, 1994) and error prone PCR (Cadwell and Joyce, 1992). 
 
1.3.2.5.  Transgenic mice 
It is now possible to produce transgenic mice that are capable, upon immunization, 
of producing a full repertoire of human antibodies in the absence of endogenous 
immunoglobulin production.  Transgenic mice have been generated in which 
endogenous immunoglobulin heavy and light chains have been replaced by 
exogenous human immunoglobulin loci, so that the mice produce fully humanized 
antibodies (Bruggemann et al., 1991; Bruggemann and Taussig, 1997). 
 
Another way in which to produce human antibodies is with the use of severe 
combined immunodeficient (SCID) mice.  Human lymphoid cells are stimulated in 
vitro with antigen and grafted into SCID mice.  The mice are challenged with the 
antigen several times.  Cells are harvested and used for cloning or hybridoma 
fusion (Duchosal et al., 1992).  Since SCID mice lack antibody-producing cells, the 
mice grafted with human cells produce human antibodies. 
 
1.4.  THERAPEUTIC USES OF MONOCLONAL ANTIBODIES 
 
Initially, antibody engineering involved the modification of pre-existing antibodies 
to improve their characteristics.  Now, antibody engineering encompasses the 
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generation of novel antibody specificities and the expression of large amounts of 
antibody for eventual therapeutic use.  In part, the potential therapeutic utility of 
monoclonal antibodies stems from their specific and high affinity binding to targets 
coupled with their diversity of function.  Antibodies are not only being developed 
for administration as soluble proteins, but also as intracellular molecules to alter 
cell function (reviewed by George, 1999). 
 
A useful therapeutic needs to be effective and safe.  The important issues relating 
to efficacy include the affinity and specificity, tissue penetration, clearance times, 
and the mode of action of the effector element of the engineered antibody.  Safety 
concerns include inappropriate uptake by tissues and the patient reaction to the 
foreign protein or the pharmaceutical composition (reviewed by Adair, 1992). 
 
Murine mAbs have inherent disadvantages as human therapeutics: 
i. They require more frequent dosing to maintain a therapeutic level of mAb 
because of a shorter circulating half-life in humans than human antibodies. 
ii. Repeated administration of murine immunoglobulin creates the likelihood that 
the human immune system will recognise the mouse protein as foreign, 
generating a HAMA response.  This can cause a severe allergic reaction or 
result in the rapid clearance of the murine antibody upon repeated 
administration, and hence reduced therapeutic efficacy (Riva et al., 1989). 
 
Recent advances in the design, construction, and expression of antibody 
fragments (Winter and Milstein, 1991) have paved the way to the production of a 
new range of diagnostic and therapeutic reagents.  mAbs have provided reagents 
with unique target specificity and affinity for a wide variety of antigens and 
haptens.  Fab and Fv fragments can be used to replace the parent mAb in 
situations where monovalent binding specificity is required.  An advantage of using 
these smaller molecular fragments, apart from protein stability, is the potential to 
use bacterial expression systems for high-level synthesis (Glockshuber et al., 
1990; Hoogenboom et al., 1991). 
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1.4.1.  Engineered mAbs as pharmacological tools 
 
Cancer is one of the leading causes of death.  Considerable attention has, thus, 
been given to the construction of genetically engineered antibodies for use in 
cancer prevention/treatment.  ScFv molecules have certain advantages over the 
use of whole mAbs in cancer immunotherapy.  Whole mAbs penetrate tumours 
poorly due to their size.  ScFvs, which are one fifth of the molecular weight of an 
IgG, are able to penetrate faster and deeper into tissues and clear more rapidly 
from the blood.  scFvs also lack constant regions and are not bound by Fc 
receptors found in most tissues and organs, thus further reducing their side effects 
(Yokota et al., 1992; Yamaguchi et al., 1998).  Although IgGs penetrate tissues 
poorly, they are found at higher concentrations on the surface of tumours than 
scFvs.  This is because IgGs have a longer half life and hence higher levels in the 
blood.  The ratio of tumour to blood levels of IgG, however, remains low.  In 
contrast, the tumour to blood ratio for scFvs is fairly high despite the low number 
that localise to the tumour because of their rapid clearance from the blood.  A 
short half life is favourable for cancer imaging whereas rapid and efficient antibody 
uptake by the tumour is beneficial for therapeutic applications.  The size of 
recombinant antibodies have been altered and multivalent molecules constructed 
for improved tumour penetration and higher affinity, respectively.  These 
improvements will stimulate the development of new reagents for cancer imaging 
and therapy (reviewed by Wu and Yazaki, 2000). 
 
1.4.2.  Recombinant antibodies in clinical use 
 
The Food and Drug Administration (FDA) has approved a number of recombinant 
antibody derived medicines for treatment of cancer, cardiovascular disease, 
Crohn’s disease, rheumatoid arthritis, and for the prevention of organ rejection 
following transplantation (Table1.3).  Many more recombinant antibodies are in 
late stage clinical trials for a broad range of disease indications.  Antibodies now 
account for the single largest group of biotechnology derived molecules in clinical 
trials (reviewed by Green, 1999). 
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Table 1.3:  A select list of FDA approved mAbs. 
Product 
Name 
Manufacturer Therapeutic 
Applications 
Antibody 
Type 
Approved 
Date 
Rituxan/ 
Rituximab 
IDEC/Genentech Non-Hodgkin’s 
Lymphoma 
Chimeric 1997 
Herceptin Genentech Breast cancer Chimeric 1998 
Simulect Novartis Organ Rejection Chimeric 1998 
Remicade Johnson & 
Johnson 
Rheumatoid 
Arthritis, 
Crohn’s Disease
Chimeric 1998 
Zenapax Roche Organ rejection Chimeric 1997 
Mylotarg American Home 
Products 
Acute Myeloid 
Leukaemia 
CDR-grafted 2000 
Campath Millenium Chronic Myeloid 
Leukaemia 
CDR-grafted 2001 
Humira Abbott Labs Rheumatoid 
Arthritis 
Phage Display 2002 
Xolair Genentech/ 
Novartis 
Asthma CDR-grafted 2003 
Raptiva Genentech & 
Xoma 
Psoriasis CDR-grafted 2003 
Avastin Genentech Colorectal 
Cancer 
CDR-grafted 2004 
Erbitux Imclone & Bristol-
Myers Squibb 
Colorectal 
Cancer 
Chimeric 2004 
Zevalin IDEC/Schering 
AG 
Non-Hodgkin’s 
Lymphoma 
Murine 
Radiolabelled 
2002 
Bexxar Corixa/GSK Non-Hodgkin’s 
Lymphoma 
Murine 
Radiolabelled 
2003 
Table reproduced from Hudson and Souriau, 2003 
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1.4.3.  The use of recombinant antibodies in diabetes research 
 
Recombinant antibodies can serve as tools for epitope mapping (Padoa et al., 
2005) and detection of epitope shifts in different stages of a disease such as type 
1 diabetes and Stiff Person Syndrome (Padoa et al., 2003; Raju et al., 2005). 
 
1.4.3.1.  Autoantibodies in the sera of diabetic patients 
Autoantibodies to the 65kDa isoform of glutamate decarboxylase (GAD65Abs) are 
accepted markers for type 1 diabetes and, together with insulin autoantibodies 
(IAA) and a protein tyrosine phosphatase-like islet cell antigen (IA-2), predict the 
disease (Vandewalle et al., 1995).  GAD65Abs have recently been implicated in 
GAD65 presentation to T cells (Jaume et al., 2002; Reijonen et al., 2000) and 
may, therefore, play a role in the pathogenesis of type 1 diabetes.  The 
identification and characterization of type 1 diabetes-specific GAD65 and insulin 
autoantibody epitopes is important to further our understanding of the pathogenic 
involvement of these autoantibodies in the progression of type 1 diabetes. 
 
The identification of disease-specific GAD65Ab epitopes in type 1 diabetes has 
been hampered by the fact that the epitopes are conformational (Tuomi et al., 
1994; Schwartz et al., 1999).  Epitope identification has been attempted using 
GAD65/67 fusion proteins.  Using these fusion proteins it has been shown that 
sera of type 1 diabetes patients recognize conformational epitopes located in the 
middle (amino acid 240-435) and the carboxy-terminal end (amino acid 451-570) 
of GAD65 (Daw and Powers, 1995; Hampe et al., 2000; Padoa et al., 2003).  This 
reactivity pattern differs significantly from that of GAD65Abs in stiff-man syndrome 
patients (Björk et al., 1994; Daw et al., 1996), autoimmune polyendocrine 
syndrome type 1 patients (Björk et al., 1994), first degree relatives of type 1 
diabetes patients, the general population, and type 1.5 diabetes patients (Hampe 
et al., 2000). 
 
Information about conformational disease-specific GAD65Abs and their epitopes 
was limited (Ziegler et al., 1996) despite valuable data provided by the analysis of 
autoantibody binding patterns using GAD65/67 fusion proteins (Falorni et al., 
2000; Hampe et al., 2000).  Changes in GAD65Ab epitopes were observed in 
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prediabetic children (Bonifacio et al., 2000), indicating that the humoral response 
to GAD65 changes as an individual progresses to type 1 diabetes.  Padoa and 
colleagues (2003) cloned rFab of well characterized GAD65-specific mAbs to 
characterise GAD65Abs present in the sera of patients with type 1 diabetes.  The 
use of rFab rather than intact immunoglobulins prevents potential steric hindrance.  
The six GAD65-specific rFab were cloned from human mAbs b96.11, DP-C, DP-A, 
and DP-D (derived from autoimmune disease patients), and from murine mAbs 
144 and 221-442.  The epitope regions recognized by the six mAbs were spread 
over the length of the GAD65 molecule ensuring that different epitope specificities 
were represented.  Although the patients’ sera present a polyclonal mixture of 
GAD65Abs with different epitope specificities, the binding of GAD65Ab in type 1 
diabetes patients to GAD65 was significantly reduced in the presence of the six 
rFab, supporting previous reports that major GAD65Ab epitopes in type 1 diabetes 
are located in the middle region and the carboxy-terminus of the molecule (Daw 
and Powers, 1995; Schwartz et al., 1999).  The competition pattern in type 1 
diabetes patients was different from that in GAD65Ab-positive type 1.5 diabetes 
patients, first degree relatives, and healthy individuals.  These findings support the 
view that type 1 diabetes is associated with disease- and epitope-specific 
GAD65Abs and the opinion that the middle epitope is disease-specific.  These 
GAD65-specific rFab should prove useful in predicting type 1 diabetes (Padoa et 
al., 2003). 
 
Previous data has shown that GAD65Abs can modulate GAD65 processing and 
presentation to MHC class II-restricted T cells and thus have a pathogenic role in 
the development of type 1 diabetes (Jaume et al., 2002; Reijonen et al., 2000).  
The DP-D, DP-C, and DP-A antibodies were shown to promote the presentation of 
GAD65 epitopes outside their own binding sites, while inhibiting the presentation 
of their specific epitope to T cells (Jaume et al., 2002).  This is in conjunction with 
the observation that antibodies can suppress the presentation of certain epitopes 
due to their high affinity binding (Simitsek et al., 1995; reviewed by Watts, 1997) 
and highlights the possible involvement of GAD65Abs in the modulation of T cell 
responses to GAD65.  The rFab b96.11, DP-C, and other type 1 diabetes-specific 
rFab may represent a novel tool to modulate this processing and will be of 
importance in elucidating the mechanisms by which GAD65Abs may influence 
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disease progression.  Future experiments will be needed to determine the effect of 
rFab b96.11 or DP-C on the action of pathogenic serum antibodies in order to 
reveal whether these disease-specific GAD65Abs are pathogenic or the result of 
epitope spreading induced by disease progression.  Epitope spreading is the 
phenomenon whereby there is a shift in the position of the epitopes from one 
domain of the antigen to another as an autoimmune disease progresses.  Thus, 
antibodies to GAD65 are initially produced against the middle and C-terminal 
regions of the antigen in type 1 diabetes.  The autoimmune response may then 
undergo intramolecular epitope spreading towards epitopes on the N-terminus and 
further epitopes located in the mid-region of GAD65 in genetically predisposed 
individuals which leads to onset of the disease (Schlosser et al., 2005). 
 
Raju and colleagues (2005) used these same GAD-specific rFab to study the 
epitopes recognised by GAD65Abs present in the sera of Stiff Person Syndrome 
patients.  They identified a disease specific linear epitope on the GAD65 molecule 
in these patients.  This epitope was not recognised by GAD65Abs in the sera of 
type 1 diabetes patients. 
 
Similar studies have also been performed using insulin-specific mAbs and their 
rFab.  IAA are among the first autoantibodies to appear in individuals prior to the 
clinical onset of type 1 diabetes (Ziegler et al., 1999).  Their appearance is 
inversely correlated with age (Graham et al., 2002).  This makes them especially 
important as markers for type 1 diabetes in children (Karjalainen et al., 1989).  
Little is known about the epitopes recognized by IAA.  In the past, researchers 
have utilised naturally occurring isoforms of insulin for the analysis of IAA 
epitopes.  In two studies, human, bovine, and porcine insulin were used to reveal 
differences in the binding characteristics of IAA and antibodies to exogenously 
administered insulin (IA), locating the major binding site of IA to the A-chain, while 
type 1 diabetes-associated IAA recognise a conformational epitope requiring both 
the A and B chain (Diaz and Wilkin, 1987; Wilkin et al., 1988).  Differences in 
epitope specificities of IAA and IA were also detected using random peptide phage 
display (Devandra et al., 2003).  Monoclonal antibodies and their rFab are being 
successfully used in the epitope analysis of other autoantibodies in type 1 diabetes 
(Schlosser et al., 1997; Schwartz et al., 1999; Kolm-Litty et al., 2000; Padoa et al., 
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2003).  This method is particularly useful in the study of conformational epitopes 
since the structure of the antigen remains intact (Binder et al., 2004). 
 
The use of rFabs allows the detailed analysis of disease specific epitopes without 
disrupting the conformational structure of the antigen.  In type 1 diabetes, the 
characterisation of disease specific GAD65 and insulin autoantibody epitopes will 
provide important information to further the understanding of the 
immunopathologic mechanisms involved in the aetiology of this disease.  
Characterization of possible antigenic hot spots on GAD65 and insulin may 
provide insights into the mechanism by which these autoantibodies are induced. 
 
The identification of disease specific epitopes may also provide new methods for 
the treatment/prevention of type 1 diabetes.  If a disease specific epitope is 
identified, patients can be treated with a peptide that binds to this epitope, 
effectively blocking the autoantibody from binding to the antigen.  A study 
performed by Daniel and Wegmann (1996) showed that when NOD mice were 
administered with the B-(9-23) insulin fragment, either subcutaneously or intra-
nasally, a delay in disease onset occurred and the incidence of diabetes 
decreased when compared to mice given a control peptide. 
 
Insulin autoantibody assays have posed major problems in terms of reproducibility, 
sensitivity, and specificity.  With the advent of antibody engineering it is envisioned 
that rFabs specific to insulin and its precursors can be constructed and used to 
standardise and improve the IAA assay.  Also, the construction of rFabs which 
could recognise disease specific IAAs, would greatly enhance the usefulness of 
insulin radio-binding assays (RBAs). 
 
1.4.3.2.  Recombinant antibodies and type 2 diabetes 
Type 2 diabetes is a heterogeneous and polygenic disorder resulting from the 
interaction of genetic and environmental factors.  The disease is characterised by 
a failure of the pancreatic β cells to secrete sufficient quantities of insulin in the 
presence of reduced insulin sensitivity.  Type 2 diabetes accounts for about 90% 
of all cases of the disease, affecting 150 million people worldwide (King et al., 
1998). 
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Studies have shown that high levels of proinsulin and des-31,32 proinsulin indicate 
future progression to type 2 diabetes (Nijpels et al., 1996; Wareham et al., 1999).  
Specificity, however, poses a major problem in insulin/proinsulin assays due to the 
similarity in the tertiary structures of insulin and its intermediates: proinsulin and 
the split proinsulins contain the structures of both C-peptide and insulin.  As a 
result, these insulin-like peptides may cross-react in immunoassays for either C-
peptide or insulin.  The converse also holds: C-peptide and insulin may cross-react 
in proinsulin assays (Sobey et al., 1989). 
 
The production of antibodies against novel proinsulin epitopes may be possible 
and this will be extremely useful in developing specific assays for des-31,32 
proinsulin since no monoclonal antibody that specifically binds to this protein 
exists.  The only method currently available to measure this intermediate is using 
two assays; total proinsulin and intact proinsulin.  The difference between the two 
assay values representing the amount of des-31,32 proinsulin (Sobey et al., 1989).  
The ability to accurately measure these molecules may provide important 
information on ß-cell dysfunction in type 2 diabetic patients.  Similarly, these novel 
antibodies could be used in assays designed to measure insulin and its precursors 
and screen populations who have a high risk of developing type 2 diabetes.  
Furthermore, genetic engineering will help improve the performance of 
immunoassays and provide better reagents for clinical diagnosis.  The production 
and genetic manipulation of novel mAbs that only contain the antigen binding 
domains of immunoglobulins will also help reduce non-specific binding (Warren et 
al., 2005). 
 
1.4.4.  Other uses of recombinant antibodies 
 
Recombinant antibodies are also used in high-resolution X-ray crystallographic 
studies of antigen binding sites.  The size of antibodies and the flexibility of the 
hinge connecting Fab arms and the Fc domain have prompted crystallographers to 
turn to Fab (Saul and Poljak, 1992) and Fv fragments (Boulot et al., 1990). 
 
scFv can also be fused to various proteins or fluorochromes (e.g., alkaline 
phosphatase and fluorescein isothiocyanate) to produce coating or detection 
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reagents that can be used in immunoassays for direct single-step detection of 
target antigen (Wozniak et al., 2003), double antibody sandwich ELISAs 
(Kerschbaumer et al., 1997), or in immunofluorescence and phenotyping by flow 
cytometry techniques for the diagnosis of various diseases (Reimann et al., 1994). 
 
The main advantage of the use of recombinant antibodies over monoclonal and 
polyclonal antibodies, in traditional immunoassays, is the ability to genetically alter 
the antibodies binding affinity and specificity.  The use of bispecific antibodies 
where one arm binds to a target antigen and the second to an enzyme will also be 
invaluable in enzyme immunoassays.  Secondly, the use of recombinant antibody 
fragments in ELISAs provide a less time consuming screening/detection method 
for certain molecules (e.g., heroin) in drug monitoring than the conventional 
methods that are employed (thin layer chromatography, gas chromatography and 
high performance liquid chromatography).  In addition, the traditional methods are 
expensive and require skilled personnel to perform the tasks (Brennan et al., 
2002). 
 
Genetically engineered antibodies have similarly been used to improve the 
performance of immunoassays.  A number of false-positive results are obtained in 
immunoassays due to the interference by heterophilic antibodies (naturally 
occurring human antibodies to immunoglobulins of animal origin).  ScFvs lack the 
constant domain of an antibody and, therefore, interference is essentially 
eliminated.  When such a scFv was used in an assay, it showed considerably less 
non-specific interference than the assay in which the parent mAb was used 
(Warren et al., 2005). 
 
In summary, due to technological innovations such as the production and 
engineering of mAbs, immunoassays have been substantially improved in terms of 
their sensitivity, specificity, and ease of use since the first radioimmunoassay (RIA) 
for the determination of plasma insulin concentration was described some 45 
years ago by Yalow and Berson (1959). 
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1.5.  INSULIN ASSAYS 
 
1.5.1.  The development of the insulin assay 
 
Assays of insulin and its precursors are of little diagnostic use but are important 
tools for investigating the aetiology and pathology of diabetes.  This has been the 
driving force behind the development of better insulin assays.  The RIA for insulin 
described by Yalow and Berson (1959) used a polyclonal antiserum to insulin 
taken from human diabetes patients who had been treated with commercial 
mixtures of bovine and porcine insulins.  The antisera was incubated with 131I-
labelled bovine insulin in the presence of known quantities of non-labelled bovine 
insulin.  The antibody-bound, labelled, insulin complexes were separated from the 
free insulin by chromatoelectrophoresis.  A future discovery that guinea pig anti-
beef insulin antiserum bound human insulin led to the development of a RIA for 
the human hormone.  Problems arose, however, due to difficulties experienced in 
the efficient separation of the soluble antibody-bound insulin from free insulin. 
 
New techniques for separation were developed and the resultant assays provided 
new information on β cell function in type 2 diabetes patients.  The importance of 
the immunometric measurement of insulin and its precursors has not been 
diminished by time.  The basic assay principle has changed little, but many 
improvements have been made to the original insulin RIA methodology.  These 
include the use of a more stable isotope, namely 125I-insulin, simpler separation of 
the antibody-bound molecules from the free molecules by centrifugation, and more 
sensitive and specific RIAs that are easier to run and allow the measurement of 
many different types of biologically active molecules. 
 
1.5.2.  Problems encountered with insulin RIAs 
 
A number of problems may be encountered with insulin RIAs.  One example is the 
lack of standardisation for the insulin assay due to inaccurate methods.  This is 
evidenced by disparate values for fasting plasma insulin levels and the range of 
results reported by different laboratories and external quality assessment 
schemes, respectively.  A number of factors, such as the source of standards, 
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properties of the antisera, adsorption of insulin onto glass or plastic tubes, stability 
of insulin in plasma, and haemolysis are responsible for these inaccuracies 
(reviewed by Temple et al., 1992). 
 
1.5.2.1.  Assay specificity and sensitivity 
There is a great demand, both clinically and in research, for assays of insulin, 
proinsulin, and proinsulin-like molecules that are specific, sensitive, and precise.  
Specificity poses a major problem due to the similarities in the tertiary structures of 
insulin and its intermediates: proinsulin and split proinsulins contain the structures 
of both C-peptide and insulin (Figure 1.11).  As a result, these insulin-like peptides 
may cross-react in immunoassays for either C-peptide or insulin.  The converse 
also holds: C-peptide and insulin may cross-react in proinsulin assays.  Proinsulin 
and split proinsulins are usually present in lower concentrations in plasma than 
insulin which further compounds the problems of specificity (Sobey et al., 1989).  
Assays need to be sensitive and precise especially if the results are to be used for 
diagnosis, monitoring treatment, or for screening purposes. 
 
Doubts as to the specificity of human plasma insulin RIAs were raised following 
the finding that proinsulin-like molecules exists in human plasma (Roth et al., 
1968; Melani et al., 1970) and the demonstration that human proinsulin reacts 
similarly to human insulin in the insulin assays (Heding, 1972).  Proinsulin-like 
molecules only account for 10 to 20% of immunologically insulin-like molecules in 
plasma from normal subjects.  The poor specificity of insulin RIAs should not, 
therefore, be problematic when assaying insulin in normal subjects.  In contrast, 
the lack of specificity of insulin RIAs are particularly important in the study of type 
2 diabetes in which proinsulin concentrations are known to be raised in the plasma 
(Temple et al., 1989).  Also, proinsulin molecules are known to cross-react (38 to 
100%) in many insulin RIAs based on polyclonal antibodies.  Since their biological, 
insulin-like activity is very much lower than that of insulin, their measurement as 
‘insulin’ may lead to incorrect conclusions concerning the insulin deficiency in type 
2 diabetics (Melani et al., 1970; Temple et al., 1990). 
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Figure 1.11:  Diagrammatic representation of the insulin biosynthetic pathway. 
 
1.5.3.  Developments of insulin assays 
 
The immunoradiometric assay (IRMA), using labelled antibody (Hales and 
Woodhead, 1980) was developed as a means of increasing the sensitivity of 
insulin assays.  The two-site assay, in which one antibody is labelled and the 
second is coupled to a solid phase, has the advantage of improved specificity and 
the most convenient format.  However, it was only following the production of large 
quantities of mAbs that scientists were able to overcome the problems of 
sensitivity and specificity encountered in these assays.  The use of mAbs raised 
against conformational epitopes specific for insulin, or the initial separation of 
insulin from proinsulin and conversion intermediates followed by a nonspecific 
assay can improve specificity. 
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A number of groups have produced mAbs to insulin and insulin intermediates and 
designed two-site assays (Gray et al., 1987; Chevenne et al., 1994; Vieira et al., 
1995).  However, the specificity of mAbs is not absolute.  Specificity may be 
improved by the careful selection of pairs of mAbs to particular epitopes on the 
analyte of interest.  Generally, the higher affinity antibody is labelled to improve 
sensitivity and the second antibody is attached to a solid phase.  Only molecules 
that have epitopes that bind to both mAbs will be detected in this two-site assay.  
The mAbs 3B1 and 14B bind to insulin and 65,66 split proinsulin.  Therefore, when 
these mAbs were used simultaneously in an assay, only insulin would be 
measured since the levels of 65,66 split proinsulin are very low in human serum.  
When mAb A6, which binds to proinsulin, was used in conjunction with mAb 3B1, 
proinsulin was measured (Sobey et al., 1989).  Cross-reaction with the split 
molecule did not interfere with the assay because the levels of this split proinsulin 
are very low. 
 
A third approach was recently developed based on a new principle of exclusion 
between mAbs, which results in a RIA specific for insulin.  This assay requires 
three mAbs (S1, S2, and S53) selected for their specificity, affinity, and interactive 
properties when mixed.  S1 is directed against the B10 region of the insulin 
molecule, S2 to the junction between the A chain and C-peptide of proinsulin and 
32, 33 split proinsulin, and S53 is directed towards the B chain, C-peptide junction 
of proinsulin and 65,66 split proinsulin.  This assay relies on the fact that 
preincubation of serum samples with both S2 and S53 leaves insulin as the sole 
reactant with S1.  This method proved that it is possible to separate insulin from 
proinsulin and its conversion intermediates, thus, producing a highly specific RIA 
for insulin (Deberg et al., 1998). 
 
Much time and effort has been spent attempting to develop insulin assays using 
non-isotopic labels, such as luminescent and fluorescent compounds and 
enzymes, to avoid the problems associated with radioisotopes (limited shelf life 
and biological hazards).  An immunofluorometric assay (IFMA) for insulin was 
described by Vieira et al. (1995).  mAbs against insulin were produced and used to 
develop the IFMA.  One mAb was immobilised in the wells of a microtitre plate and 
used for capture of insulin.  The second mAb was labelled with Europium and 
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used as the tracer antibody.  This assay showed greater sensitivity and specificity 
than the classical RIA. 
 
1.6.  PROINSULIN ASSAYS 
 
1.6.1.  Early methods of proinsulin measurement 
 
The original methods for the measurement of proinsulin were based on proinsulin 
reacting with insulin antibodies.  Serum was applied to a column of Sephadex and 
two peaks were identified, one for insulin and the second representing the 
proinsulin molecules (Roth et al., 1968; Melani et al., 1970).  Insulin RIA of the 
fractions revealed that proinsulin-like material consisted of about 20% of 
immunoreactive insulin in the fasting state in control subjects.  These procedures 
are not suitable for the routine analysis of a large number of samples as they are 
time consuming, insensitive, and imprecise.  In addition, an insulin RIA can only be 
used for the measurement of proinsulin if the recovery of proinsulin in that 
particular RIA has been determined. 
 
To improve proinsulin assay specificity, a new method was developed that used 
an insulin-specific protease (Kitabchi et al., 1971).  These proteases degraded 
insulin in the blood.  The remaining insulin-like immunoreactivity, assumed to be 
due to the presence of unaltered proinsulin, was then measured using an insulin 
RIA.  Before samples were treated with the proteases, insulin levels were 
assessed by measuring immunoreactivity.  Although this method was quick, it 
consistently produced higher fasting proinsulin concentrations than those obtained 
by gel filtration.  This discrepancy was due to the fact that the proteases only 
partially degraded insulin, degradation was insulin concentration dependent, 
proinsulin was also being degraded, and the enzyme activity varied from one 
plasma sample to the next (Cresto et al., 1974). 
 
At the time, it was not possible to develop a direct radioimmunoassay, since 
production of antibodies was difficult to achieve for two reasons: 
i. insufficient human pancreatic proinsulin available for large scale immunisation 
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ii. proinsulin antibodies produced cross-reacted with insulin and C-peptide (Melani 
et al., 1970). 
 
This problem was overcome with the aid of biosynthetic human proinsulin, which 
was available in sufficient quantities for immunisation.  RIAs and IRMAs have 
since been developed.  Indirect RIAs (Ward et al., 1986; Bowsher et al., 1992) 
require the separation of insulin or C-peptide before measuring proinsulin, and 
direct RIAs (Heding, 1977; Cohen et al., 1985;) are based on the use of specific 
polyclonal antibodies to proinsulin which do not distinguish intact proinsulin from 
its intermediate forms.  Problems with both direct and indirect RIAs include poor 
sensitivity and a lack of specificity.  Two ELISAs, which include antibodies to 
insulin and C-peptide, have improved sensitivity but the specificity is still poor 
(Dhahir et al., 1992; Kjems et al., 1993).  IRMAs, immunoenzymometric assays, 
and IMFAs have now been developed to measure proinsulin with good sensitivity 
and improved specificity.  They do, however, still cross-react with des 64,65 
proinsulin and split 65,66 proinsulin (Sobey et al., 1989; Alpha et al., 1992; Engling 
et al., 1995).  The concentration of des 31,32 proinsulin can only be calculated via 
two assays; total proinsulin and intact proinsulin.  The difference between the two 
assay values is equal to the amount of des 31,32 proinsulin. 
 
1.6.2.  Limitations and solutions of insulin and proinsulin assays 
 
A number of clinical studies, that have used insulin and proinsulin assays have 
been published.  Insufficient information is frequently given concerning the assays 
and it is, therefore, difficult to interpret the results accurately.  As a result, false 
conclusions are often drawn due to the lack of understanding of the limitations of 
the assays.  It is important to include information that is necessary for validation 
and interpretation of clinical data obtained from an assay in publications as even 
minor changes to protocols can lead to significant changes in assay performance.  
It has also been difficult to assess the accuracy of proinsulin assays due to the 
lack of standardisation of assays and the lack of choice of commercially available 
quality control materials (reviewed by Temple et al., 1992). 
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Future progress in assay technology will undoubtedly produce further 
improvements in the specificity and sensitivity of assays for insulin and its 
precursors, ensuring that they remain an important analytical tool for the study of 
the aetiology and pathology of type 2 diabetes.  Advances in assay methodology 
have already allowed the specific measurement of insulin and proinsulin in type 2 
diabetes subjects and have demonstrated β cell dysfunction as an important 
component in the disease process.  In the near future genetic engineering may 
lead to the manufacture of antibodies that can differentiate between all the 
proinsulin-like molecules and that are sensitive enough to measure the des 64,65 
proinsulin molecule. 
 
1.7.  INSULIN 
 
The primary amino acid sequence of porcine insulin was discovered by Sanger in 
1955 (Brown et al., 1955) for which he was awarded the Nobel Prize in 1958.  This 
auspicious occasion marked the first time that a protein had had the order of its 
amino acids (the primary sequence) determined.  Fifteen years after the sequence 
of porcine insulin was reported, Hodgkin and her colleagues elucidated the three-
dimensional structure of insulin using X-ray crystallography (Hodgkin, 1971; 
Blundell et al., 1971).  Since these initial discoveries, the primary sequence and 
structure for more than 70 insulin and insulin-like molecules have been unravelled. 
 
1.7.1.  The structure of the insulin molecule 
 
Insulin is a 5 808 Dalton (Da) protein composed of two peptide chains referred to 
as the A chain and B chain.  The two chains are linked by two disulphide bonds 
between cysteine residues on each chain (Sanger, 1959; Figure 1.12).  There is a 
third disulphide bridge within the A chain that links the 6th and 11th residues of the 
A chain together (Ryle et al., 1955).  The two chains fold together to form a 
compact molecule with the hydrophobic core buried within a hydrophilic surface, 
except for two non-polar regions.  In 1967, Steiner and Oyer discovered proinsulin, 
a precursor of insulin.  They showed that the A and B chains of insulin are initially 
linked via the C-peptide.  In most species, the A chain consists of 21 amino acids, 
the B chain of 30 amino acids, and the C-peptide of 30 to 35 amino acids.  The 
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insulin gene, located on chromosome 11p15.5 (Owerbach et al., 1980; Harper et 
al., 1981), contains 3 exons and 2 introns; exon 2 encodes the signal peptide, the 
B chain, and part of the C peptide, while exon 3 encodes the remainder of the C 
peptide and the A chain. 
 
1.7.2.  Phylogeny of the insulin molecule 
 
Insulin is phylogenetically ancient.  Not only is it found in mammals, but also in 
birds, reptiles, teleost and elasmobranch fish, and the very primitive hagfish 
(Emdin and Falkmer, 1977).  The primary sequence and chemical structure of 
insulin from a number of species have been determined (Figure 1.13).  In most 
species, the length and amino acid composition of the A and B chains are similar, 
and certain segments of the molecule are highly conserved.  These include the 
positions of the three disulfide bridges, both ends of the A chain and the C-
terminal residues of the B chain.  The homology evident in the amino acid 
sequence of different insulins (Harris et al., 1956), leads to a three dimensional 
conformation of insulin that is very similar among species.  Insulin from one animal 
is, therefore, very likely biologically active in other species.  Thus, pig insulin can 
be used to replace deficient human insulin levels in diabetes patients.  Nowadays, 
due to the mass production of human proinsulin by bacteria (recombinant insulin), 
porcine insulin is seldom used (Goeddel et al., 1979; Miller and Baxter, 1980).  
Human insulin differs from porcine insulin by a single amino acid at the end of the 
B chain (Threonine [Thr] in man, Alanine [Ala] in the pig), and from bovine insulin 
by substitutions at two additional residues in the A chain (positions 8 and 10: Thr 
and Isoleucine [Ile] in man and Ala and Valine [Val] in the ox, respectively) (Figure 
1.12). 
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A chain S S
S 
 
 
Gly   Ilu   Val   Glu Gln Cys Cys Thr Ser  Ilu  Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys Asn 
 
 
 
 
 Phe Val Asn Gln His Leu Cys.Gly  Ser His Leu Val Glu Ala Leu Tyr Leu Val Cys Gly Glu 
                                                                                                                                                  Arg 
 
                                                                                                                                                   Gly 
 
                                                                                                                                                    Phe    
                                                                                                                                                 Phe 
                                                                                                                Thr Lys Pro Thr Tyr  
    
 B30 A8 A10 
Human Thr Thr Ile 
Porcine Ala The Ile 
Bovine Ala Ala Val 
 
 
Figure 1.12:  Primary structure (amino acid sequence) of human insulin (adapted  
from Pickup and Williams, 1991). 
The highlighted residues are those which differ in porcine and bovine 
insulins. 
 
 
 
S 
S B chain 
S 
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A chain 
 
Amino acid 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 
Gly Ilu Val Glu Gln Cys Cys Thr Ser Ilu Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys Asn HUMAN 
   Asp    Ala Gly Val             
 
Mammalian 
         Thr             
   Asp    Thr Ser Ilu  Ser Leu Tyr   Gln Asn    Asp 
        Gly Thr  Thr Arg His   Leu Ser     
       Ala Asn Val    Asn   Met Thr     
 
Hystrico-
morph 
                Glu      
   Asp    His Asn Thr             Avian 
       Glu  Pro             
Reptilian        Glu Asn Thr       Gln      
  Val Glu    His Arg Pro  Asn Ilu Phe Asp  Gln Asp     
  Leu Asp     His   Asp Lys  Glx   Ser     
 
Teleost 
        Lys         Asn     
Elasmobranch     HIs   His Asn Thr     Asp   Gly    Gln 
Cyclostome        His Lys Arg   Ilu  Asn  Gln      
 
 
B chain 
 
Amino acid     -1      1     2     3     4     5     6     7     8     9     10     11     12     13     14     15     16     17     18     19     20     21     22     23     24     25     26     27     28     29     30     31     32 
                              Phe  Val Asn Gln His Leu Cys  Gly Ser    His   Leu   Val    Glu    Ala   Leu   Tyr    Leu   Val   Cys   Gly    Glu   Arg   Gly    Phe   Phe   Tyr   Thr    Pro   Lys    Thr    HUMAN 
Mammalian                                  Lys                            Pro                                                                                                                                                                             Not     Ala 
                                                                                                                                                                                                                                                                                   Ser                    
                              Phe        Asn Gln His                                His                      Glu    Ala                    Leu                      Gly   Glu   Arg                      Phe   Tyr   Thr             Lys 
Hystrico-                Tyr         Gly  Arg Arg                               Asn                     Asp    Thr                    Ser                      Gln   Asp  Asp                      Tyr    Arg   Ilu              Ser    Asp 
morph                                  Ser  Lys                                      Glu                                                                                     Lys   Asn                                               Arg            Asn    Glu 
                                                                                                                                                                                          Arg   His                                                                  Met    Ala 
                                                                                                                                                                                                                                                                                    Ser 
Avian                     Ala  Ala                                                                                                                                                                                                              Ser                      Thr            
                                                                                                                                                                                                                                                                                    Ala 
Reptilian                Ala  Pro                                                                                                          Pho   Ilu                                                                                      Ser             Arg    Thr 
                                                                                                                                                                                                                                                                                    Ser 
                      Val   Ala  Pro  Pro  Gln                                                                 Glu                      
Teleost          Met                 Ala   Pro                                                                 Asp                                                                                                                      Gln             Lys 
                                             Asn                                                                                                                                                                                                     Asn 
Elasmobranch       Leu Pro  Ser                                                                                                             Phe                             Pro   Lys                    Tyr              Leu                      Asx   Glx   Val 
Cyclostome           Arg  Thr  Thr   Gly                           Lys    Asp                      Asn                              Ilu     Ala                     Val                                                Asp             Thr    Lys   Met 
 
 
Figure 1.13:  The species variation in the amino acid sequence of insulin for the A- and B-chains (Hodgkin et al., 1983). 
The sequence for human insulin is given in full.  Each variation where it occurs is written below.
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1.7.3.  Insulin biosynthesis and secretion 
 
1.7.3.1.  The insulin biosynthetic pathway 
The synthesis of insulin begins with the translation of the insulin gene, which 
resides on chromosome 11p13 (Figure 1.14).  During translation, the two introns 
are spliced out of the mRNA product, which encodes a protein of 110 amino acids 
in length.  This primary translation product is called preproinsulin and is inactive 
(Chan et al., 1976).  The first 24 amino acids form a signal peptide which is 
required for the protein to cross the endoplasmic reticulum membrane.  
Preproinsulin is rapidly transported into the lumen of the rough endoplasmic 
reticulum, of the pancreatic β cells, where a proteolytic enzyme cleaves the signal 
peptide from preproinsulin to yield proinsulin (Patzelt et al., 1978).  Proinsulin, a 9 
kDa peptide, consists of three domains: an amino terminal B chain, a carboxyl-
terminal A chain, and a small linker peptide chain - the C peptide.  A major 
function of the C peptide is to facilitate the correct folding of the A and B chains 
and alignment of their disulphide bridges before eventual cleavage.  Proinsulin is 
transported by microvesicles to the Golgi apparatus, where it is packaged into 
vesicles and surrounded by a membrane containing an ATP-dependent proton 
pump (Farquhar and Palade, 1981).  The conversion of proinsulin to insulin is 
initiated in the Golgi complex and continues within the maturing secretory granule 
through the sequential action of two distinct site-specific endopeptidases (PC1/3 
and PC2) and carboxypeptidase H (Steiner et al., 1974; Davidson et al., 1988). 
 
1.7.3.2.  Detailed features of proinsulin conversion 
Depending upon the conversion route taken, discrete conversion intermediates will 
be generated; split 32,33-, split 65,66-proinsulins; and des 31,32-, des 64,65-
proinsulins (Figure 1.11) (de Haen et al., 1978).  If the B chain/C-peptide junction 
is the first site cleaved (by PC1) and trimmed, des 31,32 split proinsulin is 
generated as the conversion intermediate.  Cleavage by PC2 at the alternative 
junction, linking C-peptide and the A-chain, generates des 64,65 split proinsulin 
(Davidson et al., 1988).  PC2 can also cleave at the alternative junction but with a 
greatly reduced efficiency.  It has also been shown that PC2 only cleaves the C-
peptide/A-chain junction of intact proinsulin relatively slowly, preferring des 31,32 
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split proinsulin as its substrate.  The proinsulin conversion route via des 31,32 
proinsulin appears to be the predominant pathway (Rhodes et al., 1992). 
 
In the β cell, and in the circulation, it is generally accepted that the major 
conversion intermediates found are des 31,32 and des 64,65 proinsulins and not 
the split proinsulins (Given et al., 1985; Sobey et al., 1989).  Endoproteolytic 
cleavage at either of the two proinsulin junctions seems to be the rate limiting step 
by comparison with the very rapid and efficient subsequent cleavage of the newly 
exposed C-terminal amino acid by carboxypeptidase H (also known as E).  The 
conversion intermediates recovered from granules, β cells, or encountered in the 
circulation, are thus typically in their trimmed state, without C-terminal basic 
residues (Halban, 1994).  Insulin and C peptide are stored together in the granule 
sac and are ultimately released in equimolar amounts (Steiner et al., 1971).  Under 
normal conditions, 95% of the biosynthetic product is secreted as insulin and less 
than 5% as unconverted proinsulin. 
 
1.7.3.3.  Proinsulin and conversion intermediates in type 2 diabetes mellitus 
Using assays that are able to distinguish between insulin, proinsulin and des 31,32 
proinsulin (Sobey et al., 1989), it has been shown that the ratio of proinsulin and/or 
des-31,32 split proinsulin to insulin is often elevated in type 2 diabetes (Temple et 
al., 1989; Ostrega et al., 1995).  The explanation for these unusually elevated 
ratios is uncertain.  The comparison of circulating levels of proinsulin and 
conversion intermediates in the basal and stimulated states indicates that these 
products, like insulin, are being released by the regulated pathway in these 
patients.  It has been suggested that there may be a fundamental impairment of 
proinsulin processing in type 2 diabetes (Kahn and Halban, 1997), but the 
evidence is circumstantial.  It seems more likely, when looking at the available 
data, that increased demand upon the β cell, and in particular an imbalance 
between rates of synthesis, intracellular degradation, and release could simply 
lead to the granular contents being discharged before conversion is complete.  
This explanation is, however, flawed as not all situations in which there is 
increased demand upon the β cell lead to unusual ratios of proinsulin/conversion 
intermediates to insulin. 
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Figure 1.14:  Biosynthesis of preproinsulin and its subsequent conversion to  
proinsulin and insulin (Pickup and Williams, 1991). 
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1.8.  DIABETES MELLITUS 
 
Diabetes mellitus is a chronic illness characterised by hyperglycaemia resulting 
from impairments in insulin secretion, defects in insulin action, or both.  The 
chronic hyperglycaemia is associated with the development of microvascular and 
macrovascular complications.  In the majority of cases the diagnosis can be made 
with certainty but the underlying aetiology and pathogenesis remain largely 
obscure. 
 
1.8.1.  The classification of diabetes mellitus 
 
The classification of diabetes has evolved over the last three centuries.  In 1875 
diabetes was differentiated into two forms, ‘diabète maigre’ and ‘diabète gras’ 
which have different prognoses and require different management.  Diabetes was 
later classified according to the age of onset of the disease, using the terms 
‘juvenile-onset’ and ‘maturity-onset’.  In 1936 the disease was characterised 
according to the requirement of insulin as ‘insulin sensitive’ or ‘insulin resistant’.  
Twenty years later the terms ‘type 1’ and ‘type 2’ diabetes emerged; this distinction 
was based on clinical criteria.  Type 1 diabetes was later subdivided according to 
whether destruction of the β cells was autoimmune (type 1a), a viral infection or 
other agent (type 1c), or a combination of the two (type 1b) (Pickup and Williams, 
1991). 
 
In 1979, the National Diabetes Data Group (NDDG) published a provisional 
consensus classification, which became the basis for that recommended by the 
World Health Organisation (WHO) Expert Committee on Diabetes in 1980.  The 
WHO classification represented a landmark by providing standardised diagnostic 
criteria for diabetes and a uniform terminology suitable for clinical and 
epidemiological research, which have now been widely adopted. 
 
Over the years, our knowledge about the aetiology and pathogenesis of diabetes 
and about the predictive value of different blood glucose levels for development of 
complications has increased significantly.  This has led to diabetes, and the criteria 
thereof, being re-examined, redefined and re-classified by both the American 
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Diabetes Association (ADA) and the WHO.  There is currently a move away from a 
system where the classification of the disease was primarily distinguished by the 
requirement for insulin therapy, toward a system based on pathogenesis of the 
disease (Table 1.4) wherever possible (The Expert Committee on the Diagnosis 
and Classification of Diabetes Mellitus, 2003).  However, the impetus for the 
classification and diagnosis scheme proposed in 1979 still holds true.  That is, 
 
‘the growth of knowledge regarding the aetiology and pathogenesis of 
diabetes has led many individuals and groups in the diabetes community to 
express the need for a revision of the nomenclature, diagnostic criteria, and 
classification of diabetes.  As a consequence, it was deemed essential to 
develop an appropriate, uniform terminology and a functional, working 
classification of diabetes that reflects the current knowledge about the 
disease’ (NDDG, 1979). 
 
Table 1.4:  Aetiological classification of diabetes mellitus. 
A.  Diabetes mellitus 
¾ Type 1 diabetes (β cell destruction, usually leading to absolute insulin 
deficiency) 
- Autoimmune 
- Idiopathic 
¾ Type 2 diabetesΩ (results from a progressive insulin secretory defect on 
the background of  insulin resistance) 
¾ Other specific types of diabetes 
- Genetic defects of β cell function or in insulin action 
- Diseases of the exocrine pancreas 
- Endocrinopathies 
- Drug- or chemical-induced 
- Infections 
- Uncommon forms of immune-mediated diabetes 
- Other genetic syndromes sometimes associated with diabetes 
¾ Gestational diabetes (diagnosed during pregnancy) 
 
Ω  Patients with any form of diabetes may require insulin treatment at some stage of their disease.  Such use of insulin does 
not, of itself, classify the patient.  Table adapted from ADA, 2005b. 
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1.8.1.1.  The new classification criteria 
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus 
(2003) proposed changes to the NDDG/WHO classification scheme.  The main 
features of these changes are as follows: 
i. The terms insulin-dependent diabetes mellitus (IDDM) and non-insulin-
dependent diabetes mellitus (NIDDM) have fallen away and are replaced with 
the terms type 1 and type 2 diabetes.  Arabic numerals, rather than Roman 
numerals, are to be used. 
ii. Type 1 diabetes encompasses cases due to the destruction of the pancreatic 
β cells and that are prone to ketoacidosis.  Included in this category are cases 
due to an autoimmune process and those for which an aetiology is unknown.  
Subjects in whom there is no evidence of autoimmunity are classified as type 
1 idiopathic. 
iii. Type 2 diabetes is the most prevalent form of the disease, which results from 
insulin resistance with an insulin secretory defect. 
iv. Malnutrition diabetes has been removed from the classification list due to the 
lack of convincing evidence proving that diabetes can be directly caused by 
protein deficiency. 
v. The term IGT (impaired glucose tolerance) is retained and the similar 
intermediate stage of fasting glucose is named impaired fasting glucose (IFG).  
IGT and IFG are officially termed ‘pre-diabetes’.  These individuals are at 
increased risk of developing diabetes. 
vi. Selective screening is recommended for glucose intolerance in pregnancy. 
vii. Diabetes can be staged according to the severity of the metabolic abnormality. 
viii. It is more important to understand the pathogenesis of the hyperglycaemia 
and to treat it appropriately than to assign a label to the disease i.e., type 1 or 
type 2 diabetes. 
 
1.8.2.  Diagnostic criteria for diabetes mellitus 
 
The revised criteria for the diagnosis of diabetes mellitus and hyperglycaemia are 
shown in Table 1.5 (WHO, 1999).  The major change from the previous WHO 
recommendation is a lower FPG (fasting plasma glucose) value ≥ 7.0 mmol/l to 
diagnose diabetes (previously ≥ 7.8 mmol/l).  For whole blood, the proposed new 
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level is ≥ 6.1 mmol/l (previously ≥ 6.7 mmol/l).  This recommendation was primarily 
based on a review of the results of more than 15 years of research which showed 
that a fasting blood glucose of ≥ 7.0 mmol/l is associated with an increased risk of 
microvascular and macrovascular complications.  These complications often 
developed before the diagnosis of diabetes when the diagnosis was based on a 
blood glucose value ≥ 7.8 mmol/l.  It is believed that earlier diagnosis and 
treatment can prevent or delay the costly and burdensome complications of 
diabetes. 
 
For epidemiological or population screening purposes, the fasting or 2 h value 
after 75 g oral glucose may be used alone.  For clinical purposes, the diagnosis of 
diabetes should always be confirmed by repeating the test on another day, unless 
there is unequivocal hyperglycaemia with acute metabolic decompensation or 
obvious symptoms. 
 
An intermediate group of subjects (IFG) are recognised whose glucose levels are 
too high to be considered normal yet do not meet the criteria for diabetes.  The 
categories of FPG values are as follows (ADA, 2005b): 
• FPG < 5.6 mmol/l = normal fasting glucose; 
• FPG ≥ 5.6 mmol/l and < 7.0 mmol/l = IFG; 
• FPG ≥ 7.0 mmol/l = provisional diagnosis of diabetes. 
The corresponding categories when the OGTT is used are the following: 
• 2-h PG < 7.8 mmol/l = normal glucose tolerance; 
• 2-h PG ≥ 7.8 mmol/l and <11.1mmol/l = IGT; 
• 2-h PG ≥ 11.1 mmol/l = provisional diagnosis of diabetes. 
 
The ADA recommends the use of FPG alone for clinical diagnosis and 
epidemiological studies, whereas the WHO report (1999) advocates the continued 
use of the OGTT. 
 
In summary, the diagnostic criteria are now revised to avoid the discrepancy 
between the FPG and 2-h PG cut-off values and facilitate and encourage the use 
of a simpler and equally accurate test - FPG - for diagnosing diabetes. 
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Table 1.5:  Values for diagnosis of diabetes mellitus and other categories of hyperglycaemia. 
 Glucose concentration (mmol/l [mg/dl]) 
 Whole blood Plasma 
 Venous Capillary Venous Capillary 
Diabetes Mellitus 
Fasting 
or 2 h post glucose load 
or both 
 
≥ 6.1 (≥ 110) 
≥ 10.0 (≥ 180) 
 
≥ 6.1 (≥ 110) 
≥ 11.1 (≥ 200) 
 
≥ 7.0 (≥ 126) 
≥ 11.1 (≥ 200) 
 
≥ 7.0 (≥ 126) 
≥ 12.2 (≥ 220) 
Impaired glucose 
tolerance (IGT) 
Fasting (if measured) 
and 2 h post glucose load 
 
 
< 6.1 (< 110) 
≥ 6.7 (≥ 120) and 
< 10.0 (< 180) 
 
 
< 6.1 (< 110) 
≥ 7.8 (≥ 140) and 
< 11.1 (< 200) 
 
 
< 7.0 (< 126) 
≥ 7.8 (≥ 140) and 
< 11.1 (< 200) 
 
 
< 7.0 (< 126) 
≥ 8.9 (≥ 160) and 
< 12.2 (< 220) 
Impaired fasting 
glycaemia (IFG) 
Fasting 
 
and 2 h post glucose load 
(if measured) 
 
 
≥ 5.6 (≥ 100) and 
< 6.1 (< 110) 
< 6.7 (< 120) 
 
 
≥ 5.6 (≥ 100) and 
< 6.1 (< 110) 
< 7.8 (< 140) 
 
 
≥ 6.1 (≥ 110) and 
< 7.0 (< 126) 
< 7.8 (< 140) 
 
 
≥ 6.1 (≥ 110) and 
< 7.0 (< 126) 
< 8.9 (< 160) 
Table reproduced from WHO (1999). 
  62
1.8.3.  Symptoms of diabetes mellitus 
 
In type 1 diabetes, sudden weight loss, frequent urination, and constant thirst are 
the classical symptoms.  In type 2 diabetes, symptoms may be more subtle and go 
unnoticed, or even be absent altogether (WHO, 1999).  Type 2 diabetes is often 
diagnosed through the detection of other problems associated with having had 
diabetes for some years (e.g., leg pain or ulcers caused by nerve damage and/or 
poor circulation). 
 
Acute, life-threatening consequences of diabetes are hyperglycaemia with 
ketoacidosis or the nonketotic hyperosmolar syndrome.  Long-term complications 
of diabetes include retinopathy with potential loss of vision; nephropathy leading to 
renal failure; peripheral neuropathy with risk of foot ulcers, amputation, and 
Charcot joints; and autonomic neuropathy causing gastrointestinal, genitourinary, 
and cardiovascular symptoms and sexual dysfunction (reviewed by Gerich, 1986). 
 
1.9.  TYPE 1 DIABETES MELLITUS 
 
1.9.1.  Autoimmune Diabetes Mellitus 
 
Type 1 diabetes, previously referred to by the terms Insulin-Dependent Diabetes 
Mellitus (IDDM: because of the clinical requirement for insulin) or juvenile diabetes 
(because of the early age of onset), is widely thought to be an organ-specific 
autoimmune disease.  Type 1 diabetes results from a deficiency of insulin due to 
the destruction of the insulin-producing β cells situated in the islets of Langerhans 
within the pancreas (WHO, 1999).  The destruction process is manifested by 
infiltration of the pancreatic islets by mononuclear cells, and may proceed over a 
period of many years (Gorsuch et al., 1981; Johnston et al., 1989).  A large 
proportion (60 to 80%) of the β cells are destroyed by the time clinical symptoms 
appear (reviewed by Notkins and Lernmark, 2001).  Younger children present with 
more severe symptoms at diagnosis, because children younger than 7 have lost 
on average 80% of the islets, compared to 60% in those 7 to 14 years old and 
40% in those older than 14 (Foulis et al., 1986).  This prediabetic period offers an 
opportunity to identify those individuals who are likely to become insulin-
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dependent later and to start intervention aimed at delaying or preventing the 
manifestation of clinical disease (Kulmala et al., 1998). 
 
The rapidly progressive form is commonly observed in children and adolescents 
who may present with ketoacidosis as the first manifestation of the disease.  The 
slowly progressive form generally occurs in adults who may retain residual β-cell 
function, sufficient to prevent ketoacidosis, for many years.  These individuals 
eventually become dependent on insulin.  This form of diabetes is referred to as 
latent autoimmune diabetes in adults (LADA) or type 1.5 diabetes (Tuomi et al., 
1993; WHO, 1999). 
 
1.9.1.1.  Idiopathic form 
There are some forms of type 1 diabetes which have no known aetiology.  Some 
of these patients have permanent insulinopenia, but have no evidence of 
autoimmunity.  This form of diabetes is more common among individuals of African 
and Asian origin.  Individuals with this form of diabetes suffer from episodic 
ketoacidosis and exhibit varying degrees of insulin deficiency between episodes.  
This form of diabetes is strongly inherited, lacks immunological evidence for β-cell 
autoimmunity, and is not HLA associated.  An absolute requirement for insulin 
replacement therapy in affected patients may come and go (WHO, 1999). 
 
1.9.2.  The epidemiology of type 1 diabetes 
 
In 2000, it was estimated that 171 million adults ≥ 20 years of age have diabetes 
(Wild et al., 2004).  Type 1 diabetes accounts for 5 to 10% of all of the cases of the 
disease.  Thus, roughly 10 to 20 million individuals worldwide suffer from type 1 
diabetes (King et al., 1998; Wild et al., 2004).  The majority of the patients 
(approximately 40%) are diagnosed and classified with type 1 diabetes within the 
first two decades of life, making it one of the most common, severe, chronic 
diseases of childhood.  However, an increasing number of cases are being 
recognised in older individuals: 1:300 children and as many as 1:100 adults 
develop this disease in the United States, where 30 000 new cases are described 
each year (Rewers et al., 1988).  The prevalence of type 1 diabetes in children 
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aged less than 15 years ranges from 0.05 to 0.3% in most European and North 
American populations (Rewers et al., 1988). 
 
One of the most striking characteristics of type 1 diabetes is the large geographical 
variability in the incidence (Diabetes Epidemiology Research International Group, 
1988; Karvonen et al., 2000).  Scandinavia (35/100 000 in Finland) and the 
Mediterranean island of Sardinia have the highest incidence rates in the world 
while Oriental populations have the lowest rates (1.7/100 000 per year in Japan) 
(reviewed in Notkins and Lernmark, 2001).  In Finland, the incidence has more 
than tripled from 1953, when it was 12/100 000/year (reviewed by Pitkäniemi et al., 
2004), with an average increase of 2.4 percent per year.  A recent analysis of data 
on published incidence trends showed that the incidence of type 1 diabetes is 
globally increasing by 3.0% per year, and that in 2010 the incidence of type 1 
diabetes will be 40% higher than in 1998 (Onkamo et al., 1999). 
 
The incidence of type 1 diabetes varies markedly over time, both seasonally and 
annually.  In the northern hemisphere, the incidence declines during the warm 
summer months; similarly in the southern hemisphere, the seasonal pattern 
exhibits a decline during the warm months of December and January, implicating a 
climatic factor (Gamble, 1980).  This seasonal pattern only appears to occur in 
older children and adolescents (Dahlquist et al., 1982, Kostraba et al., 1992a), 
suggesting that factors triggering diabetes may be related to school attendance or 
viral infections. 
 
The incidence of type 1 diabetes changes with age.  The incidence rises from birth 
to 12 years, reaching a peak at age 11 to 13 years before falling to a much lower 
rate.  These peaks in incidence are perhaps due to alterations in the pattern of 
infections or increases in insulin resistance.  The incidence decreases in the third 
decade of life (Joner and Sovik, 1991; Bruno et al., 1993), but increases again in 
the fifth to seventh decades of life (Christau et al., 1977; Melton et al., 1983). 
 
There are noticeable racial differences in type 1 diabetes risk in multiracial 
populations.  For example, in the United States, non-Hispanic whites are 
approximately one and a half times as likely to develop type 1 diabetes as African 
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Americans (Diabetes Epidemiology Research International Group, 1988) or 
Hispanics (Kostraba et al., 1992a). 
 
In most instances, there is no difference in the incidence of type 1 diabetes in 
males and females (Gale and Gillespie, 2001), with the pubertal peak of incidence 
in females preceding that in males by 1 to 2 years.  Examples where the incidence 
may differ among the sexes are in lower risk populations, such as Japan or United 
States blacks, where there is a female preponderance.  Conversely, in the high 
risk groups there is a slight male excess (Karvonen et al., 1997). 
 
1.9.3.  Autoimmunity 
 
The trigger that leads to autoimmune destruction of the pancreatic β cells is still 
unknown.  The basis for the current thinking regarding the cause of β cell 
destruction comes from two discoveries made in the 1970s.  The first of these was 
the strong linkage between type 1 diabetes and the highly polymorphic human 
leukocyte antigen (HLA) class II immune recognition molecules located on 
chromosome 6 (Singal and Blajchman, 1973; Nerup et al., 1974).  A number of 
studies have revealed many high- and low-risk HLA alleles (reviewed by Schranz 
and Lernmark, 1998).  As a result HLA genotyping has become an important 
research tool for identifying individuals at risk of developing type 1 diabetes.  This 
association supported the hypothesis that the disease has an autoimmune 
component because it is well known that HLA molecules play a role in antigen 
presentation. 
 
Further evidence for the autoimmune nature of type 1 diabetes came from the 
discovery of autoantibodies in the sera of type 1 diabetic patients.  Sera from type 
1 diabetes patients were incubated with normal, frozen pancreatic tissue sections.  
Immunofluorescence revealed that type 1 diabetic patient’s sera stained 
pancreatic islets (Bottazzo et al., 1974; MacCuish et al., 1974).  These islet cell 
antibodies (ICAs) have since been widely used to study the clinical course and 
pathogenesis of type 1 diabetes. 
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Autoimmunity is defined by the presence of autoantibodies because their 
measurement is reliable and standardized across laboratories, in contrast to the 
cellular markers (reviewed by Atkinson and Eisenbarth, 2001).  The initial ICA 
assay, using immunofluorescence and pancreatic tissue (Bottazzo et al., 1974) 
has been notoriously difficult to standardize and has been replaced by a 
combination of specific β cell autoantibodies to insulin (Palmer et al., 1983), 
GAD65 (Baekkeskov et al., 1982; Baekkeskov et al., 1990), and IA-2 (Passini et 
al., 1995).  These tests have been shown to be quite sensitive and predictive in 
relatives of type 1 diabetes patients (Bingley et al., 1994; Verge et al., 1996) and in 
the general population (Bingley et al., 1997).  Autoantibodies are, therefore, 
currently the most frequently used markers for the prediction of type 1 diabetes. 
 
1.9.4.  Autoantibodies in type 1 diabetes 
 
The most thoroughly characterised immune phenomena associated with type 1 
diabetes is the presence of circulating antibodies to various islet cell proteins.  
Most type 1 diabetes patients (90%) have these ICAs in their sera in the 
asymptomatic period that precedes clinical onset of type 1 diabetes. 
 
1.9.4.1.  Identification of autoantigens 
The principal three autoantigens recognised by ICA were identified in the 1980s 
and early 1990s.  The first autoantigen described in1982 was a 64 kDa islet cell 
protein.  This protein was later identified as the enzyme glutamic acid 
decarboxylase 65 (GAD), and was shown to be one of the major antigens for 
autoantibodies in sera from patients with type 1 diabetes (Baekkeskov et al., 1982; 
Baekkeskov et al., 1990).  The GAD65 gene is located on chromosome 10p11 and 
encodes a protein of 585 amino acids (Table 1.6).  There are two isoforms of GAD 
which share 65% homology; GAD67 with a molecular weight of 67 000 Da and 
GAD65, a 65 000 Da protein (Bu et al., 1992).  They are expressed in both 
neurons and pancreatic islet cells.  GAD65 predominates in the latter, but its 
function is unknown.  GAD65 plays a role in the conversion of glutamic acid to γ-
aminobutyric acid (GABA), a major neurotransmitter inhibitor.  Autoantibodies in 
sera of type 1 diabetic patients are directed primarily to the middle (amino acid 
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245-449) and C-terminal (amino acid 450-585) regions of the molecule (Hampe et 
al., 2000; Padoa et al., 2003). 
 
The association of insulin autoantibodies (IAA) with type 1 diabetes was reported 
in 1983 when they were found in 18% of untreated, newly diagnosed diabetic 
patients (Palmer et al., 1983).  IAA are the first markers to appear during the 
symptomless period which precedes diabetes and they have been observed in up 
to 80% of patients diagnosed before the age of five years and they occur in 
approximately 30% of patients with clinical disease manifestation in adult age 
(reviewed by Potter and Wilkin, 2000).  IAA appear to be inversely correlated with 
age in both new-onset type 1 diabetic patients and their high-risk non-diabetic 
relatives.  A possible explanation for the production of autoantibodies to insulin 
before the development of diabetes could be that islet cells undergoing 
autoimmune lysis may release immunogenic fragments, or proinsulin, that may 
induce a secondary immunisation depending on differences in the HLA class II 
phenotypes associated with diabetes.  Another possible explanation for early 
development of IAA could be the recognition by the immune system of insulin as 
antigen leading to the autoimmune response initiating islet cell lysis. 
 
Insulin is a short polypeptide of 51 amino acids.  The insulin gene is located on 
chromosome 11p15.  Autoantibodies to insulin, in the sera of type 1 diabetic 
patients, are primarily directed to conformational epitopes.  In the case of insulin, 
the epitopes map to the B chain of human proinsulin or insulin (Diaz and Wilkin, 
1987). 
 
The third autoantigen identified was a protein tyrosine phosphatase-like molecule, 
IA-2 (Lan et al., 1996).  IA-2 (Mr 106 000), also known as ICA512, is located on 
chromosome 2q35 (Lan et al., 1996) and is a member of the transmembrane 
protein tyrosine phosphatase (PTP) family.  Due to a critical amino acid 
substitution at position 911 (Asp for Ala), in the catalytic domain of the molecule, 
IA-2 lacks enzymatic activity.  The 979 amino acid protein is expressed in 
secretory granules in brain and neuroendocrine cells including pancreatic islet α 
and β cells (Solimena et al., 1996).  Although IA-2 has been localised to the 
  68
secretory vesicles of endocrine and neuronal cells by immunofluorescence 
studies, its function remains unknown. 
 
IA-2β, also called phogrin, is another autoantigen in type 1 diabetes and is closely 
related to IA-2.  The aminoterminal intralumenal domains show only modest 
homology to each other (20%), whereas their cytoplasmic domains are closely 
related (80%) (Wasmeier and Hutton, 1996).  IA-2β has a molecular weight of 111 
000 Da and is situated on chromosome 7q36.  It carries the same amino acid 
substitution in its catalytic domain as IA-2, and is similarly expressed in 
neuroendocrine tissues.  Autoantibodies to IA-2 and IA-2β are directed exclusively 
to their intracellular domains (reviewed by Leslie et al., 1999).  Most sera that 
recognise IA-2β also recognise IA-2.  Conversely, not all sera that recognise IA-2 
recognise IA-2β.  Thus, IA-2 is the chosen protein for most immunoassays. 
 
International workshops have been held and extensive studies carried out in an 
effort to standardise the assays for autoantibodies to GAD65, IA-2 and insulin 
(Verge et al., 1998; Mire-Sluis et al., 2000).  Radioligand binding assays for 
GAD65 and IA-2 are accepted as being precise and reproducible whereas 
considerable interlaboratory variation and lack of reproducibility is observed for the 
insulin autoantibody assays.  There are numerous other autoantibodies to 
antigens (e.g., carboxypeptidase H, ICA69, GLUT-2, etc.) that have been reported.  
These have not been used in routine clinical studies due to the fact that they occur 
at a considerably lower frequency than the GAD65, IA-2, and insulin 
autoantibodies.  It has been suggested that autoantibodies to GAD65, IA-2 and 
insulin replace ICA in the prediction of type 1 diabetes (Kulmala et al., 1998). 
 
1.9.4.2.  Autoantibodies as predictors of type 1 diabetes 
Autoantibodies to GAD65 are present in 70 to 80% of newly diagnosed type 1 
diabetic patients and a slightly smaller percentage of patients (50 to 80%) have 
autoantibodies to IA-2.  Overall, fewer patients appear to have autoantibodies to 
insulin.  However, IAA are the first of the islet-related antibodies to appear during 
early insulitis, thus children have a markedly higher frequency of autoantibodies to 
insulin than teenagers or young adults (Hagopian et al., 1995; Myers et al., 1995). 
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Table 1.6:  Major autoantigens in type 1 diabetes. 
 GAD65 IA-2 Insulin 
Amino acid length 
Mr (Da) 
Chromosome 
Cell type in which 
expressed 
 
Intracellular location 
Function 
585 
65 000 
10p11 
Neuroendocrine, 
pancreatic islet 
cells 
Neuron-like small 
vesicles 
Converts glutamic 
acid to GABA: 
inhibitory 
neurotransmitter 
979 
106 000 
2q35 
Neuroendocrine, 
pancreatic islet 
cells 
Secretory vesicles 
 
Enzymatically 
inactive member 
of PTP family 
51 
6 000 
11p15 
Pancreatic islet β 
cells 
 
Secretory vesicles 
 
Ligand for the 
insulin receptor; 
regulation of blood 
glucose 
Table reproduced from Notkins and Lernmark, 2001. 
 
Some type 1 diabetics only have autoantibodies to a single autoantigen, whereas 
others may have autoantibodies to all three of the major autoantigens present.  Up 
to 90% of newly diagnosed type 1 diabetic patients’ have autoantibodies to one or 
more of these autoantigens.  The percentage positivity depends on a variety of 
factors, including the age of the subjects, the duration of the disease, and in some 
instances their ethnicity.  Assay variability also exists, particularly at the limit of its 
range of detection.  The performance characteristics of the autoantibody assays 
have a critical impact on their predictive value.  Continuous quality control of the 
assays is, therefore, essential (Kulmala et al., 1998).  In general, the presence of 
GAD65 autoantibodies in type 1 diabetic patients is stable.  On the other hand, IA-
2 autoantibodies tend to decrease with duration of disease, and the measurement 
of insulin autoantibodies is of no use after initiation of insulin therapy. 
 
Initially, interest was focused on the presence of autoantibodies at the time of 
diagnosis and during follow-up of patients.  However, it soon became apparent 
that these autoantibodies precede the development of diabetes by many months 
or years (Christie et al., 1997).  The presence of autoantibodies in otherwise 
healthy individuals can be used as a marker to identify those who are at high risk 
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of future development of type 1 diabetes (Mayrhofer et al., 1996).  Expression of 
two or more autoantibodies has a positive predictive value for type 1 diabetes 
greater than 90% among relatives of type 1 diabetics.  A single autoantibody 
carries a lower risk of approximately 20% (reviewed by Devendra and Eisenbarth, 
2003).  Only about 1% of the general population have autoantibodies to GAD65, 
IA-2, or insulin.  Thus the presence of multiple anti-islet autoantibodies will be just 
as predictive in the general population as it is in relatives. 
 
1.9.4.3.  Autoantibodies and latent autoimmune diabetes in adults 
GAD65 and insulin autoantibodies are also found in 5 to 10% of patients classified 
with type 2 diabetes (Tuomi et al., 1999; Pietropaolo et al., 2000).  Initially these 
patients do not require insulin treatment.  However, the β cell mass in these 
patients will typically decline over time and necessitate insulin treatment (Groop et 
al., 1986).  This form of diabetes is often referred to as latent autoimmune 
diabetes in adults (LADA) (Tuomi et al., 1993) or type 1.5 diabetes (Harris and 
Zimmet, 1992).  A subgroup of LADA patients, with clinical characteristics similar 
to those of typical type 1 diabetes, have high titres of GAD65Ab and/or GAD65Ab 
directed towards C-terminal epitopes of GAD.  This group of LADA patients are at 
high risk of becoming insulin dependent.  A second group of LADA individuals are 
characterised by low titres of GAD65Ab, or the exclusive presence of GAD65Ab 
directed to the middle epitopes of the autoantigen.  These patients are almost 
indistinguishable from GAD65Ab-negative type 2 diabetic patients (Falorni and 
Calcinaro, 2002). 
 
1.9.4.4.  Mapping epitopes for autoantibodies to the type 1 diabetes 
autoantigens GAD65, IA-2 and insulin 
Autoantigenic epitope mapping represents a critical issue in autoimmune 
diseases.  The identification of the whole spectrum of autoantibody epitopes 
should further the investigation of the role of these autoantigens in the 
pathogenesis of type 1 diabetes.  While epitope mapping for GAD65Ab and IA-
2Ab has been the focus of many studies using fusion proteins (Hampe et al., 2000; 
Binder et al., 2004) and monoclonal antibodies (Schlosser et al., 1997; Padoa et 
al., 2003), epitope mapping of IAA has been limited to naturally occurring insulin 
analogues.  As a result, their epitopes are not well characterized (Castano et al., 
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1993).  Only recently phage display was used to define idiotypes of insulin 
antibodies (Devendra et al., 2003; Devendra et al., 2004). 
 
Epitopes responsible for IA-2 autoantibody binding are mostly conformational but 
have only been partially defined (Farilla et al., 2002).  GAD65 autoantibodies 
present in the sera of newly diagnosed type 1 diabetic patients have been mapped 
to the middle and C-terminal regions of the GAD molecule.  Human, bovine, and 
porcine insulin have been used to reveal differences in the binding characteristics 
of IAA and antibodies to exogenous administered insulin (IA).  The major binding 
site of IA was located on the A chain, while type 1 diabetes-associated IAA 
recognized a conformational epitope requiring both the A and B chain (Diaz and 
Wilkin, 1987; Wilkin et al., 1988). 
 
Monoclonal antibodies and their Fab are being successfully used in the epitope 
analysis of other autoantibodies in type 1 diabetes (Schlosser et al., 1997; 
Schwartz et al., 1999; Padoa et al., 2003).  This method is particularly useful in the 
study of conformational epitopes since the structure of the antigen remains intact 
(Binder et al., 2004). 
 
1.9.5. Susceptibility 
 
Type 1 diabetes is a heterogeneous and polygenic disorder.  The onset of type 1 
diabetes is attributed to both an inherited risk and external triggers, such as diet or 
an infection.  The search for these risk factors is ongoing (Cox et al., 2001). 
 
1.9.5.1.  Genetic susceptibility 
The concordance for type 1 diabetes is approximately 50% for monozygotic twins 
(Kaprio et al., 1992), and the risk to a first-degree relative is roughly 5%.  The risk 
for offspring when the father has diabetes is about 12% compared to a 6% risk 
when the mother is diabetic (Warram et al., 1984). 
 
About 18 regions of the genome have been linked with influencing type 1 diabetes 
risk.  These regions, each of which may contain several genes, have been labelled 
IDDM1 to IDDM18.  IDDM1 (containing the HLA system) and IDDM2 (containing 
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the insulin gene) were both originally identified using case-control studies.  The 
remaining type 1 diabetes susceptibility loci, IDDM3 to DM18, were mainly 
discovered by genome scan linkage studies (Davies et al., 1994).  The IDDM loci 
are found on several different chromosomes and contain many genes, many of 
which have now been identified (Figure 1.15). 
 
       
 
Figure 1.15:  Location of the different type 1 diabetes susceptibility genes 
(http://www.ncbi.nlm.nih.gov/books/bookres.fcgi/diabetes/pdf_ch2.pdf). 
 
The two major susceptibility regions that have been identified are IDDM1, the 
major histocompatibility complex (MHC) region on chromosome 6p21, and IDDM2, 
the insulin gene region on chromosome 11p15.5. 
 
The best studied is IDDM1, which contains the HLA genes which code for HLA 
class II antigens; complex cell surface glycoproteins found on antigen-presenting 
cells.  The IDDM1 locus contains many diabetes susceptibility genes (Table 1.7). 
 
 
  73
Table 1.7:  Susceptibility loci for type 1 diabetes. 
HLA-DR DQA1 DQB1 DRB1 Susceptibility
DR2 
DR2 
DR2 
DR3 
DR4 
DR4 
DR4 
DR4 
DR4 
DR4 
DR4 
DR4 
DR7 
DR6 
0102 
0102 
0103 
0501 
0301 
0301 
0301 
0301 
0301 
0301 
0301 
0301 
0201 
0101 
0602 
0502 
0601 
0201 
0302 
0302 
0302 
0302 
0302 
0302 
0301 
0301 
0303 
0503 
1501 
1601 
1502 
0301 
0401 
0401 
0402 
0403 
0404 
0405 
0401 
0403 
0701 
1401 
Protective 
Predisposing 
Neutral 
Predisposing 
Predisposing 
Predisposing 
Predisposing 
Neutral 
Neutral 
Neutral 
Neutral 
Neutral 
Positive 
Protective 
Table reproduced from Devendra and Eisenbarth, 2003. 
 
Fine mapping of this locus suggests that the two HLA haplotypes, DR3 and DR4, 
are strongly associated with type 1 diabetes susceptibility (Wolf et al., 1983; Herr 
et al., 2000).  The vast majority (90%) of type 1 diabetics have either DR3,DQ2 
(DQ2 = DQA1*0501, DQB1*0201) or DR4,DQ8 (DQ8 = DQA1*0301, DQB1*0302) 
haplotypes, whereas 40% to 50% of most white populations have one or the other 
of these haplotypes.  Between 30% and 50% of patients with type 1 diabetes are 
heterozygotes with DR3,DQ2/DR4,DQ8 compared with only 2.4% of the general 
population.  The DR3/DR4 haplotype is found more frequently (50%) before the 
age of 5 years in children with diabetes.  This same haplotype is present in less 
than 30% of adults with type 1 diabetes (Rewers et al., 1996; reviewed by 
Devendra and Eisenbarth, 2003). 
 
There are specific DR and DQ alleles which can protect from type 1 diabetes in an 
autosomal dominant manner (Platz et al., 1981; Redondo et al., 2000).  One of the 
protective HLA haplotypes is DQA1*0102, DQB1*0602.  Approximately 20% of the 
American and European populations have this haplotype, whereas these alleles 
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are found in less than 1% of children with type 1 diabetes (reviewed by Gottlieb 
and Eisenbarth, 1998; Redondo et al., 2000).  Once the diabetes disease process 
begins, however, the mechanism that protected these individuals from diabetes is 
lost, suggesting that inheriting these alleles does not prevent diabetes but may 
somehow delay or arrest the progression of the disease (Greenbaum et al., 2000). 
 
The IDDM2 locus accounts for about 10% of the susceptibility toward type 1 
diabetes (Bennett et al., 1995).  This locus maps to a variable number of tandem 
repeat (VNTR) minisatellites upstream of the insulin gene (INS) (Bell et al., 1981; 
Bell et al., 1984; Owerbach and Gabbay, 1993; Pugliese et al., 1997; Cox et al., 
2001).  There are three classes of VNTRs in the insulin gene (Bennett and Todd, 
1996): 
• Class I has alleles that range from 26 to 63 repeat units. 
• Class II has alleles that average around 80 repeat units. 
• Class III has alleles ranging from 141 to 209 repeat units. 
 
The class I VNTRs, ranging in size from 30 to 44 repeats, predominate (70%) in 
Caucasians.  The remaining alleles tend to fall into the class III category.  The 
intermediate lengths (class II) are rare.  The short class I VNTR alleles predispose 
to type 1 diabetes, whereas the longer class III alleles have a dominant protective 
effect (Congia et al., 1998).  The presence of at least one class III allele is 
associated with a three-fold reduction in the risk of developing type 1 diabetes 
(Vafiadis et al., 2001). 
 
1.9.5.2.  Environmental factors 
Candidates for environmental components include viral infections (Rayfield, 1978), 
early introduction of cow's milk in infancy (Virtanen et al., 1993), short duration of 
breast feeding (Virtanen et al., 1992), or nitrites and nitrosamines in the diet 
(Dahlquist et al., 1990, Kostraba et al., 1992b).  Conflicting reports, however, exist 
as to the role of these environmental agents in triggering type 1 diabetes. 
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1.9.6.  Pathogenesis 
 
Type 1 diabetes is caused by the progressive autoimmune destruction of the β 
cells.  Despite numerous studies, the exact mechanism involved in the initiation 
and progression of β cell destruction remains unclear.  Destruction of the β cells is 
believed to be triggered by the presentation of β cell-specific autoantigens by 
macrophages or dendritic cells (antigen-presenting cells) to naïve CD4+ Th0 helper 
cells in conjunction with MHC class II molecules (Figure 1.16).  Activated 
macrophages secrete interleukin (IL)-12 which stimulates CD4+ Th0 cells to 
differentiate into Th1 cells, which in turn secrete interferon (IFN)-γ and IL-2.  
Resting macrophages are activated by IFN-γ and subsequently release other 
cytokines which are toxic to pancreatic β cells (e.g., IL-1β, tumour necrosis factor 
(TNF)-α, and free radicals).  CD8+ precytotoxic T cells migrate to the inflamed 
islets, stimulated by IL-2 and other cytokines.  Upon recognition of β cell-specific 
autoantigen bound to MHC class I molecules, these CD8+ precytotoxic T cells 
differentiate into cytotoxic effector T cells.  These cells cause β-cell damage by 
releasing perforin and granzyme and by Fas-mediated apoptosis.  Continued 
destruction of β cells eventually results in the onset of diabetes (reviewed by 
Kukreja and Maclaren, 1999). 
 
Natural killer T cells can prevent β cell destruction by secreting IL-4 at the 
beginning stages of the differentiation of Th0 cells.  Thus the Th2 type response is 
favoured and Th1 cells are down regulated.  β cell destruction and diabetes are, 
therefore, prevented by the secretion of IL-4 and IL-10 by CD4+ Th2 type cells and 
reduced secretion of IL-2 and IFN-γ (reviewed by Kukreja and Maclaren, 1999; 
Homann and von Herrath, 2004). 
 
The role of β cell autoantibodies in the pathogenesis of type 1 diabetes is not 
understood.  While in the past the autoantibodies have been perceived as a by-
product of the autoimmune destruction of the β cells, recent studies indicate that 
GAD65Ab may be involved in antigen presentation and thus may contribute to the 
pathogenesis of the disease (Reijonen et al., 2000; Banga et al., 2004). 
 
 
  76
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.16:  A schematic description of the roles of various subsets of T cells and  
their cytokines in β cell destruction, leading to diabetes (adapted from 
Kukreja and Maclaren, 1999). 
 
1.9.7.  Prediction of type 1 diabetes 
 
Many reasons prevent the recommendation to test individuals routinely for the 
presence of any of the immune markers outside of a clinical trials setting.  First, 
cut-off values for some of the assays for immune markers have not been 
completely established for clinical settings.  Second, the cost effectiveness of such 
screening is questionable, at least until an effective therapy is available.  Lastly, 
there is no consensus yet as to what action should be taken when a positive 
autoantibody test is obtained as there are no proven measures as to how the 
disease may be delayed or prevented.  Animal models of type 1 diabetes have 
been invaluable for developing prevention methods. 
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1.9.8.  Treatment of type 1 diabetes 
 
Insulin remains the essential therapy for type 1 diabetes.  Therapy has been 
improved by the introduction of long acting human insulin analogues and insulin 
pumps.  Despite such advances, once most β cells have been destroyed, diabetes 
management is difficult, and there are multiple acute and chronic complications. 
 
Pancreatic transplantation, and recently islet transplantation, are possible options 
for selected type 1 diabetes patients with severe complications such as recurrent 
problematic hypoglycaemia.  Both can result in reversal of hyperglycaemia and 
prevent life-threatening hypoglycaemia.  Long-term follow-up of islet transplants is 
lacking, but recent results with the Edmonton protocol (Lakey et al., 1997) indicate 
that with immunosuppression, significant islet function can be achieved for one 
year in more than 80% of patients (Ryan et al., 2002). 
 
A new molecule that may be used in the near future as a treatment for type 1 and 
type 2 diabetes was recently described (Fukuhara et al., 2005).  This 52 kDa 
protein is a cytokine which is secreted by bone marrow, muscle, liver, and 
adipocytes.  This protein has been previously described as a pre-B cell colony-
enhancing factor (PBEF) (Samal et al., 1994).  However, as it is found abundantly 
in visceral fat, Fukuhara et al. (2005) have renamed this molecule visfatin.  
Examination of visfatin’s biological and physiological functions revealed that it 
lowers plasma glucose levels in mice.  The effects seen with visfatin were similar 
to those observed when insulin was used.  Visfatin mimicked the effects of insulin 
in all biochemical pathways/reactions examined.   Visfatin also binds to the insulin 
receptor at a position other than the alpha subunit.  Thus, visfatin can activate the 
insulin receptor independently of insulin.  These findings suggest that visfatin may 
provide a useful alternative therapy for type 1 diabetes (Fukuhara et al., 2005). 
 
1.9.9.  Animal models of diabetes 
 
The utilisation of animal models has made decisive contributions to the study of 
diabetes and related fields.  Much of our current knowledge concerning the 
aetiology, pathogenesis, treatment, and prevention of human diabetes would 
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never have been obtained without the study of animal models of diabetes.  These 
can be categorised as animals with spontaneously developing diabetes (BB rats, 
NOD mice) and as animals with induced diabetes (e.g. by virus).  None of the 
models are perfect, but each has contributed to our present knowledge of the 
disease in some way. 
 
The NOD mouse and BB rat develop diabetes at age 80 to 200, and 60 to 120 
days, respectively.  In the NOD mouse, the incidence of diabetes in the male is 
only 10% to 50%.  The onset of diabetes is characterised by the appearance of the 
classic symptoms observed in humans: hypoinsulinaemia, hyperglycaemia, 
glycosuria, ketonuria, and polyuria.  Both models develop insulitis before the 
clinical onset of the disease.  In addition, BB rats develop lymphocytopenia 
(Poussier et al., 1983).  In the BB rat, islet cell antibodies can be detected up to 
two weeks before the onset of the disease (Dyrberg et al., 1984).  NOD mice also 
display islet cell antibodies as well as islet cell surface antibodies with a peak after 
age 6 months.  Insulin autoantibodies are present in about 80% of the mice after 3 
months of age (Reddy et al., 1988).  GAD antibodies and GAD-reactive T-cells 
have been reported in BB rats, as well as in NOD mice. 
 
Insulin, GAD65 and the heat shock protein 65 are just a few of the autoantigens 
believed to initiate β cell destruction (reviewed by Roep, 1996).  Of these, GAD65 
and insulin have been studied the most, both in animal models and man.  
Prophylactic treatment with these β cell antigens has been used to specifically 
modify T-cell autoimmunity and diabetes development in experimental models of 
type 1 diabetes. 
 
Administration of monoclonal antibodies to GAD65 has been reported to inhibit the 
progression of type 1 diabetes in the NOD mouse (Menard et al., 1999).  The 
authors hypothesise that the T cells do not recognise GAD65 as it is bound by the 
mAb and thus initiation of β cell destruction is inhibited.  The administration of 
insulin by subcutaneous injection (Atkinson et al., 1990) or oral administration 
(Zhang et al., 1991) has similarly been shown to prevent diabetes development in 
the NOD mouse and the diabetes-prone BB (DP-BB) rat (Gotfredsen et al., 1985). 
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Using intramuscular DNA vaccination for antigen administration, Karges et al. 
(2002) have shown that preproinsulin (ppIns) can adversely trigger autoimmune 
diabetes in the NOD and RIP-B7.1 mouse models of type 1 diabetes.  Diabetes 
development was enhanced after ppIns DNA treatment in female NOD mice, and 
natural diabetes resistance in male NOD mice was diminished.  In RIP-B7.1 mice, 
diabetes occurred in 70% of animals after ppIns vaccination.  Following GAD65 
treatment, however, spontaneous development of diabetes was not observed.  
Diabetes was characterised by diffuse CD4+ and CD8+ T-cell infiltration of 
pancreatic islets and severe insulin deficiency.  ppIns, proinsulin, and insulin DNA 
were equally effective at inducing the disease (Karges et al., 2002). 
 
Based on the results found for the animal models these experiments were 
extrapolated to humans.  A very large trial, the Diabetes Prevention Trail 1, was 
carried out using oral insulin as a therapeutic agent in relatives of type 1 diabetic 
patients.  The administration of oral insulin to these subjects did not delay or 
prevent type 1 diabetes (Pozzilli, 2002). 
 
1.10.  TYPE 2 DIABETES MELLITUS 
 
Type 2 diabetes (previously known as Non-Insulin Dependent Diabetes Mellitus 
[NIDDM], type II diabetes, or adult-onset diabetes) is characterized by insulin 
resistance in peripheral tissue and an insulin secretory defect of the β cells 
(Reaven et al., 1976; Turner et al, 1979).  Insulin resistance and 
hyperinsulinaemia eventually lead to impaired glucose tolerance.  Defective β cells 
become exhausted, further fuelling the cycle of glucose intolerance and 
hyperglycaemia. 
 
This is the most common form of diabetes mellitus, accounting for approximately 
90% of all diabetic people.  Type 2 diabetes tends to develop very slowly over a 
period of years and may go unnoticed.  If symptoms are present they are usually 
relatively mild.  Nevertheless, such patients are at increased risk of developing 
macrovascular and microvascular complications.  The majority of type 2 patients 
are obese, which itself causes some degree of insulin resistance.  Many of those 
who are not obese by traditional weight criteria may have an increased percentage 
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of body fat distributed predominantly in the abdominal region (Coon et al., 1992; 
Kohrt et al., 1993). 
 
Type 2 diabetes mellitus is multifactorial disease.  It is often associated with a 
strong genetic predisposition; however, the genetics of this form of diabetes are 
complex and not clearly defined.  Little is known about specific diabetogenic 
genes, other than the fact that the concordance rate among monozygotic twins is 
high (33 to 76%; 5 to 15 year follow up) (Medici et al., 1999).  There is also a 
convincing behavioural component. 
 
1.10.1.  The epidemiology of type 2 diabetes 
 
The prevalence of type 2 diabetes (between 5 and 7%) is now at epidemic 
proportions and the number of new cases being diagnosed continues to rise.  In 
1990, 4.9% of the American population were diagnosed with diabetes.  This 
increased to 7.9% by the year 2001 (Mokdad et al., 2001).  It has been estimated 
that of the children born in the year 2000, a third will suffer from diabetes at some 
point in their lifetime (Narayan et al., 2003).  Diabetes is predicted to become one 
of the most common diseases in the world within a couple of decades, affecting at 
least half a billion people (King et al., 1998). 
 
In the past, type 2 was rarely seen in young individuals, hence its original name of 
‘adult-onset diabetes’.  Today, however, type 2 diabetes is increasingly being 
diagnosed in young adults and even in children.  This young generation of 
diabetics will have many decades in which to develop the complications of the 
disease.  The driving force behind the high prevalence of diabetes is the rise of 
obesity in the population.  In today's society, the combination of ample food and a 
sedentary lifestyle, make it difficult to maintain a healthy weight. 
 
1.10.2.  Risk Factors for type 2 Diabetes 
 
In their revised criteria the ADA (2005a) suggested that adults aged 45 years and 
older be tested for diabetes.  If their blood glucose is normal at the first test, they 
should be tested at 3 year intervals.  Individuals younger than 45 years of age 
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should be tested if they are at high risk for diabetes. These high-risk factors 
include: 
• Obesity, being more than 20% above ideal body weight or having a body mass 
index ≥ 27 kg/m2.  Insulin resistance increases with body weight. 
• Having a first degree relative with diabetes. 
• Race, a number of populations are at increased risk of type 2 diabetes, 
including Hispanics, Native Americans, people of Asian or African-Caribbean 
descent, people of Aboriginal descent and Pacific Islander groups. 
• Age, nearly all people diagnosed with type 2 diabetes are over 30 years old.  
Half of all new cases are aged 55 and older. 
• High-fat diet - a key cause of obesity. 
• Sedentary lifestyle.  Insulin resistance increases with lack of exercise. 
• Women who have had gestational diabetes.  Previous gestational diabetes 
increases risk of type 2 diabetes developing later on in life. 
• Giving birth to a baby weighing more than 4 kg. 
• Having blood pressure at or above 140/90 mmHg. 
• Having abnormal blood lipid levels, such as high density lipoprotein cholesterol 
less than or equal to 35 mg/dL (0.90 mmol/L) or triglycerides greater than or 
equal to 250 mg/dL (2.82 mmol/L). 
• Having abnormal glucose tolerance when previously tested for diabetes. 
 
As many as 2.7% of the general adult population have undiagnosed type 2 
diabetes (Harris et al., 1987).  Undiagnosed diabetes is a serious condition as 
there is epidemiological evidence that complications arise many years before the 
clinical diagnosis of type 2 diabetes is made (Harris, 1993).  These individuals are 
at significantly increased risk for coronary heart disease, stroke, and peripheral 
vascular disease.  In addition, they have a greater likelihood of having 
dyslipidaemia, hypertension, and obesity (Klein, 1995). 
 
Thus, early detection and consequently early treatment might well reduce the 
burden of type 2 diabetes and its complications.  Although the relatively low 
prevalence of diabetes in the general population makes it unlikely that mass 
screening will be cost effective, testing for diabetes in people with risk factors for 
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type 2 diabetes or with diabetes-associated conditions is likely to result in more 
benefit than harm and will lead to overall cost savings. 
 
1.10.3.  Prevention strategies for type 2 diabetes 
 
Primary approaches to preventing diabetes in a population include programmes 
targeting high-risk individuals in the community (such as those with IGT or 
obesity), high-risk ethnic groups and programmes designed to promote physical 
activity and healthy eating in adults or children (Simmons et al., 1997; Daniel et al., 
1999). 
 
1.10.4.  Treatment of type 2 diabetes 
 
The first line of attack for people who have diabetes and are overweight is usually 
dietary control and a weight loss programme.  Physical activity and weight loss 
makes the body’s cells more responsive to insulin.  Most people are therefore 
treated by diet and exercise when newly diagnosed.  Dietary modification that 
targeted a low calorie diet with reduced fat intake and moderate intensity physical 
activity of at least 150 minutes/week resulted in the risk for diabetes being reduced 
by 58% at 4 years (Tuomilehto et al., 2001; Knowler et al., 2002).  If the diet and 
exercise approach is unsuccessful then there are a number of oral medications 
that can be used to help treat the hyperglycaemia in type 2 diabetes; but it is 
seldom restored to normal.  These either increase the production of insulin or help 
the body to use the insulin more effectively.  A study using metformin significantly 
decreased progression to diabetes by 31% (Knowler et al., 2002; The Diabetes 
Prevention Program Research Group, 2003).  Similarly, a study using acarbose, 
reduced the risk of progression to type 2 diabetes by 30% (Chiasson et al., 2002).  
The right combination of diet, exercise, and adequate medication when needed is 
the key to effective management of type 2 diabetes. 
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1.11.  AIMS OF THE STUDY 
 
Autoantibodies to GAD65 are accepted markers for type 1 diabetes and, together 
with IAA and IA-2, predict the disease.  IAA are often the first autoantibodies 
detected in type 1 diabetics and can be present before the onset of clinical 
diabetes.  These autoantibodies and their epitopes are however not well 
characterized.  We explored the use of monoclonal antibodies and their rFab as 
reagents for epitope analysis.  The reason for generating rFabs is that their 
smaller size, in comparison to the whole mAb, prevents steric hinderance.  The 
study of antibody epitopes is, therefore, enhanced by the use of rFabs as opposed 
to mAbs. 
 
The identification of type 1 diabetes-associated insulin and GAD65 autoantibody 
epitopes is important as this will provide us with a better understanding of the 
pathogenic involvement of these autoantibodies in the disease progression and 
also, how best to block insulin and GAD65 autoantibody binding as a possible 
treatment method.  Approximately 17 million people worldwide have type 1 
diabetes and this number is increasing.  Type 1 diabetes is a serious, debilitating 
disease with life threatening complications.  The financial burden associated with 
the management of this disease is enormous.  Early diagnosis and intervention 
can, therefore, improve the morbidity and mortality. 
 
i. To produce a gene construct containing the light chain and Fd heavy chain 
fragment of insulin and GAD65 binding monoclonal antibodies (mAbs). 
ii. To clone the constructs into an expression vector. 
iii. To test the expression products for their ability to bind insulin and GAD65. 
iv. Map the epitope to which the Fab binds to on insulin by 3D computer modelling 
and competition assays with anti-insulin mAbs that have defined epitopes. 
v. To analyse insulin and GAD epitopes recognized by autoantibodies present in 
the sera of newly diagnosed type 1 and type 1.5 diabetic patients. 
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CHAPTER 2 
 
2.  SUBJECTS AND METHODS 
 
All reagents, suppliers, and solutions used are listed in Appendix 1. 
 
2.1.  SUBJECTS 
 
2.1.1.  Subjects used in the study of insulin rFabs 
 
Newly diagnosed IAA-positive type 1 diabetes patients (n=16) (median age: 9 
years, range: 1 - 15 years; 10 female) were part of a study conducted at the St. 
Görans Children Hospital, Stockholm, Sweden.  The serum samples were 
obtained at the clinical diagnosis of diabetes.  The second set of newly diagnosed 
type 1 diabetes patients (n=21) (median age: 22 years, range: 15 - 34 years, 5 
female) used in this study were registered in 1992 to 1993 in the Diabetes 
Incidence Study in Sweden (DISS) and were previously identified to be IAA-
positive. 
 
Newly diagnosed type 1.5 diabetes patients (LADA) (n= 14) (median age: 42 
years, range: 24 - 61 years, 6 female) were part of a screening programme in the 
greater Seattle area.  The patients were classified with type 2 diabetes according 
to the 1997 American Diabetes Association criteria and were previously identified 
to be IAA-positive.  The majority of patients (86%; 12/14) were GAD65Ab positive.  
All patients had been diagnosed with diabetes within 12 months of blood sampling.  
Characteristics of type 1.5 diabetes include: 
• Adult age at diagnosis (usually over 25 years of age). 
• Initial presentation masquerades as non-obese type 2 diabetes (insulin 
resistant; does not present as diabetic ketoacidosis). 
• Initially can be controlled with diet with or without medication (not insulin). 
• Insulin dependency gradually occurs, frequently within months. 
• Autoantibody positivity, especially to GAD65. 
• Low C-peptide levels. 
  85
• Unlikely to have a family history of type 2 diabetes (Pozzilli and Di Mario, 
2001; Schernthaner et al., 2001). 
 
None of the patients had been on insulin therapy prior to sampling. 
 
2.1.1.  Subjects used in the study of GAD65 rFabs 
 
Newly diagnosed GAD65Ab-positive type 1 diabetes patients (n=61) (mean age: 
10 years, range: 0 - 16 years; 33 female) were part of a study conducted at the St. 
Görans Children Hospital, Sweden and represented 80% of all children diagnosed 
in Stockholm during 1993 - 1995.  The serum samples of all diabetes patients 
were obtained at the clinical diagnosis of diabetes. 
 
Healthy GAD65Ab-positive first-degree relatives of type 1 diabetes patients (n=38) 
(mean age: 46 years, range: 8 - 74 years) were identified by screening first degree 
relatives in families identified in the Diabetes Incidence Study in Sweden (DISS) 
and the Swedish Childhood Diabetes registry.  None of the GAD65Ab-positive 
first-degree relatives developed diabetes within 2 to 12 years of blood sampling. 
 
Type 1.5 diabetes patients (n=44) (mean age: 51 years, range: 31 - 77 years, 16 
female) were part of a screening programme in the greater Seattle area.  The 
patients were initially classified with type 2 diabetes according to the 1997 ADA 
criteria and were previously identified to be GAD65Ab-positive (Hampe et al., 
2002).  All patients had been diagnosed with diabetes within 12 months of blood 
sampling. 
 
Healthy individuals (n=14) (mean age: 50 years, range: 30 - 60 years, 9 female) 
with a GAD65Ab index above the cut-off index (0.05, using the 98th percentile) were 
detected in a population-based screen of 2157 Swedish adults (Rolandsson et al., 
1999).  None of the GAD65Ab-positive healthy individuals developed type 1 
diabetes within eight years of sample collection (Rolandsson et al., 2001). 
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All subjects in this study, their parents or legal guardians, gave informed consent.  
Local institutional ethics committee approval was obtained prior to collection of all 
serum samples. 
 
2.2.  HYBRIDOMAS 
 
Four hybridoma cell lines that secreted anti-insulin monoclonal antibodies were 
used in this study.  Three of these (HB-123, HB-126, HB-127) were purchased 
from the American Type Culture Collection (ATCC).  A single article (Schroer et 
al., 1993), in which epitope mapping had been performed, was cited when a 
literature search was performed for insulin-specific hybridomas.  From the list of 18 
mAbs in this publication, six were available from the ATCC.  We chose three 
(listed above) for our study.  The fourth hybridoma cell line, termed IE2, was a kind 
gift from Nick Hales, Department of Clinical Biochemistry at the University of 
Cambridge, United Kingdom.  These four monoclonal antibodies belonged to the 
IgG1 heavy chain group and the kappa light chain group.  The fifth mAb used in 
this study, which binds to GAD65, was isolated from a GAD65 autoantibody 
positive type 1 diabetes patient using combined EBV transformation with CD40 
activation of peripheral B cells (Madec et al., 1996).  This monoclonal antibody 
was termed DP-D and binds to a conformational epitope located at the N-terminus 
of GAD65 (Schwartz et al., 1999).  Monoclonal antibody N-GAD65 was raised to a 
peptide representing amino acid residues 4 to 22 of GAD65, and was used as a 
negative control (Hampe et al., 2001) 
 
The three ATCC hybridoma cell lines were produced by the fusion of BALB/c 12 – 
14 day primary immune lymph node cells with Sp2/0-Ag14 myeloma cells (Schroer 
et al., 1993) whereas the 1E2 hybridoma was produced by the fusion of murine 
spleen cells with NS0 myeloma cells (Crowther et al., 1994). 
 
Two mAbs were used for epitope analysis: mAb 125 (Schroer et al., 1983) which 
recognizes an epitope located at the A chain loop (residues A8 - A10) of insulin, 
and mAb1 (BIØDESIGN, Saco, ME) which binds to the B chain with special 
dependency on amino acid B30. 
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2.2.1.  Growing hybridomas 
 
2.2.1.1.  Tissue culture 
The hybridoma cell lines were shipped frozen in 1 ml aliquots.  The cells were 
thawed in a 37°C water bath.  When almost thawed, the tube was wiped with 70% 
ethanol, and taken to the tissue culture hood.  The cells were transferred to a      
15 ml Nunc tube containing 10 ml Dulbecco’s modified Eagle’s (DME) medium 
with 4.5 g/l glucose which had been supplemented with fetal calf serum (FCS) to a 
final concentration of 10%. 
 
The cells were centrifuged for 5 minutes at 140 x g and the supernatant carefully 
decanted so as not to dislodge the pellet.  The cell pellet was resuspended in 2 ml 
of DMEM and transferred to a single well of a 6-well plate.  Cells were cultured at 
37°C in 5% atmospheric CO2.  Fresh medium was added to the wells two days 
later.  A further two days later, depending on the growth of the cells, the cells were 
transferred to a 50 ml flask and grown in 5 ml of medium until confluent. 
 
2.2.1.2.  Subculturing hybridomas 
The average doubling time of hybridomas usually depends on the myeloma fusion 
partner and will be between 12 and 24 hours.  Therefore, most hybridomas will 
need to be subcultured every 2 to 4 days, depending on the dilution used in the 
previous passage.  Fresh medium was added to the hybridomas when the 
concentration of cells reached approximately 106 cells/ml.  Hybridomas do not 
secrete any noticeably toxic by-products, so the medium was replenished by 
diluting (1:10 or 1:20) growing cultures with fresh medium.  Hybridoma cell lines 
that adhered lightly to the plastic surface were loosened by washing the plastic 
with a strong stream of medium from a pipette or by gently tapping the base of the 
flask.  The flasks were examined under the microscope to ensure that all the cells 
had been removed.  Once cells were confluent, mRNA was extracted. 
 
2.2.1.3.  Hybridoma cell line monoclonal antibody secreting test 
PEG precipitation (Simionescu et al., 1979) of monoclonal antibodies was 
performed to ensure that the cells were secreting the desired antibody. 
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Tissue culture supernatants of confluent hybridoma cell lines were collected and 
tested for the presence of the desired antibody.  Debris was removed from the 
supernatant by centrifugation at 1 000 x g for 10 minutes.  For the detection of 
insulin mAbs, 100 µl of 125I-labelled insulin (specific activity: > 15 Ci/mg Iodide;    
20 000 cpm/10 µl) was incubated with either: 
i. 100 µl of supernatant from hybridomas 
ii. 100 µl of supernatant from hybridomas that has been diluted 10-fold 
iii. 100 µl of unused DMEM (this serves as a negative control). 
 
Samples, set up in duplicate, were incubated for at least 2 hours at room 
temperature followed by the addition of 1 ml of 25% PEG solution to precipitate the 
antibody-antigen complexes.  Samples were spun for 10 minutes at 2 000 x g, the 
supernatant removed and the pellet counted on a γ-counter (Innotron hydragamma 
16).  The higher the counts obtained, the higher the concentration of anti-insulin 
antibodies present in the medium (Table 2.1). 
 
Table 2.1:  The relationship between number of counts and monoclonal antibody  
concentration. 
CELL LINE SUPERNATANT COUNTS (10 seconds) 
DMEM  
- unused medium; negative control 1 154 
NS0:  
- undiluted 1 105 
- 10x dilution 1 043 
1E2:  
- undiluted 20 369 
- 10x dilution 17 153 
- 160x dilution 10 835 
 
2.2.2.  Long term storage of cell lines 
 
Hybridoma cell lines were stored by freezing cells in an appropriate solution of 
nutrients and a cryoprotectant such as dimethylsulfoxide (DMSO). 
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2.2.2.1.  Freezing cells for liquid nitrogen storage 
Rapidly dividing cells were gently loosened from the surface of the flask, 
transferred to a sterile 15 ml Nunc tube and spun at 400 x g for 5 minutes at 4°C.  
The supernatant was discarded and the pellet resuspended in 10% DMSO/90% 
FCS.  The final cell concentration was approximately 5 x 106 - 5 x 107 cells/ml.  
The cell suspension was aliquoted into cryogen tubes (1 ml per tube).  Vials were 
placed in a freezing rack at -70°C overnight.  It is important to work as quickly as 
possible as prolonged exposure to DMSO at these concentrations is toxic to the 
cells.  The following day the vials were transferred to LN2.  Cells stored in LN2 
should be checked for viability once a year.  If the viability has dropped 
significantly (< 50%), the cells should be expanded, checked for continued 
antibody production, and refrozen. 
 
2.2.2.2.  Viability checks 
To determine the percentage of viable cells within a population, the cell 
suspension is mixed with a vital dye and observed under the microscope.  Vital 
dyes are excluded from living cells but stain dead cells.  The most common dye 
used for these stains is trypan blue. 
 
To check cell viability, the cell suspension was mixed with 0.25% (w/v) solution of 
trypan blue (1:1).  To obtain a general impression of the viability of the cells, a 
drop was placed on a slide and observed under the microscope.  For an exact 
percentage, the mixture can be transferred to a Neubauer counting chamber and 
the number of viable cells present in a given area counted.  The formula below is 
used to calculate the number of viable cells present per millilitre of supernatant. 
 
      Total number of viable cells 
      Number of squares counted 
 
 
2.2.2.3.  Counting hybridoma cells 
For most purposes the number of hybridoma cells can be estimated simply by 
observing the cells under the microscope.  When an exact cell count is needed, 
the number can be determined using a Neubauer haemocytometer.  This is a 
x   2   x   104   =   number of viable cells/ml 
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1mm 
corner 
simple device in which a special coverslip rests on supports that hold it 0.1 mm 
above the base of the slide.  The slide is engraved with a series of lines that form 
a 1 x 1 mm square.  By counting the number of cells within the 0.1 mm3 chamber 
formed by the 1 x 1 mm square and the height of the coverslip, an accurate 
quantitation of cells per millilitre can be calculated (see Figure 2.1). 
 
                     Total number of cells 
      Number of squares counted 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1:  Diagrammatic representation of a Neubauer haemocytometer. 
 
2.2.3.  Single-cell cloning by limiting dilution 
 
Cloning hybridoma cells by limiting dilution is the easiest of the single-cell cloning 
techniques.  Even though every attempt is made to ensure that the cells are in a 
single-cell suspension prior to plating, there is no way to guarantee that the 
colonies do not arise from two cells that were stuck together.  Therefore, limiting 
dilution cloning should be done at least twice to generate a clonal population. 
 
Medium (100 µl) containing 20% FCS was aliquoted into each well of a 96-well 
plate.  An aliquot (100 µl) of the rapidly growing hybridoma cell suspension was 
transferred to the top left-hand well and mixed.  Dilutions (1 in 2) were performed 
down the left-hand row of the plate (8 wells, 7 dilution steps) followed by 1 in 2 
x   104   =   number of cells/ml 
Middle 
square 
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doubling dilutions across the plate.  Clones were visible by microscopy after a few 
days and were ready to screen after 7 to 10 days.  The wells were scored by 
microscopy.  There was a line running on a 45° diagonal that contained 
approximately the same number of clones per well.  Wells with only one or two 
clones were screened.  The best wells were selected and the clones grown up. 
 
2.3.  RNA ISOLATION 
 
To protect from RNase contamination, nondisposable glassware or plasticware 
must be RNase-free.  Glassware can be washed with DEPC-water and then 
autoclaved for 20 minutes.  Plastic items can be soaked for 10 minutes in 0.5 M 
NaOH, rinsed thoroughly with water, and autoclaved.  Wipe down all work 
surfaces, pipettes, and racks with RNase Zap (Qiagen). 
 
2.3.1.  Total RNA extraction 
 
Total RNA was extracted from confluent cells using RNeasy Kits (Qiagen) based 
on the absorption of total RNA to a silica gel membrane. 
 
2.3.1.1.  The RNeasy principle and procedure 
A specialised high-salt buffer system allows up to 100 µg of RNA, longer than 200 
bases, to bind to the RNeasy silica gel membrane.  Biological samples are first 
lysed and homogenised in the presence of a highly denaturing guanidine 
isothiocyanate (GITC)-containing buffer, which immediately inactivates RNases to 
ensure isolation of intact RNA.  Ethanol is added to provide appropriate binding 
conditions, and the sample is then applied to an RNeasy mini column where the 
total RNA binds to the membrane and contaminants are effectively washed away.  
High-quality RNA is eluted in water. 
 
2.3.1.2.  The total RNA isolation protocol 
Hybridoma cells (≤ 1 x 107 cells) were centrifuged for 5 minutes at 300 x g in a    
15 ml Nunc tube.  All centrifugation steps are performed at 20 to 25°C in a 
standard microcentrifuge.  The supernatant was discarded and the cell pellet lysed 
by the addition of the appropriate volume of buffer RLT (Table 2.2). 
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Table 2.2:  Volume of buffer RLT required for cell lysis. 
Number of pelleted cells Buffer RLT (µl) 
< 5 x 106 350 
5 x 106 - 1 x 107 600 
 
The sample was homogenised by passing it through a 20-gauge needle (0.9 mm 
diameter) at least 5 times.  One volume of 70% ethanol was added to the 
homogenised lysate and mixed.  A maximum of 700 µl of the sample was applied 
to an RNeasy mini column placed in a 2 ml collection tube.  Samples were 
centrifuged for 15s at ≥ 8 000 x g and the flow-through discarded.  If the volume 
exceeded 700 µl, aliquots were loaded successively onto the RNeasy column and 
centrifuged as above.  The column was washed by the addition of 700 µl buffer 
RW1 and centrifuged for 15s at ≥ 8 000 x g.  The column was transferred to a new 
2 ml collection tube and 500 µl buffer RPE pipetted onto the column.  Samples 
were centrifuged for 15s at ≥ 8 000 x g and the flow-through discarded.  A further 
500 µl buffer RPE was added to the column followed by a 2 minute spin at ≥ 8 000 
x g to dry the RNase silica gel membrane.  To eliminate any chance of possible 
buffer RPE carryover, columns were placed into a new 2 ml collection tube and 
centrifuged at full speed for 1 minute.  Total RNA was eluted in 30 to 50 µl RNase-
free water by centrifuging the column for 1 minute at ≥ 8 000 x g.  To obtain a 
higher total RNA concentration, the second elution step was performed using the 
first eluate. 
 
2.3.1.3.  Determining the total RNA concentration 
The concentration of the eluted RNA was determined by measuring the 
absorbance at 260 nm in a spectrophotometer.  An absorbance of one unit at 260 
nm corresponds to 40 µg of RNA per ml (Sambrook et al., 1989).  Once the total 
RNA concentration was calculated, the samples were used immediately for mRNA 
extraction. 
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2.3.2.  mRNA extraction 
 
2.3.2.1.  The Oligotex principle 
The Oligotex procedure for isolation, purification, and manipulation of poly A+ RNA 
takes advantage of the fact that most eukaryotic mRNAs end in a poly-A tail of 20 
to 250 adenosine nucleotides.  In contrast, rRNAs and tRNAs, which account for 
over 95% of cellular RNAs, are not polyadenylated.  The poly-A tail thus provides 
a useful tool for separation and selective isolation of eukaryotic mRNAs.  Poly A+ 
mRNA can be purified by hybridising the poly-A tail to a dT oligomer coupled to a 
solid-phase matrix.  rRNA and tRNA species do not bind to the oligo-dT column 
and are washed away.  Since hybridisation requires high-salt conditions, the poly 
A+ mRNA can be released by lowering the ionic strength and destabilising the 
dT:A hybrids. 
 
2.3.2.2.  The Oligotex mRNA spin-column protocol 
Isolation of mRNA was carried out using Oligotex mRNA spin-columns (Qiagen) 
according to the manufacturer’s instructions.  Unless otherwise indicated, all steps, 
including centrifugation, were performed at room temperature (20 to 30°C).  All 
centrifugation steps were performed in a microcentrifuge at maximum speed      
(14 000 to 18 000 x g). 
 
The volume of total RNA was adjusted with RNase-free water according to its 
starting concentration (Table 2.3). 
 
Table 2.3:  Buffer amounts for Oligotex mRNA spin-column protocol. 
Total RNA 
concentration 
RNase-free water 
(µl) 
Buffer OBB 
(µl) 
Oligotex 
suspension (µl) 
≤ 0.25 mg 250 250 15 
0.25 - 0.50 mg 500 500 30 
0.50 - 0.75 mg 500 500 45 
0.75 - 1.00 mg 500 500 55 
 
The appropriate volume of buffer OBB (Binding buffer) and Oligotex suspension 
(37°C) (Table 2.3) was added and the samples incubated for 3 minutes in a 70°C 
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heating block to disrupt the secondary structure of the RNA.  Hybridisation 
between the oligo dT30 of the Oligotex particle and the poly-A tail of the mRNA 
occurred in the subsequent 10 minute incubation at room temperature.  The 
Oligotex:mRNA complex was pelleted by centrifugation for 2 minutes at maximum 
speed.  The pellet was resuspended in 400 µl buffer OW2 (wash buffer) and 
transferred onto a spin column.  Columns were spun for a minute, a further 400 µl 
buffer OW2 applied and the columns centrifuged for 1 minute.  Hot (70°C) buffer 
OEB (elution buffer) (20 to 100 µl) was pipetted onto the column and the resin 
resuspended by pipetting up and down three or four times.  Columns were 
centrifuged for 1 minute.  To keep the elution volume low, the first eluate (heated 
to 70°C) was used for the second elution. 
 
The isolated mRNA samples were analysed on a 1% agarose gel and visualised 
on a transilluminator under UV light.  The mRNA samples were subsequently 
stored at -70°C or used immediately to synthesise cDNA for construction of the 
antibody fragments. 
 
2.4.  CONSTRUCTION OF A scFv FRAGMENT 
 
The construction of a scFv polypeptide involves the amplification of the heavy and 
light chain variable regions (VH and VL) of an antibody.  The carboxyl terminus of 
the VL is then linked by a 15 amino acid peptide (Gly4Ser)3 to the amino terminus 
of the VH fragment, or vice versa. 
 
2.4.1.  The polymerase chain reaction 
 
In this study, PCR reactions were carried out in the Perkin Elmer Gene Amp 2400 
PCR System and the PTC-200 DNA Engine thermal cycler. 
 
2.4.1.1.  cDNA synthesis 
mRNA was extracted from the 1E2 anti-insulin secreting hybridoma cell line and 
from the NS0 cell line.  NS0 was used as the fusion partner to produce the 1E2 
hybridoma.  First strand cDNA synthesis was carried out in a 50 µl reaction 
mixture containing 5 µg mRNA, 2 x Reverse Transcriptase (RT) buffer, 0.5 mM 
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dNTP, 0.4 pmol VH1FOR-2 (heavy chain primer) or an equimolar mix of VKFOR1, 
2, 3, and 4 (light chain primers) (Orlandi et al., 1989; Clackson et al., 1991; Table 
2.4).  Samples were incubated for 5 minutes at 67°C and cooled for 15 minutes at 
room temperature.  RNase inhibitor (40 U/µl) and Avian Myoblastosis Virus (AMV) 
RT (15 U/µl) were added and the reaction allowed to continue for 1 hour at 42°C.  
The reaction was terminated with a 3 minute incubation at 100°C.  Samples were 
immediately quenched on ice and stored at -20°C until needed. 
 
Table 2.4:  Primers used for amplification of the VH and VL domains of the anti- 
insulin monoclonal antibody 1E2. 
NAME SEQUENCE (5’ to 3’) LENGTH (bp) 
HEAVY CHAIN PRIMERS: 
VH1BACK AGGTSMARCTGCAGSAGTCWGG 22 
VH1FOR-2 TGAGGAGACGGTGACCGTGGTCCC 24 
LIGHT CHAIN PRIMERS: 
VK2BACK GACATTGAGCTCACCCAGTCTCCA 24 
VKFOR1 CCGTTTGATTTCCAGCTTGGTGCC 24 
VKFOR2 CCGTTTTATTTCCAGCTTGGTCCC 24 
VKFOR3 CCGTTTTATTTCCAACTTTGTCCC 24 
VKFOR4 CCGTTTCAGCTCCAGCTTGGTCCC 24 
S = C or G, M = A or C, R = A or G, and W = A or T 
 
2.4.1.2.  Amplification of the VH and VL domains 
PCR was performed for both immunoglobulin heavy and light chain variable region 
genes using cDNA as a template and oligonucleotide primers listed in Table 2.4 
(Orlandi et al., 1989; Clackson et al., 1991).  PCR was performed on cDNA 
derived from both the 1E2 and the NS0 cell line.  PCR reactions were carried out 
in a final volume of 50 µl.  Separate reactions were set up for the heavy and light 
chain PCR products.  Control reactions were included for each primer pair used in 
the PCR reaction.  The PCR reaction was made up of 5 µl cDNA, 1 x buffer, 1 x Q 
solution, 0.25 mM dNTP, 0.2 pmol forward primer (equimolar mix of light chain 
primers VKFOR1, 2, 3, and 4 or VH1FOR-2), 0.2 pmol reverse primer, 0.5 µl BSA 
(bovine serum albumin), and 5U HotStar Taq polymerase. 
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The samples were initially denatured for 15 minutes at 94°C followed by 30 cycles 
of denaturation at 94°C for 1 minute, annealing at 63°C for 1 minute and extension 
at 72°C for 2 minutes. 
 
Following the final amplification cycle, a 10 µl aliquot of the PCR product was 
mixed with 5 µl of ficoll loading dye and the samples run on a 2% agarose gel.  
Samples were run for 45 minutes at 120 V.  PCR products of approximately 350 
bp and 300 bp are expected for the heavy and light chain fragment, respectively. 
The PCR products obtained were purified and sequenced on an ABI 377 DNA 
sequencer using the forward and reverse scFv primers (Table 2.4). 
 
2.4.1.3.  Linking of the VH and VL domains to form a scFv polypeptide 
We attempted to link the 1E2 VH and VL PCR products together with the (Gly4Ser)3 
linker using single overlap extension based PCR.  We were unable to link the two 
PCR fragments together to form a scFv.  Therefore, to overcome this problem, we 
decided to amplify the light chain and Fd fragment of the heavy chain (to form a 
Fab fragment) of our monoclonal antibodies. 
 
2.5.  CONSTRUCTION OF A FAB FRAGMENT 
 
2.5.1.  cDNA synthesis 
 
First strand cDNA synthesis was carried out in a final volume of 20 µl containing 1 
to 500 ng of mRNA, 2 µl hexanucleotide, and 0.5 mM dNTP.  Samples were 
incubated at 65°C for 5 minutes before adding 0.5 x RT buffer, 10 mM DTT and  
40 U RNase inhibitor.  Samples were incubated at 37°C for 2 minutes.  200 U of 
Moloney Murine Leukaemia Virus (M-MuLV) RT (Invitrogen) was added and the 
reaction allowed to continue for 50 minutes at 37°C followed by 15 minutes at 
70°C to allow for completion of all products.  cDNA was synthesised for all five 
mAbs. 
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2.5.2.  Amplification of the Fd heavy chain fragment and light chain genes of 
the five monoclonal antibodies 
 
PCR amplification was performed for both the Fd heavy chain fragment and light 
chain genes using the newly synthesised cDNA as a template.  The PCR reaction 
was carried out in a 50 µl volume consisting of 2 µl of cDNA, 0.5 mM forward 
primer and 0.5 mM reverse primer (Table 2.5; primer pairs 1-10 were set up in 
separate reactions), 0.25 mM dNTPs, 2.5 mM MgCl2, 1 x Taq DNA polymerase 
buffer and 1 U Taq DNA polymerase (Qiagen).  A negative control was set up for 
each primer pair. 
 
The VHCH1 fragment is amplified with primers representing the leader sequence 5 
to 8 amino acids 5' of the VH framework 1 region and amino acids 205 to 220 of 
the CH1 region. The VLCL construct is created with primers representing the leader 
sequence 5 to 8 amino acids 5' of the VL framework 1 region and amino acids 205 
to 220 of the CL region (Padoa et al., 2003).  The size of the amplified PCR 
product is 660bp.  The primers were developed to represent all mouse families.  
Although some primers may amplify genes in more than one family, the large 
number of primers is necessary to guarantee that all known families are 
represented. 
 
The samples were initially denatured for 5 minutes at 94°C.  This was followed by 
30 cycles of denaturation at 94°C for 1 minute, annealing at 60°C for 1 minute and 
extension at 72°C for 2 minutes.  Following the last cycle, there was a final 
extension of 5 minutes at 72°C to encourage completion of partial extension 
products and annealing of single stranded complementary products. 
 
PCR products were visualised on a 1% agarose gel stained with ethidium bromide.  
All PCR products of the expected size (± 660 bp) were cut from the gel and 
purified using the Geneclean kit (QBiogene). 
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Table 2.5:  PCR primers for the initial amplification of the heavy and light chain  
genes. 
NAME SEQUENCE (5’ to 3’)* LENGTH 
(bp) 
LIGHT CHAIN PRIMERS: 
VKarch1 GACAGTGCACATGAAGTTGCCTGTTAGGCTGTTGG 35 
VKarch2 GACAGTGCACATGGACATGAGGGCTCCTGCTCAG 34 
VKarch3 GACAGTGCACAGACACACTCCTGCTATGGGTGCTGC 36 
VKarch4 GACAGTGCACACTGCTCTGTGTGTCTGGTGCTCATGG 37 
VKarch5 GACAGTGCACGCTCAGTTCCTTGGTCTCCTGTTGCTC 37 
VKarch6 GACAGTGCACCTTGTGTTCTGGATCTCTGGAGCCA 35 
VKarch7 GACAGTGCACTTCCTGCTAATCATTGTCACAGTC 34 
VKarch8 GACAGTGCACATGGTATCCACACCTCAGTTCCTTG 35 
VKarch9 GACAGTGCACTGCTCTGGCTTACAGGTGCCAGATGT 36 
VKarch10 GACAGTGCACGCCCAGTTCCTGTTTCTGTTAGTGC 35 
CKFOR GACAACGCGTCTCATTCCTGTTGAAGCTCTTGAC 34 
HEAVY CHAIN PRIMERS: 
VHarch1 GACAGTGCACATGGAATGGAGCTGGGTCTTTCTCTT 36 
VHarch2 GACAGTGCACATGGAATGGAGCTGGATCTTTCTCTT 36 
VHarch3 GACAGTGCACATGGGATGGAGCTGGATCTTTCTCTT 36 
VHarch4 GACAGTGCACATGGGATGGAGCTGTATCATCCTCTT 36 
VHarch5 GACAGTGCACATGAAGTTGTGGCTGAACTGGATTTT 36 
VHarch6 GACAGTGCACATGAAATGCAGCTGGGTTATCTTCTT 36 
VHarch7 GACAGTGCACATGAAGTTGTGGTTAAACTGGGTTTT 36 
VHarch8 GACAGTGCACGGGCTCAGCTTGATTTTCCTTGTCCT 36 
VHarch9 GACAGTGCACATGTTTAACATCATTATCTTCACAGT 36 
VHarch10 GACAGTGCACCTCTTCTGCCTGGTGACATTCCCAAG 36 
MOCG12FOR GACAACGCGTCTCAATTTTCTTGTCCACCTTGGTGC 36 
MOCG3FOR GACAACGCGTCTCGATTCTCTTGATCAACTCAGTCT 36 
MOCMFOR GACAACGCGTTGGAATGGGCACATGCAGATCTCT 34 
* Primer sequences were kindly given to us by Jefferson Foote from the Fred Hutchinson Cancer Research Center in 
Seattle, Washington 
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2.6.  PURIFICATION OF DNA FROM AGAROSE GELS 
 
2.6.1.  Geneclean (BIO 101® Systems) 
 
The fact that DNA binds to silica in high salt concentrations and elutes in low salt 
makes this method especially useful as a purification procedure.  Since the DNA is 
eluted with a low salt buffer, it can be used immediately in subsequent reactions 
without precipitation or other further manipulation. 
 
2.6.2.  Geneclean protocol 
 
The DNA band of interest was excised from the ethidium bromide-stained agarose 
gel, weighed [0.1 g equals approximately 100 µl] and transferred to a 1.5 ml 
Eppendorf tube.  Tris-borate-EDTA (TBE) Modifier (0.5 volumes) and 6 M NaI (4.5 
volumes) were added to a given volume of agarose.  The tube was incubated in a 
55°C heating block until the agarose had dissolved (approximately 10 minutes).  
GLASSMILK® (50 µl) was added to the tube and allowed to incubate at room 
temperature on a rotation wheel for 30 minutes.  The silica matrix with the bound 
DNA was pelleted in a microcentrifuge for 30s at full speed.  The supernatant was 
discarded.  The pellet was washed 3 times with 750 µl prepared NEW™ Wash 
(NEW™ Wash concentrate is mixed with 280 ml distilled water and 310 ml 100% 
ethanol) with a 30s spin between each wash.  After the final wash the tube was 
spun again to remove any residual NEW™ Wash.  The pellet was dried for 15 
minutes at room temperature.  The pellet was resuspended in 50 µl of Tris-EDTA 
(TE), spun for 30s, and the supernatant containing the eluted DNA transferred to a 
new Eppendorf tube. 
 
The purified PCR products were then cloned into a vector for sequencing.  Since 
Taq polymerase was used to amplify the immunoglobulin regions, the purified 
PCR products were ligated into a sequencing vector (pCR®II-TOPO) with 
overhanging 5’ thymidines so that the 3’ adenosines on the PCR products could 
base-pair with the vector. 
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2.7.  TOPO CLONING 
 
TOPO TA Cloning® provides a highly efficient, one-step cloning strategy for the 
direct insertion of Taq polymerase-amplified PCR products into a plasmid vector. 
 
Taq polymerase has a nontemplate-dependent terminal transferase activity that 
adds a single deoxyadenosine (A) to the 3’-ends of PCR products.  The linearised 
TOPO vector (Figure 2.2) has single, overhanging 3’-deoxythymidine (T) residues.  
This allows PCR inserts to ligate efficiently with the vector.  Topoisomerase I 
(covalently bound to the vector) binds to duplex DNA at specific sites and cleaves 
the phosphodiester backbone after 5’-CCCTT in one strand.  The energy from the 
broken phosphodiester backbone is conserved by formation of a covalent bond 
between the 3’ phosphate of the cleaved strand and a tyrosyl residue (Tyr-274) of 
Topoisomerase I.  The phospho-tyrosyl bond can subsequently be attacked by the 
5’ hydroxyl of the original cleaved strand, reversing the reaction and releasing 
Topoisomerase (Figure 2.3). 
 
2.7.1.  Setting up the TOPO® cloning reaction 
 
Table 2.6 describes how to set up the TOPO® cloning reaction (6 µl) for 
transformation into chemically competent Eschericia coli (E. coli) cells.  The 
reaction was incubated for 25 minutes at room temperature and placed on ice 
before proceeding to section 2.8.2. 
 
Table 2.6:  Reagents and their volumes required for TOPO cloning. 
Reagent* Chemically competent E. coli 
Fresh PCR product 0.5 - 4 µl 
Salt solution 1 µl 
Sterile water Add to a total volume of 5 µl 
TOPO® vector 1 µl 
Final volume 6 µl 
*Store all reagents at -20°C when finished.  Salt solutions and water can be stored at room temperature or at +4°C. 
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f1 ori 
Kanamycin 
Plac lacZα 
+1 
    lacZα ATG 
M13 Reverse Primer      Sp6 Promoter 
CAG GAA ACA GCT ATG ACC ATG ATT ACG CCA AGC TAT TTA GGT GAC ACT ATA GAA 
GTC CTT TGT CGA TAC TGG TAC TAA TGC GGT TCG ATA AAT CCA CTG TGA TAT CTT 
 
            NsiI   HindIII          KpnI         SacI  BamHI    SpeI 
 
TAC TCA AGC TAT GCA TCA AGC TTG GTA CCG AGC TCG GAT CCA CTA GTA ACG GCC 
ATG AGT TCG ATA CGT AGT TCG AAC CAT GGC TCG AGC CTA GGT GAT CAT TGC CGG 
 
       BstXI     EcoRI        EcoRI  EcoRV 
 
GCC AGT GTG CTG GAA TTC GCC CTT                          AAG GGC GAA TTC TGC AGA TAT 
CGG TCA CAC GAC CTT AAG CGG GAA                         TTC CCG CTT AAG ACG TCT ATA 
 
  BstXI        NotI XhoI     NsiI XbaI           ApaI 
 
CCA TCA CAC TGG CGG CCG CTC GAG CAT GCA TCT AGA GGG CCC AAT TCG CCC TAT 
GGT AGT GTG ACC GCC GGC GAG CTC GTA CGT AGA TCT CCC GGG TTA AGC GGG ATA 
 
T7 Promoter          M13 (-20) Forward Primer 
AGT GAG TCG TAT TAC AAT TCA CTG GCC GTC GTT TTA CAA CGT CGT GAC TGG GAA 
TCA CTC AGC ATA ATG TTA AGT GAC CGG CAG CAA AAT GTT GCA GCA CTG ACC CTT 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 2.2:  Map of pCR®II-TOPO®. 
The map shows the features of pCR®II-TOPO® and the sequence 
surrounding the TOPO cloning site.  Restriction sites are labelled to 
indicate the actual cleavage site.  The arrows indicate the start of 
transcription for Sp6 and T7 polymersases. 
PCR Product
pCR®II-TOPO® 
4.0 kb 
Ampicillin 
pUC ori 
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Figure 2.3:  Diagrammatic representation of how a PCR product ligates with the  
vector in the presence of Topoisomerase. 
 
2.8.  TRANSFORMATION 
 
2.8.1.  Transformation guidelines 
 
Storage conditions: Ultracompetent cells are sensitive to small variations in 
temperature and must be stored in a -70°C freezer. 
Aliquoting cells: Keep ultracompetent cells on ice at all times and prechill any 
tubes that the cells are aliquoted into. 
Use of Falcon 2059 Polypropylene tubes: Other tubes may be degraded by β-
mercaptoethanol (β-ME) used in the transformation protocol and the incubation 
period during the heat-pulse step has been calculated specifically for the thickness 
and shape of Falcon 2059 polypropylene tubes. 
Use of β-ME: β-ME increases transformation efficiency. 
Length and temperature of the heat pulse: Optimal transformation efficiencies are 
observed when cells are heat-pulsed for 30s at 42°C. 
 
P
Tyr-274 
Tyr-274 
C  C  C  T 
G  G  G A 
A  G  G  G 
T  C   C  C PCR ProductA
T A
T
P
OH 
Topoisomerase 
Topoisomerase 
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2.8.2.  One Shot® chemical transformation 
 
A 75 µl aliquot of thawed XL 10-Gold ultracompetent cells (Stratagene) and 2 µl of 
β-ME were incubated on ice for 10 minutes.  The TOPO® cloning reaction (2 µl; 
section 2.7.2) was added to the competent cells and incubated for 25 minutes on 
ice.  Following a 30 second heat pulse at 42°C, the tubes were incubated on ice 
for 2 minutes.  SOC medium (0.9 ml) was added to each tube and the cultures 
allowed to grow at 37°C for 1 hour with shaking (225 to 250 rpm).  The 
transformation reaction (100 µl) was plated on LB (Luria-Bertani)-carbenicillin agar 
plates and incubated overnight at 37°C. 
 
To ensure that the colonies contained the TOPO vector with the immunoglobulin 
insert, plasmids were isolated from the cultures using alkaline lysis miniprep 
procedures.  An aliquot of plasmid DNA was digested with restriction enzymes that 
flank the insert site to confirm the size of the insert. 
 
2.9.  PLASMID MINIPREP 
 
2.9.1.  Growing an overnight culture 
 
Single bacterial colonies were selected and grown overnight (300 rpm; 37°C) in  
3 ml of LB medium with 0.1% carbenicillin. 
 
2.9.2.  The QIAprep principle 
 
The QIAprep miniprep procedure consists of three basic steps: 
i. preparation and clearing of a bacterial lysate, 
ii. adsorption of DNA onto the QIAprep membrane, and 
iii. washing and elution of plasmid DNA. 
 
2.9.3.  Plasmid Miniprep Protocol 
 
Overnight cultures were centrifuged for 10 minutes at 2 000 x g.  The pelleted 
bacterial cells were resuspended in 250 µl buffer P1 and transferred to a 1.5 ml 
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Eppendorf tube.  Bacteria were lysed by the addition of 250 µl buffer P2.  Proteins 
were precipitated by adding 350 µl buffer N3 and removed by centrifuging for 10 
minutes at ≥ 10 000 x g.  The supernatant containing the plasmid DNA was 
applied to a QIAprep column and centrifuged for 1 minute.  The QIAprep spin 
column was washed with 750 µl buffer PE and centrifuged for 1 minute.  Residual 
wash buffer was removed by a further 1 minute centrifugation step.  Plasmid DNA 
was eluted (1 minute centrifugation) with 50 µl buffer EB (elution buffer; 10 mM 
Tris-HCl, pH 8.5). 
 
2.9.4.  Storage of plasmid DNA 
 
Plasmid DNA can be stored in TE buffer at 4°C for several weeks or preserved for 
several years by storing at -20 or -70°C. 
 
2.10.  RESTRICTION ENDONUCLEASES 
 
Restriction endonucleases are endodeoxyribonucleases that recognise specific 
nucleotide sequences within double stranded DNA, and cleave the double 
stranded DNA within or adjacent to this site.  Restriction endonucleases are 
classified into types I, II or III.  Only type II enzymes were used in this study 
(Sambrook et al., 1989). 
 
2.10.1.  Restriction endonuclease digestion of plasmid minipreps 
 
Restriction endonuclease cleavage is accomplished simply by incubating the 
enzyme(s) with the DNA in appropriate reaction conditions.  The amounts of 
enzyme and DNA, the buffer and ionic concentrations, and the temperature and 
duration of the reaction will vary depending upon the specific application and 
enzyme being used. 
 
The plasmid DNA was digested with EcoRI (this enzyme cleaves on either side of 
the inserted PCR fragment; refer to Figure 2.2) to ensure the presence of the PCR 
fragment in the TOPO vector.  The digestion reaction was carried out in a 20 µl 
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volume consisting of 5 µl plasmid DNA, 1 x restriction enzyme buffer, and 2 U 
EcoRI.  Samples were incubated in a 37°C incubator or water bath for an hour.  
Following restriction digest, samples were run on a 1% agarose gel (Figure 2.4). 
 
 
 
 
 
 
 
 
Figure 2.4:  Schematic representation of the possible products obtained after  
restriction digest of plasmid minipreps. 
Lane 1: molecular weight marker, Lane 2: digested plasmid with PCR 
insert, Lane 3: linearised plasmid, Lane 4: blank. 
 
If the plasmids contained an insert, a single clone was analysed by DNA 
sequencing to further ensure that the inserts were immunoglobulin regions.  
Samples were sequenced using the TOPO-specific Sp6 and T7 primers.  
Sequence determination was performed using an ABI PRISM instrument and the 
BigDye terminator method.  DNA sequences obtained were compared to those in 
GenBank to ensure that they were immunoglobulin regions. 
 
2.11.  SEQUENCING 
 
Sequencing was performed on an automated ABI 377 DNA sequencer which is 
able to detect DNA fragments by fluorescence from four different dyes that are 
used to identify the adenosine (A), guanosine (G), cytosine (C), and thymidine (T) 
extension reactions.  Four chemically related, yet distinguishable, fluorescence-
tagged dideoxynucleoside triphosphates (ddNTPs) are used to label the DNA with 
a suitable DNA polymerase.  The growing chain is, therefore, simultaneously 
terminated and labelled with the dye that corresponds to a particular base.  Each 
dye emits light at a different wavelength when excited by the laser beam.  All four 
colours can be detected and distinguished in a single gel lane by polyacrylamide 
1 2 3 4
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gel electrophoresis (Prober et al., 1987).  Analysis of the fluorescent emission of 
each fragment allows one to identify the terminating nucleotide and assign the 
sequence directly in real time. 
 
2.11.1.  Pre-treatment of PCR products for sequencing 
 
To obtain high quality sequencing data that are easy to interpret, it is important 
that the PCR be as specific as possible.  Poor quality sequencing data will be 
obtained if the PCR products contain large amounts of residual primers, 
nucleotides, and spurious bands.  The PCR product must, therefore, be purified 
prior to sequencing.  Depending on the purity of the amplified PCR product, one of 
two methods was used for purification. 
 
2.11.1.1.  Enzymatic purification of PCR products for sequencing 
In the absence of spurious bands, 5 µl of PCR product was purified with two 
hydrolytic enzymes: exonuclease I (1 U) and Shrimp Alkaline Phosphatase (SAP; 
1 U).  Exonuclease I degrades residual single stranded primers and any 
extraneous single stranded DNA produced by the PCR.  SAP dephosphorylates 
the excess nucleotides.  The PCR product was incubated in the Hybaid omnigene 
PCR machine for 15 minutes at 37°C followed by a further 15 minutes at 80°C to 
inactivate the two enzymes. 
 
2.11.1.2.  Gel purification of PCR products 
PCR products were run on a 1% agarose gel to separate and isolate the fragment 
of interest.  The band of interest was cut out and placed in an Eppendorf tube.  
The Geneclean kit was used to extract the DNA from the gel (section 2.6.2).  An 
aliquot of the purified DNA was checked on a 1% agarose gel to ensure its 
extraction and purity. 
 
2.11.2.  Cycle sequencing PCR amplification 
 
Two reactions were set up for each sample being sequenced: one with the forward 
primer and one with the reverse primer.  The reaction was carried out in a 10 µl 
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volume consisting of 0.5 µM stock primer (forward or reverse; Table 2.4), 200 ng 
of plasmid DNA, and 4 µl BigDye. 
 
The three steps involved in the amplification of the target sequences were: 
denaturation at 96°C for 30s, annealing at 50°C for 15s, and extension of the PCR 
product at 60°C for 4 minutes.  This cycle was repeated 30 times.  Upon 
completion of the 30 cycles, the PCR was held at 4°C. 
 
2.11.2.1.  Purification of cycle sequencing PCR products 
Once the PCR reaction was completed, samples were purified using a Sephadex 
G-50 slurry.  Sephadex (2.5 g) was weighed and placed in a 50 ml conical tube.  
The volume was made up to 40 ml with dH2O.  The sephadex slurry (650 µl) was 
added to a spin column placed in an Eppendorf tube and allowed to stand at room 
temperature for 20 minutes.  Columns were spun for 2 minutes at 770 x g and put 
into clean, labelled Eppendorf tubes.  Samples were carefully loaded onto the 
centre of the resin and spun for 2 minutes at 770 x g.  The purified product was 
dried in a speedivac at low heat for at least 20 minutes.  The dried, purified 
samples were sent to the Howard Hughes Medical Institute & Department of 
Immunology DNA Sequencing Facility (University of Washington, Seattle, WA) 
where sequence determination was performed. 
 
2.11.3.  Subcloning of the immunoglobulin genes 
 
Once we were certain that the chains that we had amplified were indeed 
immunoglobulin in nature we were ready to proceed to the cloning step.  To 
construct the expression vector, the immunoglobulin light and heavy chain genes 
were reamplified by PCR using primers (refer to Table 2.7) introducing the 
restriction sites MluI and BsrGI, and MluI and SphI, respectively to allow cloning 
into the pCXII vector. 
 
PCR was performed with the primers listed in Table 2.7 using the same conditions 
as described previously (section 2.4.1.2.).  The heavy chain primers were 
designed to add a penta-histidine tag to the 3’ end of the PCR products. 
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Table 2.7:  Primers containing restriction sites used to clone the heavy and light  
chain fragments into the pAK19 expression vector. 
NAME SEQUENCE (5’ TO 3’) ENZYME 
DPDL5” 
 
ACAAACGCGTATGCTGACATTGTGATGACCCAGTCTC
C 
MluI 
DPDL3’ 
 
CTTGTGTACAAGGGCCACGATGCGTCCGGCGTAGAG
GATCAGCTTAAGACT 
BsrGI 
DPDH5’ 
 
CAAACGCGTACGCTCAGGTGCAGCTGGTGGAGTCTG
GCCC 
MluI 
DPDH3’ 
 
CGTCGCATGCCGCGTCAGTGGTGGTGGTGGTGGTGT
TCGCCCTTGCAT 
SphI 
1E2L5’ CAAACGCGTACGCTGATATCCAGATGAC MluI 
1E2L3’ 
 
TTGTGTACAAGGGCCACGATGCGTCCGGCGTAGAGG
ATCAGCTTAACAACGGGTCTC 
BsrGI 
1E2H5’ 
 
GCTACAAACGCGTACGCTCAGGTGCAGCTGCTCGAG
T 
MluI 
1E2H3’ 
 
GTCGCATGCCGCGTTAGTGGTGGTGGTGGTGGCAGT
CACGCGGAAC 
SphI 
123L5’ ACAAACGCGTATGCTCAAATTGTTCTCACCCAGTC MluI 
123L3’ 
 
TTGTGTACAAGGGCCACGATGCGTCCGGCGTAGAGG
ATCAGCTTAACAACGGGTCTC 
BsrGI 
123H5’ 
 
ACAAACGCGTACGCTCAGGTCCAGCTGCAGCAGTCT
GG 
MluI 
123H3’ 
 
CGTCGCATGCCGCGTTAGTGGTGGTGGTGGTGGTGT
TGACAACGGGTCTC 
SphI 
126L5’ GCTACAAACGCGTATGCTGATATTGTGCTAACTCAG MluI 
126L3’ 
 
CTTGTGTACAAGGGCCACGATGCGTCCGGCGTAGAG
GATCAGCTTAACAACGGGTCTC 
BsrGI 
126H5’ GCTACAAACGCGTACGCTGAGGTCCAGCTGCAACAG MluI 
126H3’ 
 
GGGCCGTCGCATGCCGCGTCAGTGGTGGTGGTGGT
GGTGTTGACAACGGGTCTC 
SphI 
The pentahistidine tag located in the heavy 3’ primer is underlined and the MluI, BsrGI, and SphI restriction sites are shown 
in red, green, and blue respectively. 
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An aliquot of the reamplified products were checked on a 1% agarose gel and then 
digested with the respective enzymes for at least four hours.  Light chains were 
digested with MluI and BsrGI while the heavy chain products were digested with 
MluI and SphI.  The digested products were run on a gel, purified and each chain 
ligated into a separate pCXII vector (Figure 2.5) which has similarly been digested.  
The heavy and light chain were individually subcloned into the pCXII vector, as 
opposed to the pAK19 vector because of the presence of the MluI restriction site 
on both immunoglobulin chains which made direct cloning of the chains into the 
expression vector polycloning site very difficult. 
 
A.           B. 
 
 
 
 
 
 
 
 
Figure 2.5:  A. pCXII vector containing a light chain insert (MluI-BsrGI). 
          B. pCXII vector containing a heavy chain insert (MluI-SphI). 
 
2.12.  LIGATION AND CLONING 
 
Two digestion reactions were set up.  In one, the pCXII vector was digested with 
MluI and BsrGI (for insertion of the light chain fragment) and in the second 
reaction the vector was digested with MluI and SphI (for the insertion of the Fd 
heavy chain fragment).  The vector was digested for 2 hours at 37°C.  A small 
aliquot of the digest was run on a 1% agarose gel to ensure complete digestion of 
the vector and that the correct size fragments were obtained.  The vector was then 
dephosphorylated. 
 
 
BsrGIMluI 
HindIIIEcoRI 
pCXII 
vector 
~ 4.74 kb 
BsrGI SphI 
MluI
HindIIIEcoRI
pCXII 
vector 
~ 4.75 kb 
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2.12.1.  Vector dephosphorylation 
 
The digested vector was dephosphorylated in a 50 µl volume consisting of 0.5 U 
shrimp alkaline phosphatase and 1 x SAP buffer.  The reaction was incubated for 
one hour at 37°C.  The enzymes were inactivated by a 15 minute incubation at 
65°C.  The digested, dephosphorylated vector was run on a 1% agarose gel, cut 
out and purified using GLASSMILK as described above. 
 
2.12.2.  The ligation reaction 
 
The OD260 of the purified, digested DNA and vector fragments were measured and 
the concentration of each calculated.  Three ligation reactions with differing 
vector/insert ratios (1:1, 1:3 and 3:1) were set up (Table 2.8).  For example: 
 
Vector OD260 = 0.031 = 38.9 µg/ml  Vk OD260 = 0.021 = 26.6 µg/ml 
 
Size (bp) insert x 100  = ng of insert 
    Size (bp) vector 
 
      =  16.7 ng of insert 
 
Vector:      Insert: 
38.9 µg = 1 ml     26.6 µg = 1 ml 
∴ 0.1 µg = 2.57 µl     0.0167 µg insert = 0.63 µl 
 
Table 2.8:  Volumes required for a ligation reaction. 
 Insert Vector Ligase Buffer Water 
1:1 0.63 µl 2.57 µl 1 µl 1 µl 4.8 µl 
1:3 0.21 µl 2.57 µl 1 µl 1 µl 5.22 µl 
3:1 1.89 µl 2.57 µl 1 µl 1 µl 3.54 µl 
 
The ligation was allowed to continue for one hour at 16°C.  The products of the 
ligation reaction were introduced into XL 10-Gold ultracompetent E. coli cells (refer 
to section 2.8.2), and transformants identified by growth on carbenicillin plates.  
∴     680 x 100 
          4070 
1 
 
1 
1 
1 
x 
x 
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DNA was prepared from the colonies by plasmid miniprep (section 2.9) and 
subjected to restriction endonuclease mapping (MluI/BsrGI and MluI/SphI for the 
light and heavy chain respectively) in order to determine if the desired DNA 
molecule was created. 
 
The heavy chain fragment was subsequently cloned into the pCXII vector which 
contained the light chain insert.  To clone the heavy chain into the vector 
containing the light chain fragment, BsrGI and HindIII enzymes were used (refer to 
Figure 2.5).  The products of the ligation reaction were introduced into XL 10-Gold 
ultracompetent E. coli cells, transformants identified by growth on carbenicillin 
plates, and DNA prepared from the colonies by plasmid miniprep.  The Fab (light 
chain and Fd fragment of the heavy chain) was cut from the pCXII vector using the 
EcoRI and HindIII enzymes and cloned into the pAK19 expression vector (Figure 
2.6), which had been digested with the same enzymes. 
 
2.12.3.  Choosing a plasmid vector 
 
Some of the basic features to consider when selecting a plasmid vector include 
the size of the vector, its copy number, the polylinker, and the ability to select 
and/or screen for inserts. 
 
The expression vector used in this study is called pAK19.  The pAK19 vector is 
designed to co-express the light chain and heavy chain Fd fragment from a 
synthetic dicistronic operon (Figure 2.6) which is cloned between the EcoRI and 
HindIII sites of pBR322 (Bolivar et al., 1977).  This vector uses the E. coli alkaline 
phosphatase (phoA) promoter, which is inducible by phosphate starvation, and 
heat-stable enterotoxin II (stII) signal sequences precede each antibody chain.  
Gene products are directed to the periplasmic space of E. coli, from which 
correctly folded, disulfide-oxidized molecules are released after cell harvest 
(Carter et al., 1992). 
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2.12.4.  Cloning of DNA immunoglobulin heavy and light chain fragments 
 
The EcoRI and HindIII digested pAK19 vector was purified from the small remnant 
of the polycloning site by agarose gel electrophoresis.  The vector was ligated to 
the Fab fragment cut from the pCXII vector.  The resulting circular recombinant 
plasmids were introduced into 25F2 competent E. coli cells (section 2.13), and 
transformants identified by growth on carbenicillin plates.  DNA was prepared from 
the colonies by plasmid miniprep and subjected to restriction endonuclease 
mapping (MluI and SphI) in order to determine if the desired DNA molecule was 
ligated into the pAK19 vector. 
 
To express the Fab, a specific strain of E. coli cells (25F2), needed to be 
transfected with the pAK19 vector containing the Fab insert. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6:  Diagrammatic representation of the pAK19 vector and the positions  
where the heavy and light chain fragments were inserted. 
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2.13.  PREPARATION OF FRESH COMPETENT 25F2 E. COLI CELLS 
 
Two methods were used to prepare fresh competent 25F2 E.coli cells in this study: 
calcium chloride and rubidium chloride methods. 
 
2.13.1.  Calcium chloride method for preparing competent cells 
 
Competent cells were prepared using standard procedures (Mandel and Higa, 
1970).  A single colony of E. coli 25F2 cells was picked from a plate freshly grown 
for 16 to 20 hours at 37°C and transferred into 100 ml of LB broth or SOB medium 
in a 1 litre flask.  The culture was incubated at 37°C with vigorous shaking        
(300 rpm) until the cells reach an OD600 of approximately 0.375 (~108 cells/ml).  
The cells were cooled to 0°C and recovered by centrifugation at 3 000 x g for 10 
minutes at 4°C in a Beckman Model TJ-6 centrifuge.  The cell pellet was 
resuspended in 10 ml of ice-cold 0.1 M CaCl2 and stored on ice for 10 minutes.  
After an additional centrifugation step (3 000 x g for 10 minutes at 4°C) the cell 
pellets were resuspended in 2 ml of ice-cold 0.1 M CaCl2 for each 50 ml of original 
culture.  The cells were dispensed into aliquots and frozen at -70°C.  The cells 
maintain competency under these conditions, although the transformation 
efficiency may drop slightly during prolonged storage. 
 
2.13.2.  Rubidium chloride method for preparing competent cells 
 
A single colony was grown in 100 ml SOC, as for the calcium chloride method, 
until an OD600 of 0.5 was reached.  The cells were cooled on ice for 10 minutes 
and recovered by centrifugation at 3 300 x g for 15 minutes at 4°C.  The cell pellet 
was resuspended in 15 ml solution RF1 and put on ice for 15 minutes.  Following 
an additional spin the cell pellet was resuspended in 4 ml solution RF2 and stored 
on ice for 20 minutes.  The cells were aliquoted, snap frozen in liquid nitrogen and 
stored at -70°C. 
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E. coli 25F2 cells were transformed with the pAK19 vector and transformants 
identified by growth (37°C) on carbenicillin plates.  Very few colonies were 
observed on the plate the following morning. 
 
2.14.  EXPRESSION OF RECOMBINANT FABS 
 
Expression vectors are usually designed such that production of the foreign 
protein is tightly regulated.  This is necessary because the host cell machinery is 
co-opted to produce large quantities of the foreign protein, the shear amount of 
which may be toxic to the cell, and/or the foreign protein may encode a function 
that will inhibit cell growth or kill the host cell. 
 
2.14.1.  Expression of secreted foreign proteins 
 
Secretion of the foreign protein is accomplished by fusing the coding sequence to 
DNA encoding a signal peptide that is cleaved by signal peptidase when the 
protein is secreted into the periplasm located between the inner and outer 
membranes of E. coli.  The two major problems encountered in secretion of 
foreign proteins are that yields are often low and cleavage of the signal peptide 
may not occur or may occur at an inappropriate position. 
 
A single colony was picked from the agar plate and grown in 5 ml LB containing 
tetracycline for approximately 6 hours.  The E. coli 25F2 cells containing the 
recombinant plasmids were then transferred to 500 ml complete MOPS medium 
with tetracycline and grown for 16 hours at 30°C (250 rpm).  Cells were 
subcultured and grown in the absence of phosphate for 4 hours at 30°C to induce 
expression of the Fab and secretion into the periplasmic space. 
 
2.14.2.  Purification of the antibody recombinant Fab 
 
The bacteria were harvested by centrifugation at 8 000 x g for 15 minutes.  The 
pellet was subjected to a freeze (dry ice-ethanol bath)-thaw (15 minutes on ice) 
cycle and resuspended in lysis buffer (2 to 5 ml per gram of pellet) containing 
lysozyme (1 mg/ml).  After a 30 minute incubation step on ice, the lysate was 
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sonicated using a microtip sonicator with six 10s bursts at 200 to 300 W with a 10s 
cooling period between each burst.  Cellular debris was removed by centrifugation 
at 10 000 x g for 30 minutes at 4°C.  The supernatant was stored at 4°C. 
 
The rFab was isolated from the cleared supernatant by two subsequent affinity 
chromatography steps.  Initially the rFab were bound to Ni-NTA Agarose via a 
histidine Tag at the C-terminus of the heavy chain.  Lysate (4 ml) was added to 1 
ml of Ni-NTA agarose and incubated for 1 hour at 4°C on a rotator.  A column was 
loaded with the lysate-agarose suspension and the flow through collected.  The 
column was washed with 8 mls of lysis buffer.  The bound proteins were eluted in 
1 ml fractions with step-wise increases of imidazole (10, 50, 100, and 300 mM) in 
lysis buffer.  The eluates were examined by immunoblot (section 2.16) for the 
presence of rFab and the positive fractions pooled and further purified on Protein 
G Sepharose (PGS).  rFab fractions (1 ml) were incubated with 200 µl of PGS at 
4°C on a rotator for one hour.  Samples were spun for 5 minutes at 2 600 x g and 
washed with 1 ml wash buffer.  This was repeated five times.  Bound rFab was 
eluted with 0.1 M glycine-HCl buffer (pH 2.5).  Fractions (500 µl) were collected in 
Eppendorf tubes and immediately neutralized with 50 µl of 1 M Tris-HCl, pH 8.0.  
Fractions were examined by immunoblot for the presence of rFab and by 
radioimmunoassay (RIA) for insulin binding (section 2.17.1).  Active fractions were 
pooled and the protein concentration determined.  The yield of functional purified 
rFab was ~ 0.5 mg/l bacterial culture. 
 
2.15.  POLYACRYLAMIDE GEL ELECTROPHORESIS OF AFFINITY 
CHROMATOGRAPHY PURIFIED rFAB FRACTIONS 
 
2.15.1.  Preparation of SDS-polyacrylamide gels 
 
The gel casting apparatus was assembled according to the manufacturer’s 
instructions.  The resolving gel [2.5 ml Tris buffer (pH 8.8), 2.3 ml dH2O, 5 ml 30% 
acrylamide mix, 100 µl 10% ammonium persulphate, and 4 µl TEMED] was 
prepared and aliquoted between the glass plates, leaving sufficient space for the 
stacking gel.  The stacking gel [1.25 ml Tris buffer (pH 6.8), 2.85 ml dH2O, 820 µl 
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30% acrylamide mix, 25 µl 10% ammonium persulphate, and 2 µl TEMED] was 
pipetted directly onto the surface of the polymerised resolving gel.  A comb was 
immediately inserted into the stacking gel solution, being careful to avoid trapping 
air bubbles under the teeth.  The gel was allowed to polymerise at room 
temperature. 
 
2.15.2.  Preparation of samples for SDS-polyacrylamide gels 
 
The Ni-NTA agarose/PGS eluted rFab protein samples were heated to 100°C for 5 
minutes in 2 x SDS gel loading buffer (1:1).  β-ME (10%) was added to the gel 
loading buffer for reducing gels.  Samples were kept on ice until ready to use. 
 
2.15.3.  Running SDS-polyacrylamide gels 
 
Protein samples were analysed on a 15% SDS polyacrylamide gel in tris-glycine 
buffer.  Gels were run at 100 to 120 V for approximately 2 hours.  A molecular 
weight marker (BIORAD prestained SDS PAGE standards) was included in each 
gel.  The gel was fixed, stained with Coomassie Brilliant Blue or used to establish 
a Western blot. 
 
2.15.4.  Staining SDS-polyacrylamide gels with Coomassie Brilliant Blue 
 
Polypeptides separated by SDS-polyacrylamide gels can be stained with 
Coomassie Brilliant Blue R250.  The gel was immersed in at least 5 volumes of 
staining solution and placed on a slowly rotating platform for a minimum of 4 hours 
at room temperature. 
 
2.15.5.  Destaining SDS-polyacrylamide gels 
 
The stain was removed by soaking the gel in the destaining solution (methanol: 
water: acetic acid; 6:3:1) on a slowly rocking platform for 4 to 8 hours at room 
temperature.  The destaining solution was changed three to four times.  A piece of 
tissue paper was included in the normal destaining buffer as this absorbed the 
stain as it leached from the gel.  To make a permanent record the gel was dried. 
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2.15.6.  Drying SDS-polyacrylamide gels 
 
The major problems encountered when a gel is dried are: 
i. shrinkage and distortion, and 
ii. cracking of the gel. 
The first of these problems can be minimised if the gel is attached to a piece of 
Whatman 3MM paper before it is dried.  However, there is no guaranteed solution 
to the second problem, which becomes more pronounced with thicker gels 
containing more polyacrylamide.  Cracking generally occurs when the gel is 
removed from the drying apparatus before it is completely dried. 
 
The gel was fixed at room temperature in 5 to 10 volumes glacial acetic acid: 
methanol: water (1:2:7).  The bromophenol blue will turn yellow as the acidic fixing 
solution diffuses into the gel.  Fixation was continued for 5 minutes after all of the 
blue colour had disappeared.  The gel was washed briefly in dH2O, placed on a 
piece of Glad wrap and overlayed with a piece of dry Whatman 3MM paper.  The 
sandwich of 3MM paper/gel/Glad wrap (Glad wrap uppermost) was placed on a 
piece of 3MM paper on the gel dryer.  The gel was dried under vacuum, with low 
heat (50 to 65°C) for approximately 3 hours. 
 
2.16.  IMMUNOBLOTTING OF rFAB FRACTIONS 
 
Immunoblotting combines the resolution of gel electrophoresis with the specificity 
of immunochemical detection.  In Western blotting (Towbin et al., 1979), the 
samples to be assayed are solubilised with detergents and reducing agents, 
separated by SDS-polyacrylamide gel electrophoresis, and transferred to a solid 
support (usually a nitrocellulose filter).  The membrane is subsequently exposed to 
horseradish peroxidase (HRP) conjugated antibodies specific for the target 
protein.  Finally, the bound antibody is detected by chemiluminescence. 
 
2.16.1.  Transfer of protein from SDS-polyacrylamide gels to solid supports 
 
To transfer proteins from the polyacrylamide gel to a Millipore imobilon-P 
membrane a transfer stack was assembled (packing sponge, Whatman 3MM filter 
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paper, gel, membrane, Whatman 3MM filter paper and packing sponge).  The 
membrane was wet in methanol and water and then soaked in transfer buffer for 5 
minutes before being used.  The transfer stack was assembled on the black 
cathode side so that molecules will migrate to the membrane.  The module was 
positioned in the tank with the red side facing outward.  The transfer was carried 
out at room temperature and was completed in 1 hour at 60 V. 
 
2.16.2.  Blocking binding sites for immunoglobulins on the membrane 
 
The sensitivity of Western blotting depends on reducing non-specific binding by 
blocking potential binding sites with irrelevant proteins.  The membrane was, 
therefore, incubated for at least an hour in blocking solution (1 x TBST [Tris, 
borate, Tween 20] with 1% BSA).  The blot was rinsed three times in 1 x TBST. 
 
2.16.3.  Binding of the primary antibody to the target protein 
 
For detection of the heavy and light chain a anti-penta-His antibody-HRP 
conjugate (Qiagen; 1:4 000) and a rat anti-mouse kappa antibody-HRP conjugate 
(Stratagene; 1:4 000) were used, respectively, in the Western blot analysis.  After 
an hour incubation at room temperature, and extensive washing (3 x 10 minutes), 
the bands were visualized using standard chemiluminescence techniques, as 
described below. 
 
2.16.4.  Immunological detection of immobilised proteins by 
chemiluminescence 
 
Chemiluminescent detection is based on the oxidation of luminol in the presence 
of peroxide and is catalysed by horseradish peroxidase.  The oxidation of luminol 
emits light which is detected by exposing the blot to X-ray film. 
 
The membrane was incubated in equal volumes (7 ml) of chemiluminescence 
Solution A and B (see Appendix 1) for one minute.  The membrane was blotted dry 
and exposed to X-ray.  X-ray films were developed at 10 and 60s intervals. 
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2.17.  IMMUNOLOGICAL ASSAYS 
 
Immunoassays are one of the most powerful of all immunochemical techniques.  
They employ a wide range of methods to detect and quantitate antigens or 
antibodies and to study the structure of antigens.  With the appropriate assay, they 
can be remarkably quick and easy, yielding information that would be difficult to 
determine by other techniques. 
 
Two types of detection systems are commonly used for immunoassays.  These 
are iodinated reagents and enzyme-labelled reagents.  Assays that use iodinated 
reagents are easier to quantitate than enzyme labelled reagents, while enzyme 
assays will often yield a quicker result.  RIAs, using 125I-labelled insulin and 35S-
labelled GAD65, were used in this project. 
 
2.17.1.  Radioimmunoassays 
 
2.17.1.1.  The GAD65 autoantibody assay 
Recombinant [35S]-GAD antigens were produced in an in vitro coupled 
transcription/translation system with SP6 RNA polymerase and nuclease treated 
rabbit reticulocyte lysate (Promega) as described previously (Grubin et al., 1992).  
The in vitro translated [35S]-antigen was kept at -70°C and used within 2 weeks.  
Binding of rFab DP-D to radiolabelled antigen was determined by a previously 
described RIA (Grubin et al., 1992; Grubin et al., 1994) using PGS as the 
precipitating agent. 
 
The capacity of the rFab DP-D to inhibit GAD65 binding by human serum 
GAD65Abs was tested in a competitive RIA using PAS as the precipitating agent.  
Fab lack the CH2 domain of the Fc region and do not bind protein A.  Serum 
samples were first tested at a dilution of 1/25.  Samples that were competed only 
partially were diluted to a final serum dilution of 1/100 and reanalysed.  The rFab 
was added at the maximal concentration, as determined in competition assays 
(Padoa et al., 2003) using the intact mAb as a competitor.  A reduction in binding 
by > 10% and < 50% was defined as partial inhibition.  A reduction in binding of    
> 50% of the maximal binding was defined as full inhibition of antigen binding.  
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Human sera contain GAD65Abs of different epitope specificities, therefore, a 
complete inhibition of GAD65 binding (100%) was not expected. 
 
2.17.1.2.  The insulin autoantibody assay 
The binding capacity of serum samples, intact mAbs, and rFab were determined in 
the insulin antibody radiobinding assay (RBA). 
 
2.17.1.2.1.  Preparation of antigen 
The lyophilised (3-[125I]iodotyrosylA14)insulin product (AEC Amersham; specific 
activity: > 15 Ci/mg Iodide) was reconstituted to 100 µCi/ml. 
The target cpm was 20 000/25 µl (or 800 cpm/µl).  To calculate the amount of 
iodinated antigen required to reach the target cpm, the following formula was 
used: 
(800 cpm/µl) x (1.2 µCi/2 x 106 cpm) x (10 µl/1 µCi) x (total volume [µl] needed for 
the assay) = µl of antigen to add to the buffer. 
 
15 000 cpm A14-125I-radiolabeled recombinant human insulin (> 2 000 Ci/mmol), 
per 35 µl buffer, was incubated overnight, at room temperature, with 7 µl of serum 
samples, mAb, or rFab (in triplicate). 
 
2.17.1.2.2.  Precipitation 
The overnight reaction was transferred to a nitrocellulose microtitre plate 
(precoated with 200 µl per well of coating buffer overnight; Millipore) containing   
50 µl of 40% protein A sepharose (PAS) or PGS per well.  The Millipore plate had 
been incubated with coating buffer (200 µl/well) overnight at 4°C and washed twice 
with wash buffer before use.  The immunocomplexes were allowed to bind to the 
PAS or PGS for 90 minutes at 4°C (on a shaker).  The bound complexes were 
washed eight times (200 µl/well) on a Millipore vacuum manifold.  The plate was 
dried for approximately 30 minutes, 50 µl of scintillation fluid added to each well 
and samples counted in a β-scintillation counter. 
 
Results for rFab or human serum were expressed in arbitrary units derived from a 
standard curve.  The standard curve was established by running dilutions of serum 
from an insulin autoantibody positive control patient in the IAA assay.  Samples 
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were considered positive if they had levels above the 97.5th percentile of 50 
healthy controls (0.2 units). 
 
2.17.1.3.  Competition assays using rFab 126 
The capacity of the rFab to inhibit the binding of human serum IAA to labelled 
insulin was tested in a competitive RBA (as for section 2.17.1.2) using PAS as the 
precipitating agent.  Fab lack the CH2 domain of the Fc region and therefore do not 
bind to PAS.  Serum samples were tested at a serum dilution of 1/6.  The optimal 
concentration of rFab 126 was determined in competition assays using intact mAb 
126 as the competitor.  The rFab concentration determined in these experiments 
to achieve maximal competition of its intact IgG was used in all other competition 
assays.  GAD65-specific rFab N-GAD65 was used to determine unspecific binding 
to insulin. 
 
2.17.1.3.1.  Purification of whole mAbs by adsorption to PAS 
Although many techniques have been developed to purify IgG molecules, the 
method of choice is adsorption to, and elution from, beads coated with protein A, a 
component of the cell wall of S. aureus (Hjelm et al., 1972).  This protein (Mr = 42 
000) binds strongly to sites in the second and third constant regions of the Fc 
portion of the immunoglobulin heavy chain (Deisenhofer, 1981). 
 
The tissue culture supernatant containing the desired mAb was incubated for 1 to 
2 hours with 2.5 ml of 40% PAS before being gravity loaded into an empty column.  
After washing the column with 10 bed volumes of PBS, the immunoglobulin was 
eluted with 100 mM glycine (pH 3.0).  The 0.5 ml fractions were collected into 
Eppendorf tubes containing 50 µl of 1 M Tris-Cl (pH 8.0).  The immunoglobulin-
containing fractions were identified by measuring their absorbance at 280 nm.  
Fractions that contained immunoglobulin were pooled. 
 
2.18.  EPITOPE MAPPING 
 
The epitope specificity of the rFab 126 was determined by competitive RBA (refer 
to section 2.17.1.2).  Binding to insulin by mAb 1, and mAb 125 was competed 
with rFab 126.  Competition of insulin binding by both monoclonal antibodies at 
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half maximal binding (0.08 and 0.04 mg/ml, respectively) by different 
concentrations of rFab 126 was tested. 
 
The epitope that rFab DP-D binds to on GAD65 was mapped according to Padoa 
et al., 2003 (Appendix 7). 
 
2.19.  STATISTICAL ANALYSIS 
 
Binding of IAA to insulin in the presence of rFab was expressed as follows: cpm of 
125I insulin bound in the presence of rFab/cpm of 125I insulin bound in the absence 
of rFab x 100.  The cut off for specific competition was determined as > 10% by 
using rFab NQ22/61.1 as a negative control (a kind gift from Dr. J. Foote, Fred 
Hutchinson Research Center, Seattle), specific to an irrelevant target, phenyl 
oxazolone, at 5 µg/ml. 
 
All samples were analyzed in triplicate determinations and the average IAA intra-
assay coefficient of variation was 5% (range: 1.6 to 9%).  Similarly, all samples 
were run in triplicate for the GAD65 assay and the intra-assay average coefficient 
of variation was 7%, with the highest value being 20 and the lowest 0.1.  Positive 
and negative controls were included on each assay plate to correct for inter-assay 
variations.  Significance of competition within serum groups was tested using the 
Wilcoxon matched pair test.  Differences in competition between serum groups 
were tested for significance with the non-parametric Mann-Whitney U-test.  The 
significance of correlation of competition levels was analysed using Spearman’s 
rank correlation test.  A p-value < 0.05 was considered significant. 
 
2.20.  HOMOLOGY MODELLING 
 
The 3-dimensional structure of a target protein that has not been solved 
empirically by X-ray crystallography or NMR can be predicted by ‘comparative 
modelling’ or ‘homology modelling’.  For this method to be successful the 
sequence of the target protein must be sufficiently similar (≥ 50% sequence 
identity) to a protein for which the 3-dimensional structure has been empirically 
determined. 
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The 3-dimensional structure of rFab 126 and rFab DP-D were determined using 
the automated ESyPred3D homology modelling programme (Lambert et al., 2002).  
Alignments are obtained by combining, weighting, and screening the results of 
several multiple alignment programmes.  After submitting the rFab sequences, 
atomic coordinate PDB files were created and the final 3-dimensional structure 
built from these files using the Deep View Swiss-PDB Viewer modelling package 
software (which can be downloaded from http://au.expasy.org/spdbv/). 
 
2.20.1.  Requirements for homology modelling 
 
Three items of input were needed to perform homology modelling: 
i. The target protein sequence with unknown 3D structure. 
ii. A template protein - chosen because it exhibits the highest sequence identity 
with the target sequence and it has a known 3D structure.  The template 3D 
structure must be determined by reliable empirical methods.  These structures 
are from the Protein Data Bank (http://www.rcsb.org/pdb/; Berman et al., 2000). 
iii. An alignment between the target and template sequences. 
 
The homology modelling software arranged the backbone of the target sequence 
according to that of the template protein.  Sequence alignment of the two proteins 
determined where to position each residue.  For a highly successful homology 
model the template must have ≥ 60% sequence identity with the target for a 
success rate > 70%.  Below 40% sequence identity, serious errors begin to appear 
more frequently. 
 
2.21.  MOLECULAR DOCKING 
 
PatchDock (http://bioinfo3d.cs.tau.ac.il/PatchDock/FAQ.html; Schneidman-
Duhovny et al., 2003), an algorithm for molecular docking, was used in an attempt 
to further define the epitope that rFab 126 binds to on the insulin molecule.  PDB 
files of insulin and the rFab are entered online and a list of potential complexes, 
sorted by shape complementarity criteria, was returned.  The files were 
downloaded and the antigen-antibody complex viewed using the Deep View 
Swiss-PDB-Viewer.
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CHAPTER 3 
 
3.  RESULTS 
 
3.1.  HYBRIDOMA CELL LINES 
 
In this study, four hybridoma cell lines (1E2, HB-123, HB-126, and HB-127) that 
secreted monoclonal antibodies against insulin and B-cell clone (DP-D) that 
secretes monoclonal antibodies against GAD65 were used. 
 
The 1E2 hybridoma cell line was chosen because the epitope that the 1E2 mAb 
binds to on insulin had been mapped to the N-terminus of the B chain (B1, B3, 
B10 and B13; Crowther et al., 1994).  The remaining three hybridoma cell lines 
that secrete mAbs against insulin were selected for epitope analysis studies due to 
their commercial availability.  The GAD65 mAb DP-D was selected for epitope 
analysis of autoantibodies present in the sera of diabetic patients. 
 
3.1.1.  Fusion partners 
 
All hybridomas were generated using the non-secreting fusion partner Sp2/0-
Ag14, except for 1E2 where NS0 was used.  NS0 is also a non-secreting fusion 
partner.  Both NS0 and Sp2/0-Ag14 are mutant myeloma cells, which do not 
secrete their own immunoglobulins, derived from the original MOPC-21 tumour 
(Carroll et al., 1988).  Thus, the hybridoma cell lines only secrete antibodies 
originating from the B cell fusion partner.  However, because these cells can still 
synthesise nontranslatable immunoglobulin RNA transcripts, the analysis of the 
immunoglobulin cDNA from the hybridoma cells is problematic. 
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3.2.  ISOLATION OF RNA 
 
3.2.1.  Determination of total RNA concentration 
 
Total RNA was extracted from the five hybridoma cell lines using the RNeasy kit 
from Qiagen.  The concentration of total RNA (Table 3.1) was determined spectro-
photometrically (OD260) ([RNA] = OD260 x 0.04 µg/µl x dilution factor) and an 
aliquot run on a 1% agarose gel to confirm the presence of intact total RNA 
(Figure 3.1). 
 
Table 3.1:  Total RNA concentration extracted from the five hybridoma cell lines. 
HYBRIDOMA CELL LINE No. OF CELLS RNA CONCENTRATION 
1E2 ~ 6.0 x 106 480 ng/µl 
NS0 ~ 5.6 x 106 380 ng/µl 
HB-123 ~ 5.4 x 106 295 ng/µl 
HB-126 ~ 6.0 x 106 340 ng/µl 
HB-127 ~ 6.4 x 106 355 ng/µl 
DP-D ~ 5.7 x 106 336 ng/µl 
 
 
 
 
Figure 3.1:  Photograph of total RNA extracted from the 1E2 and NSO (fusion  
partner) cell lines and run on a 1% agarose gel. 
Lane 1: Molecular weight marker, Lane 2: 1E2 total RNA (15 µl), Lane 
3: NS0 total RNA (15 µl). 
28S ribosomal RNA (5 kb) 
18S ribosomal RNA (1.9 kb) 
1      2     3 
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3.2.2.  Isolation and concentration determination of mRNA 
 
mRNA was immediately isolated from the total RNA samples using Oligotex spin 
columns from Qiagen and the concentration determined spectrophotometrically 
(Table 3.2). 
 
Table 3.2:  The concentration of mRNA. 
HYBRIDOMA CELL LINE OD260 mRNA CONCENTRATION 
1E2 0.0297 30 ng/µl 
NS0 0.0185 18.5ng/µl 
HB-123 0.1514 24 ng/µl 
HB-126 0.0776 12.5 ng/µl 
HB-127 0.0915 14.5 ng/µl 
DP-D 0.1148 18.4 ng/µl 
 
Initially, our aim was to produce a single-chain Fv fragment that contained the 
antigen binding domain of an anti-insulin IgG monoclonal antibody secreted by the 
1E2 cell line. 
 
3.3.  CONSTRUCTION OF THE scFv FRAGMENT 
 
3.3.1.  PCR amplification of the 1E2 anti-insulin mAb heavy and light chain 
variable genes 
 
Messenger RNA was isolated from the 1E2 anti-insulin producing hybridoma cells 
and the NS0 cell line.  NS0 was the fusion partner used for the production of the 
1E2 hybridoma cell line.  cDNA was synthesised from the mRNA and PCR 
performed using immunoglobulin V region specific oligonucleotide primers (Figure 
3.2).  PCR products of the amplified light and heavy chain variable region genes 
are in the range of 300 – 340bp.  With the use of the heavy chain specific primers, 
two different VH cDNA products, in the correct size range (~ 340 bp and ~ 300 bp), 
were obtained from the 1E2 hybridoma cell line and a single PCR product (~300 
bp) was observed in the NS0 cell line (Figure 3.2A).  The light chain specific 
primers produced a single PCR band in the correct size range (~ 330 bp) which 
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was present in both the 1E2 hybridoma and NS0 cell line (Figure 3.2B).  Despite 
numerous attempts to optimise the PCR (e.g. adjusting the annealing temperature, 
MgCl2 concentrations, use of different Taq polymerases) it was not possible to 
remove the spurious bands that are visible in Figure 3.2.  However, because these 
were not in the predicted size range of the heavy and light chain gene PCR 
products, they did not interfere with downstream applications. 
 
 
                     
 
Figure 3.2:  PCR of murine immunoglobulin variable regions from 1E2 and NS0. 
A.  Light chain variable region amplification. 
Lane 1: Marker (Promega, 100bp DNA ladder; 100, 200, 300, 400, 
500, 600, 700, 800, 900, 1 000, 1 500); Lanes 2-3: 1E2 light chain 
gene product; Lanes 4-5: NS0 light chain gene product; Lane 6: 
Negative control. 
B.  Heavy chain variable region amplification. 
Lane 1: Marker (Promega, 100bp DNA ladder; 100, 200, 300, 400, 
500, 600, 700, 800, 900, 1 000, 1 500); Lanes 2-3: 1E2 heavy chain 
gene product; Lanes 4-5: NS0 heavy chain gene product; Lane 6: 
Negative control. 
 
Aberrant heavy (Vidarsson et al., 2001) and light (Carroll et al., 1988) chain mRNA 
transcripts have been reported in standard fusion partners derived from the 
original MOPC-21 tumour.  In order to determine whether or not we amplified the 
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functional heavy and light chain genes, and not the aberrant transcripts, the PCR 
products (indicated by an arrow in Figure 3.2) were cut out of the agarose gel, 
purified, and sequenced directly (Figure 3.3).  The nucleotide and deduced amino 
acid sequence of the variable light (Figure 3.4) and variable heavy (Figure 3.5) 
chains are shown for 1E2 and NS0.  Results are only shown for the lower 1E2 
heavy chain PCR product (Figure 3.2B) as we were unable to obtain readable 
sequence for the larger heavy chain band. 
 
A. 
 
B. 
 
 
Figure 3.3:  Electropherogram of sequencing results obtained for: 
         A.  NS0 light chain (VK1FOR). 
         B.  1E2 heavy chain (VH1BACK). 
 
 
cagctgacccagtctccagcttccttagctgtatctctggggcagagggccaccatctcatacagg 
 Q  L  T  Q  S  P  A  S  L  A  V  S  L  G  Q  R  A  T  I  S  Y  R  
gccagcaaaagtgtcagtacatctggctatagttatatgcactggaaccaacagaaaccaggacag 
 A  S  K  S  V  S  T  S  G  Y  S  Y  M  H  W  N  Q  Q  K  P  G  Q  
ccacccagactcctcatctatcttgtatccaacctagaatctggggtccctgccaggttcagtggc 
 P  P  R  L  L  I  Y  L  V  S  N  L  E  S  G  V  P  A  R  F  S  G  
agtgggtctgggacagacttcaccctcaacatccatcctgtggaggaggaggatgctgcaacctat 
 S  G  S  G  T  D  F  T  L  N  I  H  P  V  E  E  E  D  A  A  T  Y  
tactgtcagcacattagggagcttacacgttcggagggggcaccaagctggaaataa 
 Y  C  Q  H  I  R  E  L  T  R  S  E  G  A  P  S  W  K  *  
 
Figure 3.4:  Nucleotide and deduced amino acid sequence of 1E2/NS0 light  
chain variable region. 
A single sequence is shown as the sequences obtained for 1E2 and 
NS0 were identical. 
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A. 
 
 
 
 
 
 
B. 
 
 
 
 
 
Figure 3.5:  Nucleotide and deduced amino acid sequence of: 
A.  1E2 heavy chain variable region (lower band ~ 300 bp) 
B.  NS0 heavy chain variable region. 
 
The 1E2 and NS0 heavy chain sequences were aligned for homology comparison 
(Figure 3.6).  The 1E2 and NS0 heavy chains were 95% homologous at the 
nucleotide level (Appendix 2). 
 
 
 
Figure 3.6:  1E2 and NS0 heavy chain amino acid sequence alignment. 
 
These sequences were then compared to the published sequences for the 
aberrant kappa and heavy chain transcripts.  The nucleotide sequence obtained 
for the 1E2/NS0 kappa chain PCR products showed 99% homology (Appendix 3) 
ggaggcttagtgcagcctggagggtcccggaaactctcctgtgcagcctctggattcactttcagt
 G  G  L  V  Q  P  G  G  S  R  K  L  S  C  A  A  S  G  F  T  F  S  
acctttggaatgcactggattcgtcaggctccagagaggggactggagtgggtcgcatacattagt 
 T  F  G  M  H  W  I  R  Q  A  P  E  R  G  L  E  W  V  A  Y  I  S  
agtggcagtagtgccatctactatgcagactcagtaaagggccgtttcaccatctccagagacaat 
 S  G  S  S  A  I  Y  Y  A  D  S  V  K  G  R  F  T  I  S  R  D  N  
cccaagaacaccctgttcctgcaaatgaccagtctaaggtctgaggacacggccatgtattactgt 
 P  K  N  T  L  F  L  Q  M  T  S  L  R  S  E  D  T  A  M  Y  Y  C  
gcaaga 
 A  R 
ggaggcttagtgcagcctggagggtcccggaaactctcctgtgcagcctctggattcactttcagt
 G  G  L  V  Q  P  G  G  S  R  K  L  S  C  A  A  S  G  F  T  F  S  
agctttggaatgccctgggttcgtcaggctccagagaaggggctggagtgggtcgcatacattagt 
 S  F  G  M  P  W  V  R  Q  A  P  E  K  G  L  E  W  V  A  Y  I  S  
agtggcagtagtaccctccactatgcagacacagtgaagggccgattcaccatctccagagacaat 
 S  G  S  S  T  L  H  Y  A  D  T  V  K  G  R  F  T  I  S  R  D  N  
cccaagaacaccctgttcctgcaaatgaaactaccctcactatgctatggactactggggtcaagg 
 P  K  N  T  L  F  L  Q  M  K  L  P  S  L  C  Y  G  L  L  G  S  R  
  130
to the kappa chain transcript reported by Carroll et al. (1988).  The 1E2 heavy 
chain nucleotide sequences exhibited 81% and 86% homology (Appendix 4) to 
two fragments of the aberrant heavy chain transcript (AberrG7) described by 
Vidarsson and colleagues (2001).  The NS0 heavy chain nucleotide sequence was 
72% identical to the AberrG7 aberrant heavy chain transcript (Appendix 5). 
 
Expression levels of the non-functional kappa chain transcript must have been 
relatively high in the 1E2 hybridoma cell line, exceeding that of the 1E2 functional 
kappa chain transcript.  Thus, we were only able to amplify the aberrant 1E2 light 
chain transcript.  Similarly, it appeared that we were only able to amplify the 
aberrant heavy chain transcript.  It was, therefore, decided to construct a Fab 
fragment instead of the scFv. 
 
3.4.  CONSTRUCTION OF THE FAB FRAGMENTS 
 
3.4.1.  Amplification of the light chain and Fd fragment of the heavy chain of 
the five mAbs 
 
The mRNA was isolated from four anti-insulin producing hybridoma cell lines (1E2, 
HB-123, HB-126, and HB-127), NS0 (the fusion partner for 1E2) and the DP-D B 
cell clone that secretes monoclonal antibodies against GAD65 (Madec et al., 
1996).  mRNA was reverse transcribed to produce cDNA which was used in the 
subsequent PCR reactions to amplify the heavy and light chain fragments of the 
anti-insulin and anti-GAD65 monoclonal antibodies.  The VHCH1 construct was 
created with primers representing the leader sequence 5 to 8 amino acids 5' of the 
variable heavy chain framework 1 region and amino acids 205 to 220 of the first 
constant heavy chain region.  The VLCL construct was created with primers 
representing the leader sequence 5 to 8 amino acids 5' of the variable light chain 
framework 1 region and amino acids 205 to 220 of the constant light chain region.  
Control (negative) PCR reactions were set up for each primer pair.  Figure 3.7 
illustrates the results obtained from the amplification of mAb 126 light and heavy 
chain genes.  Similar results were obtained from amplification of the other four 
mAbs (results not shown).  Table 3.3 summarises the results obtained from the 
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amplification of the heavy and light chain regions of the five monoclonal antibodies 
studied and those obtained for the NS0 myeloma cell line. 
 
 
 
        
 
 
 
 
 
 
 
 
 
    
 
 
 
 
 
 
 
Figure 3.7:  A.  PCR amplification of the light chain regions from mRNA isolated  
from insulin-specific hybridoma cell line HB-126. 
Lane 1: Marker (Promega, 100bp DNA ladder), Lanes 2-8: PCR 
products obtained with the light chain primers 2-6, 8, and 9, 
respectively; Lanes 9-15: Negative controls for the light chain primers 
2-6, 8, and 9. 
B.  PCR amplification of the Fd heavy chain fragment from mRNA 
isolated from insulin-specific hybridoma cell line HB-126. 
Lane 1: Marker (Promega, 100bp DNA ladder), Lanes 2-5: PCR 
products obtained with the heavy chain primers 1-4, respectively; 
Lanes 6-9: Negative controls for the heavy chain primers 1-4. 
A. 1      2      3      4      5      6      7      8      9     10    11    12     13    14    15
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Table 3.3:  PCR products amplified from the five hybridoma cell lines using ten  
pairs of primers specific for the heavy and the light chain genes. 
PCR AMPLIFICATION WITH PRIMER PAIR: CELL 
LINE 1 2 3 4 5 6 7 8 9 10 
NS0 (L)   9        
NS0 (H)        9   
1E2 (L)  9 9 9 9   9 9  
1E2 (H)        9   
HB-123 (L)  9 9 9 9  9   9 
HB-123 (H) 9 9 9 9  9     
 9 9 9 9 9  9 9  HB-126 (L) 
HB-126 (H) 9 9 9 9       
HB-127 (L)  9 9 9 9    9  
HB-127 (H) We were not able to amplify the heavy chain 
9 9 9 9 9 9 9    DP-D (L) 
DP-D (H) 9 9 9 9 9 9     
L = Light chain, H = Heavy chain 
 
As can be seen from Table 3.3, we again had amplification of heavy and light 
chain genes from the NS0 cell line.  The PCR product obtained for the 1E2 light 
chain primer pair 3 was, as a result, not used in any further downstream 
applications due to the presence of an amplification product, with the same primer 
pair, in the NS0 cell line.  A single heavy chain PCR product was amplified for the 
1E2 and NS0 heavy chain (primer 8).  This PCR product was sequenced and 
compared with that obtained for the 1E2 heavy chain when constructing the scFv 
(Figure 3.5).  When the two sequences were aligned, they showed 100% 
homology for the variable region of the heavy chain gene (Figure 3.8).  Due to the 
amplification of the aberrant 1E2 heavy chain transcript, no further experiments 
were carried out on this cell line. 
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Figure 3.8:  1E2 scFv and Fab heavy chain amino acid sequence alignment. 
 
3.4.2.  Subcloning of the heavy and light chains into the TOPO vector for 
sequencing 
 
Following PCR amplification of the Fd heavy and light chain genes from the four 
cell lines (HB-123, HB-126, HB-127, and DP-D), all PCR products in the correct 
size range (approximately 660 bp; Table 3.3) were cut out of the gel, purified and 
ligated into the TOPO vector.  Ultracompetent E. coli cells were transfected with 
the resultant TOPO vector and colonies allowed to grow on LA plates overnight.  
To ensure that the colonies contained the TOPO vector with the immunoglobulin 
insert, plasmids were isolated using alkaline lysis miniprep procedures and an 
aliquot of the plasmid DNA digested with EcoRI (this restriction enzyme flanks the 
insert site) to confirm the presence and size of the insert (Figure 3.9). 
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Primer 4 
 
         
 
Figure 3.9:  Screening of murine immunoglobulin light chain recombinant  
plasmids: a 1% agarose gel showing the EcoRI digested TOPO vector 
and the presence or absence of the approximately 700 bp A) HB-126 
light chain insert [obtained from amplification with light chain specific 
primers 2, 6, and 8] and B) HB-126 heavy chain insert (obtained from 
amplification with heavy chain specific primers 1, 2, 3, and 4). 
A.  Lane 1: Marker (Promega, 100bp DNA ladder), Lanes 2-11: 
Plasmid miniprep samples digested with EcoRI. 
B.  Lane 1: Marker (Promega, 100bp DNA ladder), Lanes 2-11: 
Plasmid miniprep samples digested with EcoRI. 
 
Recombinant plasmids with the correct size heavy/light chain insert, for each 
primer pair that amplified a PCR product, from each of the four cell lines (HB-123, 
HB-126, HB-127, and DP-D), were selected, and sequenced.  All the heavy and 
light chain sequences for a particular mAb were aligned and analysed using the 
computer software programme Sequencher.  A single heavy and light chain 
sequence, for each mAb, was selected based on the alignments.  These 
nucleotide sequences were blasted against known sequences in GenBank to 
confirm the presence of immunoglobulin sequence (data not shown).  A single 
recombinant plasmid containing the immunoglobulin light chain insert and a 
recombinant plasmid containing the immunoglobulin heavy chain insert, for each 
mAb, were selected for the production of rFab fragments. 
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3.4.3.  Construction of expression plasmids for production of rFab fragments 
 
The cloned mAb-derived light chains and Fd fragments of the heavy chains were 
reamplified with primer pairs to introduce the restriction sites necessary for 
directional subcloning of the PCR products into the pCXII vector (4.7 kb).  The 
heavy chain fragment was subsequently isolated from the plasmid using BsrGI 
and HindIII restriction sites flanking the insert.  This was ligated into the pCXII 
vector containing the light chain gene insert using the same enzymes.  The entire 
light and heavy chain construct was then cut out with EcoRI and HindIII and 
ligated into the expression vector pAK19 (6.4 kb).  The ligated plasmids were 
transformed into competent E. coli 25F2 cells, and recombinant bacteria identified 
using carbenicillin resistance as a selective marker.  To ensure that the colonies 
contained the expression vector with an intact light chain and Fd fragment of the 
heavy chain, vectors were isolated using alkaline lysis miniprep procedures and an 
aliquot of the plasmid DNA digested with MluI and SphI.  This digest will effectively 
result in the presence of two bands visible upon agarose gel electrophoresis; the 
MluI restriction sites flank the light chain insert and MluI and SphI are situated 5’ 
and 3’, respectively, of the heavy chain insert.  The construction of the pAK19 
expression vector is summarised in the flow diagram below.  All results shown are 
for the construction of the 126 Fab.  Similar results were obtained for mAbs 123 
and DP-D.  An expression vector could not be constructed for mAb 127 as we 
were not able to amplify the heavy chain gene. 
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PCR products were checked on 
an agarose gel (Figure 3.10). 
Heavy and light chain PCR 
products were reamplified with 
primers introducing restriction sites 
at the 5’ and 3’ ends. 
PCR products were digested 
(Figure 3.11), purified, cloned into 
the TOPO vector and 
ultracompetent E. coli cells 
transfected. 
The presence of the heavy and light chain in the TOPO vector was confirmed by 
restriction digest with EcoRI (Figure 3.12). 
MluI/SphI and MluI/BsrGI digested 
heavy and light chains were cloned 
into the pC vector and 
ultracompetent E. coli cells 
The pC vector was digested with 
MluI/SphI and MluI/BsrGI (Figure 
3.13) for cloning of the heavy and 
light chain, respectively. 
The presence of the heavy and light chain in the pC vector was confirmed by 
restriction digest with EcoRI/HindIII (Figure 3.14). 
The heavy chain was cut from the 
pC vector by digestion with 
BsrGI/HindIII (Figure 3.16) and 
purified. 
The pC vector with the light chain 
insert was digested with 
BsrGI/HindIII (Figure 3.15) and the 
product purified. 
  139
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The EcoRI/HindIII insert was 
purified and ligated to the similarly 
digested and purified expression 
vector pAK19 (Figure 3.18). 
E. coli cells were transfected with the pAK19 vector.  Plasmids were digested 
with EcoRI/HindIII to confirm the presence of the immunoglobulin heavy and 
light chains (Figure 3.19). 
The presence of an intact light and heavy chain insert was confirmed by 
restriction digest with MluI/SphI (Figure 3.20). 
The heavy chain was ligated into the pC vector containing the light chain insert.   
E. coli cells were transfected and recombinant plasmids digested with 
EcoRI/HindIII to confirm the presence of the immunoglobulin heavy and light 
chains (Figure 3.17). 
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A.                   B. 
                                  
 
Figure 3.10:  PCR products, run on a 1% agarose gel, of the reamplified heavy  
and light chain fragments using primers incorporating restriction sites 
at the 5’ and 3’ sites. 
A.  Heavy chain PCR products.  Lane 1: Marker (Promega, 100bp 
DNA ladder); Lanes 2-4: PCR products; Lane 5: Negative control. 
B.  Light chain PCR products.  Lane 1: Marker (Promega, 100bp 
DNA ladder); Lanes 2-5: PCR products; Lane 6: Negative control. 
 
 
 
                                            
 
Figure 3.11:  Digested heavy and light chain PCR products run on a 1% agarose  
gel. 
Lane 1: Marker (Promega, 100bp DNA ladder); Lanes 3-4: Light 
chain digested with MluI/BsrGI; Lanes 6-7: Heavy chain digested 
with MluI/SphI. 
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A. 
 
 
 
 
 
 
 
B. 
 
 
 
 
 
 
 
Figure 3.12:  TOPO vector digested with EcoRI. 
A.  Lane 1: Marker (Promega, 100bp DNA ladder); Lanes 2-7: Heavy 
chain insert (~ 720 bp).  B.  Lane 1: Marker (Promega, 100bp DNA 
ladder); Lanes 2-11: Light chain insert (~ 700 bp). 
 
 
 
 
 
 
 
 
 
Figure 3.13:  pCXII vector (containing unrelated immunoglobulin heavy and light  
chain) digested with MluI/BsrGI and MluI/SphI for cloning of the light 
and heavy chains, respectively. 
Lanes 1-2: pCXII digested with MluI/BsrGI; Lane 3: Marker 
(Promega, 100bp DNA ladder); Lanes 4-5: pCXII digested with 
MluI/SphI. 
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Figure 3.14:  pCXII vector digested with EcoRI/HindIII. 
Lane 1 and 11: Marker (Promega, 100bp DNA ladder); Lanes 2-10: 
pCXII vector with light chain insert; Lanes 12-17: pCXII vector with 
heavy chain insert. 
 
 
 
  
 
Figure 3.15:  pCXII vector with light chain insert digested with BsrGI/HindIII. 
Lane 1: Marker (Promega, 100bp DNA ladder); Lanes 2-3: Digested 
pCXII vector. 
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Figure 3.16:  pCXII vector with heavy chain insert digested with BsrGI/HindIII. 
Lane 1: Marker (Promega, 100bp DNA ladder); Lanes 2-4: Heavy 
chain insert (± 1 kb) cut from pCXII. 
 
 
 
 
      
 
Figure 3.17:  Heavy and light chain construct in pCXII vector digested with  
EcoRI/HindIII. 
Lane 1: Marker (Promega, 100bp DNA ladder); Lanes 2, 4, 7-8, 12-
13: pCXII with light chain insert only; Lanes 3, 5-6, 9-11: pCXII with 
heavy and light chain construct. 
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Figure 3.18:  Purified heavy and light chain gene construct and pAK19 vector  
which have been digested with EcoRI/HindIII for cloning. 
Lane 1: Marker (Promega, 100bp DNA ladder); Lane 2: Purified 
pAK19, Lane 3: Purified heavy chain insert. 
 
 
 
 
     
 
Figure 3.19:  Heavy and light chain construct cloned into the pAK19 vector,  
digested with EcoRI/HindIII. 
Lane 1: Marker (Promega, 100bp DNA ladder); Lanes 2-5: pAK19 
with heavy and light chain construct. 
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Figure 3.20:  Agarose gel electrophoresis of the expression vector pAK19 which  
has been digested with MluI and SphI. 
Lane 1: Marker (Promega, 100bp DNA ladder); Lanes 2-3: The two 
lower bands represent the heavy and light chain fragments cut from 
pAK19 (upper band). 
 
Before performing the expression experiments the heavy and light chain genes in 
pAK19 were sequenced to ensure that no mutations had been introduced. 
 
3.4.4.  Sequence analysis of the heavy and light chains of rFab 
 
The nucleotide and deduced amino acid sequences of rFab 126 and DP-D, 
determined by cloning and sequencing of the light chain and Fd fragment of the 
heavy chain genes, are shown in Figure 3.21 and Figure 3.22, respectively.  The 
heavy chain contains the entire variable region plus the first constant domain.  The 
light chain contains the entire variable region plus the constant kappa domain.  
Results are only shown for those rFab which showed dose dependent binding to 
their respective antigens i.e., rFab 126 and rFab DP-D. 
 
The variable region protein sequences deduced from the nucleotide sequences 
were aligned for comparison with germline sequences from the NCBI data bank 
(http://www.ncbi.nlm.nih.gov/igblast/showGermline.cgi).  The nucleotide 
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sequences for both kappa and heavy chain genes of mAb 126 were submitted to 
GenBank under accession numbers AY691554 and AY691555, respectively.  
Sequence analysis of the 126 heavy chain-specific cDNA and comparison of the 
deduced amino acid sequence revealed that VH belonged to the mouse IgG heavy 
chain subgroup 1.  Germline Vh45.21.1 (Akolkar et al., 1987) displayed the highest 
degree of identity (94%) with the 126 heavy chain.  The 20 nucleotide differences 
yielded seven amino acid residue replacements located mainly in CDR 1 and CDR 
2.  Sequence analysis of the light chain-specific cDNA and database comparison 
of the deduced amino acid sequence revealed that the VL belonged to the mouse 
kappa light chain group 1.  The germline kappa chain 23.43 (Schable et al., 1999) 
showed 100% identity on the nucleotide level.  The predicted amino acid 
sequence of rFab 126 was aligned with the amino acid sequences from the 
remaining three anti-insulin secreting hybridoma cell lines; where sequences were 
available (Figure 3.23). 
 
Sequence analysis of the DP-D heavy chain-specific cDNA and comparison of the 
deduced amino acid sequence revealed that VH belonged to the human IgG heavy 
chain subgroup 1.  Germline Vh4.4 displayed the highest degree of identity (95%) 
with the DP-D heavy chain (Matsuda et al., 1998).  The 14 nucleotide differences 
yielded six amino acid residue replacements distributed randomly in the variable 
region (i.e. in the framework and complementarity determining regions).  
Sequence analysis of the light chain-specific cDNA and database comparison of 
the deduced amino acid sequence revealed that the VL belonged to the human 
kappa light chain subgroup 4 (Klobeck et al., 1985).  The germline kappa chain B3 
showed 97% identity on the amino acid level.  The three amino acid replacements 
were located in CDR 1, 2 and 3.  The predicted amino acid sequence of rFab DP-
D was aligned with the sequences of five other GAD65 rFab (Padoa et al., 2003; 
Figure 3.24).  A comparison of the overlapping amino acid sequence in the CDRs 
of the heavy chains showed that amino acid sequences derived from the human 
rFab DP-D and DP-A were closely related to each other (60% homology), but 
while they share the same CDR1 and CDR2 classes, they differ in the CDR3 
class.  The great variety in CDR classes and sequences between the antibodies 
suggests that the antibodies do not recognise the same epitopes on GAD65. 
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A.  gatattgtgctaactcagtctccagccaccctgtctgtgactccaggagatagcgtcagt 
             D  I  V  L  T  Q  S  P  A  T  L  S  V  T  P  G  D  S  V  S 
ctttcctgcagggccagccaaagtattagcaacaacctacactggtatcaacaaaaatcacatgagtctcca 
 L  S  C  R  A  S  Q  S  I  S  N  N  L  H  W  Y  Q  Q  K  S  H  E  S  P 
aggcttctcatcaagtatgcttcccagtccatctctgggatcccctccaggttcagtggcagtggatcaggg 
 R  L  L  I  K  Y  A  S  Q  S  I  S  G  I  P  S  R  F  S  G  S  G  S  G 
acagatttcactctcagtatcaacagtgtggagactgaagattttggaatgtatttctgtcaacagagtaac 
 T  D  F  T  L  S  I  N  S  V  E  T  E  D  F  G  M  Y  F  C  Q  Q  S  N 
agctggcctcacacgttcggctcggggacaaagttggaaataaaacgggctgatgctgcaccaactgtatcc 
 S  W  P  H  T  F  G  S  G  T  K  L  E  I  K  R  A  D  A  A  P  T  V  S 
atcttcccaccatccagtgagcagttaacatctggaggtgcctcagtcgtgtgcttcttgaacaacttctac 
 I  F  P  P  S  S  E  Q  L  T  S  G  G  A  S  V  V  C  F  L  N  N  F  Y 
cccaaagacatcaatgtcaagtggaagattgatggcagtgaacgacaaaatggcgtcctgaacagttggact 
 P  K  D  I  N  V  K  W  K  I  D  G  S  E  R  Q  N  G  V  L  N  S  W  T 
gatcaggacagcaaagacagcacctacagcatgagcagcaccctcacgttgaccaaggacgagtatgaacga 
 D  Q  D  S  K  D  S  T  Y  S  M  S  S  T  L  T  L  T  K  D  E  Y  E  R 
cataacagctatacctgtgaggccactcacaagacatcaacttcacccattgtcaagagcttcaacaggaat 
 H  N  S  Y  T  C  E  A  T  H  K  T  S  T  S  P  I  V  K  S  F  N  R  N 
gagacccgttgttag 
 E  T  R  C  * 
 
B.        gaggtccagctgcaacagtctggacctgagctggtgaagcctggggcttcagtgaag 
                E  V  Q  L  Q  Q  S  G  P  E  L  V  K  P  G  A  S  V  K 
atatcctgcaagacttctggatacacattcactgaatacaccatgcactgggtgaagcagagccatggaaag 
 I  S  C  K  T  S  G  Y  T  F  T  E  Y  T  M  H  W  V  K  Q  S  H  G  K 
agccttgagtggattggaggtattaatcctaacaatggtggttctaactacaaccagaagttcaagggcaag 
 S  L  E  W  I  G  G  I  N  P  N  N  G  G  S  N  Y  N  Q  K  F  K  G  K 
gccacattgactgtagacaagtcctccagcacagcctacatggagctccgcagcctgacatctgaggattct 
 A  T  L  T  V  D  K  S  S  S  T  A  Y  M  E  L  R  S  L  T  S  E  D  S 
gcagtctattactgtgcaagatttggggcccgttactacggtagtagctacggaagctggtacttcgatgtc 
 A  V  Y  Y  C  A  R  F  G  A  R  Y  Y  G  S  S  Y  G  S  W  Y  F  D  V 
tggggcgcagggaccacggtcaccgtctcctcagccaaaacgacacccccatctgtctatccactggcccct 
 W  G  A  G  T  T  V  T  V  S  S  A  K  T  T  P  P  S  V  Y  P  L  A  P 
ggatctgctgcccaaactaactccatggtgaccctgggatgcctggtcaagggctatttccctgagccagtg 
 G  S  A  A  Q  T  N  S  M  V  T  L  G  C  L  V  K  G  Y  F  P  E  P  V 
acagtgacctggaactctggatccctgtccagcggtgtgcacaccttcccagctgtcctgcagtctgacctc 
 T  V  T  W  N  S  G  S  L  S  S  G  V  H  T  F  P  A  V  L  Q  S  D  L 
tacactctgagcagctcagtgactgtcccctccagcacctggcccagcgagaccgtcacctgcaacgttgcc 
 Y  T  L  S  S  S  V  T  V  P  S  S  T  W  P  S  E  T  V  T  C  N  V  A 
cacccggccagcagcaccaaggtggacaagaaaattgagacccgttgtcaacaccaccaccaccaccactga 
 H  P  A  S  S  T  K  V  D  K  K  I  E  T  R  C  Q  H  H  H  H  H  H  * 
 
Figure 3.21:  Nucleotide sequence and deduced amino acid sequence of the  
A) light and B) heavy chain of HB-126 mAb. 
The CDRs according to Kabat et al. (1991) are boxed and the amino 
acid residue differences in comparison to the germline sequences 
are bold. 
 
 
 
A. aacgcgtatgctgacattgtgatgacccagtctccagactccctggctgtgtctctgggcgagagg 
       N  A  Y  A  D  I  V  M  T  Q  S  P  D  S  L  A  V  S  L  G  E  R  
gccaccatcaactgcaagtccagccagattgttttatacagctccaacaacaagaactatttagcttggtac 
 A  T  I  N  C  K  S  S  Q  I  V  L  Y  S  S  N  N  K  N  Y  L  A  W  Y  
cagcagaaaccaggacagcctcctaaactgctcatttactgggcatctacccggaaatccggggtccctgac 
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 Q  Q  K  P  G  Q  P  P  K  L  L  I  Y  W  A  S  T  R  K  S  G  V  P  D  
cgattcagtggcagcgggtctgggacagatttcactctcaccatcagcagcctgcaggctgaagatgtggca 
 R  F  S  G  S  G  S  G  T  D  F  T  L  T  I  S  S  L  Q  A  E  D  V  A  
gtttattactgtcagcaatactatactactccgctcactttcggcggagggaccaaggtggagatcaaacga 
 V  Y  Y  C  Q  Q  Y  Y  T  T  P  L  T  F  G  G  G  T  K  V  E  I  K  R  
actgtggctgcaccatctgtcttcatcttcccgccatctgatgagcagttgaaatctggaactgcctctgtt 
 T  V  A  A  P  S  V  F  I  F  P  P  S  D  E  Q  L  K  S  G  T  A  S  V  
gtgtgcctgctgaataacttctatcccagagaggccaaagtacagtggaaggtggataacgccctccaatcg 
 V  C  L  L  N  N  F  Y  P  R  E  A  K  V  Q  W  K  V  D  N  A  L  Q  S  
ggtaactcccaggagagtgtcacagagcaggacagcaaggacagcacctacagcctcagcagcaccctgacg 
 G  N  S  Q  E  S  V  T  E  Q  D  S  K  D  S  T  Y  S  L  S  S  T  L  T  
ctgagcaaagcagactacgagaaacacaaagtctacgcctgcgaagtcacccatcagggcctgagctcgccc 
 L  S  K  A  D  Y  E  K  H  K  V  Y  A  C  E  V  T  H  Q  G  L  S  S  P  
gtcacaaagagcttcaacaggggagagtcttaa 
 V  T  K  S  F  N  R  G  E  S  - 
 
B. caggtgcagctggtggagtctggcccaggactggtgaagccttcggagaccctgtccctcacctgc 
       Q  V  Q  L  V  E  S  G  P  G  L  V  K  P  S  E  T  L  S  L  T  C  
actgtttctggtggctccatcagtatttactactggagctggatccgccagcccgccgcgaagggactggag 
 T  V  S  G  G  S  I  S  I  Y  Y  W  S  W  I  R  Q  P  A  A  K  G  L  E  
tggattgggcgtatctataccaatgggaccaccaattacaacccctccctcaagagtcgagtctccatgtca 
 W  I  G  R  I  Y  T  N  G  T  T  N  Y  N  P  S  L  K  S  R  V  S  M  S  
gtagacacgtccaagaaccagttctccctgaaactgacctctgtgaccgccgcggacacggccgtatattac 
 V  D  T  S  K  N  Q  F  S  L  K  L  T  S  V  T  A  A  D  T  A  V  Y  Y  
tgtgcgagacaagggggcctagtgggagccagcggacggcgtgactactttgactactggggccagggaacc 
 C  A  R  Q  G  G  L  V  G  A  S  G  R  R  D  Y  F  D  Y  W  G  Q  G  T  
ctggtcaccgtctcctcagcctccaccaagggcccatcggtcttccccctggcaccctcctccaagagcacc 
 L  V  T  V  S  S  A  S  T  K  G  P  S  V  F  P  L  A  P  S  S  K  S  T  
tctgggggcacagcggccctgggctgcctggtcaaggactacttccccgaaccggtgacggtgtcgtggaac 
 S  G  G  T  A  A  L  G  C  L  V  K  D  Y  F  P  E  P  V  T  V  S  W  N  
tcaggcgccctgaccagcggcgtgcacaccttcccggctgtcctacagtcctcaggactctactccctcagc 
 S  G  A  L  T  S  G  V  H  T  F  P  A  V  L  Q  S  S  G  L  Y  S  L  S  
agcgtggtgaccgtgccctccagcagcttgggcacccagacctacatctgcaacgtgaatcacaagcccagc 
 S  V  V  T  V  P  S  S  S  L  G  T  Q  T  Y  I  C  N  V  N  H  K  P  S  
aacaccaaggtggacaagaaagttgagcccaaatcttgtgacaaaactagtacatgcaagggcgaacaccac 
 N  T  K  V  D  K  K  V  E  P  K  S  C  D  K  T  S  T  C  K  G  E  H  H  
caccaccaccactga 
 H  H  H  H  -  
 
Figure 3.22:  Nucleotide sequence and deduced amino acid sequence of the  
A) light and B) heavy chain of DP-D mAb. 
The CDRs according to Kabat et al. (1991) are boxed and the amino 
acid residue differences in comparison to the germline sequences 
are bold. 
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Figure 3.23:  Light (A) and heavy (B) chain amino acid alignment for those cell lines for which sequence data was  
available.  The CDRs are boxed (Kabat et al., 1991) and the start of the constant regions shown by the 
arrow (        ).  High consensus is shown in red and low consensus in blue.  Consensus symbols: ! is anyone 
of IV, $ is anyone of LM, % is anyone of FY, # is anyone of NDQEBZ. 
A. 
B. 
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Figure 3.24:  Light (A) and heavy (B) chain amino acid sequence alignment of rFabs 144, 221-442, DP-A, DP-C, DP-D, 
and b96.11.  Boxes indicate the CDRs according to Kabat et al., 1991 and the start of the constant regions are shown by 
the arrow (        ).
B. 
A. 
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3.5.  THE EXPRESSION AND PURIFICATION OF rFAB 
 
3.5.1.  Expression of rFabs 
 
A single recombinant colony was grown in MOPS medium and expression of the 
rFab (HB-123, HB-126, and DP-D) induced by phosphate starvation.  rFab 
fragments were isolated from the periplasmic space. 
 
3.5.2.  Purification of rFabs 
 
The rFab fragments (HB-123, HB-126, and DP-D) were subsequently purified by 
two affinity chromatography steps on Ni-NTA agarose and PGS.  The resulting 
protein eluate was analysed by standard 15% SDS-polyacrylamide gel 
electrophoresis under reducing conditions.  Heavy and light chain protein bands 
were identified by Western blots (Figure 3.25).  In the Western blot analysis, for 
detection of the heavy and light chain, a penta-His HRP (Qiagen; 1:4 000) and rat 
anti-mouse kappa:HRP (Stratagene; 1:4 000) conjugate were used, respectively.  
After incubating the membrane at room temperature for an hour followed by 
extensive washing, the bands were visualized using standard ECL techniques.  
Results are shown for rFab 126.  Similar results were obtained for rFab HB-123 
and DP-D. 
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Figure 3.25:  SDS-PAGE analysis of recombinant, affinity purified Fab 126. 
Lane 1: Molecular weight marker (Kaleidoscope prestained 
standards: blue-7 kDa, red-18.8 kDa, orange-32.2 kDa, violet-42.3 
kDa, green-83 kDa, magenta-124 kDa, blue-206 kDa); Lanes 2-8: 
Eluted fractions from PGS purification of Fab 126.  After reduction 
with β-ME, a band of ~23 kDa (free light chain; top blot) or ~25 kDa 
(free heavy chain Fd fragment, bottom blot) was observed. 
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3.6.  ANTIGEN RECOGNITION OF rFAB 
 
3.6.1.  rFab 126 binds specifically to insulin 
 
To determine whether or not the recombinant, purified Fab fragments possessed 
the correct conformation for antigen binding, binding of rFabs 123 and 126 to 
insulin, was tested in a radiobinding assay (RBA) using PGS as the precipitating 
agent.  While rFab 126 showed dose dependent binding to 125I-insulin, no binding 
was observed for GAD65-specific rFab 144 (Figure 3.26).  Similarly, rFab 126 
showed no binding to 35S-GAD65 (data not shown).  rFab 123 did not bind to 
insulin (Figure 3.27). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.26:  RBA of rFab 126 and GAD65-specific rFab 144 to 125I-insulin. 
rFab 126 (black squares) and N-GAD65 rFab 144 (white squares) at 
the indicated concentration were incubated with 125I-insulin.  The 
immunocomplexes were precipitated using PGS.  Binding to insulin 
is expressed as cpm units. 
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Figure 3.27: RBA of rFab 123 and rFab 126 to 125I-insulin. 
Ni-NTA purified fractions (1 to 6; 7 = blank) were incubated with 125I-
insulin.  The immunocomplexes were precipitated using PGS.  
Binding to insulin is expressed as cpm. 
 
The specificity of rFab 126 was further determined by competitive binding assays.  
Binding to 125I-insulin by the intact mAb 126 at half-maximal binding concentration 
(0.04 mg/ml; Figure 3.28) was specifically competed with its rFab (Figure 3.29).  
The 126 rFab concentration (0.015 mg/ml; Figure 3.29) determined in these 
experiments to achieve maximal competition of the intact IgG was used in all 
following competition assays. 
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Figure 3.28:  Determination of mAb 126 half-maximal binding concentration in an  
insulin RBA. 
mAb 126 (black squares) was incubated at the indicated 
concentrations with 125I-insulin.  The immunocomplexes were 
precipitated using PAS. 
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Figure 3.29:  RBA of rFab 126 to 125I-insulin competed by the presence of mAb  
126 (0.04 mg/ml). 
rFab 126, at the indicated concentrations, was incubated with 125I-
insulin and mAb 126.  The immunocomplexes were precipitated 
using PAS. 
 
3.6.2.  rFab DP-D binds specifically to GAD65 
 
To determine whether or not the recombinant, purified Fab fragment possessed 
the correct conformation for antigen binding, binding of rFab DP-D to GAD65 was 
tested in a RIA using PGS as the precipitating agent.  rFab DP-D exhibited dose 
dependent binding to GAD65 and showed half-maximal binding at a concentration 
of approximately 0.1 µg/ml (Figure 3.30). 
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Figure 3.30:  GAD65-binding and affinities. 
Different amounts of rFab DP-D were incubated with radiolabelled 
35S-GAD65 and binding was tested in a RIA.  Binding is expressed 
as percent binding, with maximal binding set as 100%. 
 
3.7.  EPITOPE MAPPING 
 
3.7.1.  rFab 126 recognizes an epitope located mainly at the A chain loop 
 
In an effort to identify the epitope recognized by 126, competition assays with 
insulin-specific monoclonal antibodies mAb 1 (BIØDESIGN) and mAb 125 
(Schroer et al., 1983) were performed (Figure 3.31).  Both antibodies have well 
defined epitopes.  Binding of mAb 1 is strictly dependent on amino acid residue 
B30, while binding of mAb 125 is directed predominantly to the A chain loop (A8-
A10).  Competition of insulin binding by both monoclonal antibodies at half 
maximal binding (0.08 and 0.04 mg/ml, respectively) by different concentrations of 
rFab 126 was tested.  Insulin binding of mAb 125 was inhibited by 50% in the 
presence of 0.007 mg/ml rFab 126 and by 70% by 0.015 mg/ml rFab 126, whereas 
mAb 1 binding was inhibited by only 12% and 25% at these two concentrations of 
rFab DP-D (µg/ml)
Binding 
(%) 
  
158
competing rFab 126.  From these data we conclude that the binding site of 126 
overlaps with that of mAb 125. 
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Figure 3.31:  Epitope analysis of rFab 126. 
Different concentrations of rFab 126 were used to compete for 
insulin binding by monoclonal antibodies mAb1 (blue), mAb125 (red), 
and mAb 126 (green) at half maximal binding.  Binding to insulin is 
expressed as a percentage; non-competed binding is set as 100%. 
 
3.7.2.  Epitope mapping of rFab DP-D by binding to fusion proteins 
 
The epitope that mAb DP-D binds to on GAD65 (Figure 3.32) was previously 
determined by domain swapping and deletion mutagenesis (Schwartz et al., 1999; 
Hampe et al., 2001).  To verify the antigen region recognised by rFab DP-D, the 
binding characteristics of rFab DP-D to GAD65/67 fusion proteins (Hampe et al., 
2000) was analysed.  rFab DP-D only bound to the M and M+C fusion protein 
(Padoa et al., 2003). 
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Figure 3.32:  Epitope specificities of GAD mAbs. 
A.  The epitope specificities of mAbs 144, b96.11, DP-C, 221-442, 
DP-D, and DP-A are illustrated (Hampe et al., 2001; Schwartz et al., 
1999).  Amino acid residues bordering the epitopes are indicated for 
each mAb.  The two major epitope regions (E1 and E2) for 
GAD65Abs in type 1 diabetes are shown as shaded boxes in the 
GAD65 molecule. 
 
3.8.  ANALYSIS OF INSULIN AUTOANTIBODIES IN DIABETIC PATIENTS 
 
3.8.1.  The autoantibody status of diabetic patients analysed with rFab 126 
 
Table 3.4 and Table 3.5 summarise the autoantibody status of the type 1 and type 
1.5 diabetes patients analysed in this study.  The range of antibody levels in the 
control subjects was 0.12 to 0.0 for the GAD65Ab index and 0.016 to 0.0 for the 
IAA index.  The cut-off established for the 98th percentile was 0.05 and 0.004 units 
(corresponding to 50cpm) for GAD65Ab and IAA, respectively.  In our assays we 
only used sera with a cpm above 80. 
 
Some of the patient’s sera were diluted as they had very high antibody titers.  
Dilution of these samples ensured that the rFab/serum IgG ratio was not 
compromised. 
 
221 - 442 
221        442 
b96.11 
308      365 
144 DP-D DP-C DP-A 
4             22           96            173  195              412        483                       585 
GAD65 E1: 240-425 E2: 451-570 
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Table 3.4:  Autoantibody status of the analysed serum samples from patients with  
type 1 diabetes. 
Age 
(years) 
Gender IAA unit % Binding in 
presence of 
rFab 126 
IA-2Ab 
index* 
GAD65Ab 
index** 
1 M 65 75 0.08 0.25 
2 M 12 96 N/A 0.63 
2 F 53 94 N/A 0.80 
6 F 9 97 0.18 0.54 
6 F 6 100 1.04 0.71 
7 M 30 73 0.11 0.31 
8  12 65 0.65 0.30 
9 F 13 67 N/A 0.40 
9 F 11 56 1.18 0.17 
10 F 15 60 1.32 0.44 
12 F 17 62 0.25 0.41 
12  28 57 0.13 0.40 
12 M 21 100 N/A 0.27 
14 F 25 35 0.04 1.14 
14 F 9 96 0.01 0.30 
15 M 10 85 0.55 0.25 
15 M 5 64 0.83 0.81 
15 M 4 79 0.00 0.05 
16 M 30 51 0.00 0.01 
17 M 2 105 0.00 0.08 
19 M 3 83 0.94 0.18 
19 F 4 45 1.3 0.04 
20 M 1 88 0.00 0.15 
20 M 3 59 1.37 0.10 
20 F 10 93 1.3 0.92 
22 M 2 93 0.01 0.60 
23 M 4 77 0.35 0.21 
24 M 3 79 0.34 0.99 
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Age 
(years) 
Gender IAA unit % Binding in 
presence of 
rFab 126 
IA-2Ab 
index* 
GAD65Ab 
index** 
24 F 3 55 0.31 0.03 
25 M 2 79 0.00 0.10 
26 F 66 89 0.00 1.06 
27 M 25 86 1.35 0.35 
27 F 8 68 0.00 0.00 
32 M 2 96 0.44 0.16 
34 F 2 81 1.3 0.00 
* IA-2Ab levels were measured according to the method described by Kawasaki et al., 1997.  ** GAD65Ab levels were 
measured according to the method of Grubin et al., 1992; Grubin et al., 1994. 
 
Table 3.5:  Autoantibody status of the analysed serum samples from patients with  
type 1.5 diabetes. 
Age 
(years) 
Gender IAA unit % Binding in 
presence of rFab 
126 
IA-2Ab 
index* 
GAD65Ab 
index** 
24 F 3 70 0.39 0.21 
26 M 3 88 0.00 0.68 
32 F 4 94 1.16 0.46 
33 M 17 93 N/A 0.00 
35 M 4 94 N/A 0.55 
36 M 37 65 0.01 0.31 
41 F 2 89 0.00 0.30 
42 F 7 72 0.76 0.15 
46 M 32 85 0.00 0.39 
48 F 14 82 N/A 0.02 
49 F 3 82 0.01 0.97 
49 F 45 79 0.86 0.24 
50 M 3 98 0.00 0.31 
61 M 38 48 N/A 0.48 
* IA-2Ab levels were measured according to the method described by Kawasaki et al., 1997.  ** GAD65Ab levels were 
measured according to the method of Grubin et al., 1992; Grubin et al., 1994. 
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3.8.2.  Specificity of type 1 and type 1.5 diabetes associated IAAs determined 
with rFab 126 
 
The relevance of the epitope recognized by rFab 126 was tested in competitive 
binding assays using sera (n=49) of newly diagnosed type 1 and type 1.5 diabetes 
patients (Figure 3.33).  None of these patients had been treated with insulin prior 
to sampling.  For the majority of the serum samples (n=35, 70%) insulin binding 
was competed for by more than 10% in the presence of rFab 126.  The median 
binding of the serum samples to 125I-insulin (median IAA units: 8.8, range: 1 to 67) 
was significantly reduced by the competing rFab to a median binding of 8 IAA units 
(range: 0.9 to 60) (p < 0.0001).  No significant differences in the degree of 
competition in the type 1 diabetes patients to that in the type 1.5 diabetes patients 
was observed (Figure 3.33).  Our results indicated that 70% of the analyzed serum 
samples contained IAA that recognized the same or similar epitopes as rFab 126. 
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Figure 3.33:  rFab 126 competes with the majority of sera from IAA-positive type  
1 and type 1.5 diabetes patients. 
Insulin binding of serum samples of type 1 (n=35) (panel A) and type 
1.5 diabetes (n=14) (panel B) patients in the absence (left hand side 
diamond) and presence (right hand side diamond) of rFab 126.  The 
data is presented on a logarithmic scale. 
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3.8.3.  Statistical analysis 
 
Within the serum samples that competed with rFab 126 for binding to insulin a 
wide range of competition was observed.  Table 3.6 lists the mean/median value 
for each variable studied in the type 1 and type 1.5 diabetic patients.  With the 
exception of age, there was no difference in % binding, IAA, GAD65, and IA-2 
autoantibody levels between the type 1 and type 1.5 diabetic patients (Table 3.6).  
Similarly, no differences were found between males and females (all patients 
combined) when comparing the different variables (Table 3.7).  No correlation was 
found between the degree of competition with age of onset, IAA titre, or presence 
of other autoantibodies (Table 3.8 and Table 3.9). 
 
Table 3.6:  The difference in age, % binding, IAA, GAD65Ab, and IA-2Ab in type 1  
and type 1.5 diabetic patients. 
VARIABLE TYPE 1 PATIENTS 
(N=35) 
TYPE 1.5 PATIENTS 
(N=14) 
P VALUE 
AGE* 16.11 ± 8.47 40.86 ± 10.39 < 0.0001 
% BINDING* 76.8 ± 17.77 81.36 ± 13.73 0.3940 
IAA+ 9 (18) 5.5 (29) 0.8944 
GAD65Ab+ 0.3 (0.5) 0.31 (0.27) 0.8248 
IA-2Ab+ 0.31 (1.03) 0.01 (0.76) 0.2246 
* Data expressed as mean ± standard deviation; + Data expressed as median (interquartile range) 
 
Table 3.7:  The difference in age, % binding, IAA, GAD65Ab, and IA-2Ab in male  
and female diabetic patients. 
VARIABLE MALES 
(N=25) 
FEMALES 
(N=22) 
P VALUE 
AGE* 23.96 ±14.17 23.5 ± 15.07 0.9146 
% BINDING* 81.56 ± 15.04 75.73 ± 18.16 0.2349 
IAA+ 4 (23.25) 9 (11) 0.4951 
GAD65Ab+ 0.27 (0.36) 0.35 (0.56) 0.5649 
IA-2Ab+ 0.05 (0.50) 0.39 (1.16) 0.0974 
* Data expressed as mean ± standard deviation; + Data expressed as median (interquartile range) 
 
  
166
Table 3.8:  Correlation coefficient between % binding, age, IAA, GAD65Abs,  
and IA-2Abs using Spearman’s correlation. 
SPEARMAN CORRELATION 
      % BINDING AGE IAA GAD65Abs IA-2Abs 
 r  0.059 -0.237 0.191 -0.202 
% BINDING p  0.6802 0.1010 0.1860 0.2019 
 N  49 49 49 41 
 r 0.059  -0.225 -0.173 -0.161 
AGE p 0.6802  0.1192 0.2313 0.3089 
 N 49  49 49 41 
 r -0.237 -0.225  0.244 0.093 
IAA p 0.1010 0.1192  0.0914 0.5563 
 N 49 49  49 41 
 r 0.191 -0.173 0.244  0.028 
GAD65Abs p 0.1860 0.2313 0.0914  0.8594 
 N 49 49 49  41 
 r -0.202 -0.161 0.093 0.028  
IA-2Abs p 0.2019 0.3089 0.5563 0.8594  
 N 41 41 41 41  
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Table 3.9:  Correlation coefficient between % binding, age, IAA, GAD65Abs,  
and IA-2Abs using Pearson’s correlation. 
PEARSON CORRELATION 
        % BINDING AGE IAA GAD65AbS IA-2AbS 
 r  0.050 -0.147 0.096 -0.137 
% BINDING p  0.7306 0.3128 0.5124 0.3926 
 N  49 49 49 41 
 r 0.050  -0.061 -0.106 -0.093 
AGE p 0.7306  0.6761 0.4668 0.5646 
 N 49  49 49 41 
 r -0.147 -0.061  0.223 -0.179 
IAA p 0.3128 0.6761  0.1242 0.2627 
 N 49 49  0.22 41 
 r 0.096 -0.106 0.223  -0.075 
GAD65Abs p 0.5124 0.4668 0.1242  0.6395 
 N 49 49 49  41 
 r -0.137 -0.093 -0.179 -0.075  
IA-2Abs p 0.3926 0.5646 0.2627 0.6395  
 N 41 41 41 41  
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3.9.  ANALYSIS OF GAD65ABS IN DIABETIC PATIENTS 
 
rFab DP-D competed with its intact parent mAb for binding to GAD65 (Padoa et 
al., 2003).  The competition between rFab DP-D and GAD65Abs in sera of 61 type 
1 diabetic patients to bind GAD65 was analysed (Figure 3.34).  The median 
binding was significantly reduced by rFab DP-D (80%; P < 0.0001).  rFab DP-D 
inhibited 3% of the samples fully and 62% partially (see section 2.17.1.1 for a 
definition of partial and full inhibition).  The polyclonal nature of most patients’ sera 
is by the observation that serum samples were inhibited by more than one rFab 
(Figure 3.35).  Although samples whose GAD65 binding was competed by rFab 
b96.11 also showed competition by rFab DP-D (Figure 3.35, top panel), no 
significant correlation was observed between DP-A and rFab DP-D (Figure 3.35, 
bottom panel) (Padoa et al., 2003).  This suggests that DP-A inhibited GAD65 
binding to a different epitope to that recognised by b96.11 and DP-D (Padoa et al., 
2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.34:  GAD65-specific rFab DP-D competes with serum GAD65Abs of  
type 1 diabetic patients. 
Competed binding is presented as percentage binding related to 
uncompeted binding (100%); median binding is represented as a 
horizontal line. 
Median  =    80 
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Figure 3.35:  Correlation of competition. 
GAD65 binding of type 1 diabetic patients’ sera in the presence of 
rFab b96.11 (top panel) or rFab DP-A (bottom panel) is plotted 
against binding to GAD65 of the same samples in the presence of 
rFab DP-D.  P values for the correlation (Spearman’s rank 
correlation test) between the different competitors are indicated in 
the figure. 
 
We determined the ability of rFab DP-D to compete with GAD65Abs in sera of type 
1 diabetic patients (n = 61), LADA patients (n = 44), first-degree relatives of type 1 
Binding (%) in presence of DP-A 
Binding (%) 
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diabetic patients (n = 38), and healthy individuals (n = 14) (Figure 3.36).  The 
differences in competition using rFab DP-D in the different serum groups was 
significant when type 1 diabetic patients were compared with first-degree relatives 
(P = 0.0002; Mann-Whitney U test) (Padoa et al., 2003). 
 
   Median  =     80.0        93.3        100.0       94.0 
                           
 
 
Figure 3.36:  The capacity of rFab DP-D to compete with GAD65-binding of  
GAD65Ab-positive samples of type 1 diabetic patients, type 1.5 
diabetic patients, first-degree relatives, and healthy individuals in a 
RIA. 
Competed binding is presented as percentage binding related to 
uncompeted binding (100%); median binding is indicated as a 
horizontal line. 
 
3.10.  HOMOLOGY MODELLING OF RECOMBINANT FAB 123, 126, AND DP-D 
 
Using the ESyPred3D (Lambert et al., 2002) web server software, a 3D model of 
rFab 123, 126, and DP-D was built using the 3-dimensional structure 1QGC chain 
'4' (Fab fragment of a neutralizing antibody derived from foot and mouth disease 
virus; Figure 3.37) as a template (Hewat et al., 1997).  The choice of template was 
decided by the computer programme and was based on closest homology to 
sequences of known structure.  This template shares 72.2% identity with rFab 123 
0
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sequence, 71.0% identity with rFab 126 sequence, and 56.8% homology with rFab 
DP-D sequence.  Figure 3.38 shows the 3-dimensional ribbon model structures of 
rFab 123, rFab 126, and rFab DP-D. 
 
A. 
 
 
 
 
 
 
 
 
 
 
B. 
 
 
 
 
 
 
 
 
 
Figure 3.37:  A.  3-Dimensional structure of the Fab fragment of a neutralizing  
antibody derived from foot and mouth disease virus. 
B.  3-Dimensional structure of the Fab fragment. 
 
 
 
Main view      Bottom view 
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Figure 3.38:  A.  3-Dimensional structure of rFab 126 (ribbon model). 
B.  3-Dimensional structure of rFab DP-D (ribbon model). 
C.  3-Dimensional structure of rFab 123 (ribbon model). 
The CDRs are shown in pink (light chain) and green (heavy chain).  
The arrows indicate the β sheets and the red coils are the alpha 
helices. 
A. B. 
C. 
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3.11.  MOLECULAR DOCKING OF THE INSULIN-RECOMBINANT FAB 126 
COMPLEX 
 
Using the computer programme ‘PatchDock’ we attempted to further map the 
epitope that rFab 126 binds to on insulin.  Following the submission of the 3-
dimensional structures of insulin of rFab 126 as pdb files, PatchDock returned one 
hundred permutations of possible insulin-Fab docking.  The top three results 
obtained from PatchDock were analysed with Swiss-Pdb Viewer (Figure 3.39).  
Table 3.20 lists the different amino acid residues involved in the binding sites on 
insulin and rFab 126, respectively. 
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Model 2: 
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Model 3: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.39:  3-Dimensional structure (space-fill and ribbon model) of the insulin- 
rFab 126 complex. 
KEY: 
---  Heavy chain CDR1 
(244-248) 
---  Heavy chain CDR21 
(263-279) 
---  Heavy chain CDR3 
(312-328) 
---  Light chain CDR1 
(24-34) 
---  Light chain CDR21 
(50-56) 
---  Light chain CDR3 
(89-97) 
---  insulin epitope 
---  rFab 126 epitope 
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Table 3.10:  Amino acid residues involved in the binding of insulin to rFab 126. 
MODEL INSULIN RESIDUES rFAB 126 RESIDUES 
Model 1 A1-A5, A21, B1-B6, B9, B13, 
B16, B22-B30 
108-110, 112-115, 138, 169-
170, 200-203, 205, 207, 356-
365, 388, 390-391, 393, 411-
414 
Model 2 A18-A21, B1-B2, B5-B6, B8-B9, 
B12-B13, B16, B21-B29 
15, 79, 106, 108-115, 138, 170-
171, 200-207, 358, 361-364, 
390-391, 411 
   
Model 3 A4-A5, A8-A15, A17-A18, A20-
A21, B22, B25, B30 
39, 42, 45, 57, 59, 167-169, 
216-219, 241-244, 314, 320, 
385-386, 389-390, 392-394,  
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CHAPTER 4 
 
4.  DISCUSSION 
 
4.1.  PROBLEMS ENCOUNTERED WHEN CLONING IMMUNOGLOBULIN 
HEAVY AND LIGHT CHAIN GENES 
 
4.1.1.  Aberrant heavy and light chain transcripts 
 
Both MOPC-21 and P3X63Ag8 myeloma cell lines actively secrete 
immunoglobulin.  The 1E2 hybridoma was derived from the cellular fusion partner 
NS0.  NS0 is a nonsecreting variant of the MOPC 21 myeloma which does not 
express heavy chains (Kohler and Milstein, 1976).  Sp2/0, the fusion partner for 
HB-126, is derived by fusion of P3X63Ag8 with a splenic B-cell line.  Sp2/0 has 
lost the ability to produce heavy and light chain proteins (Klotz et al., 1981).  The 
presence of aberrant immunoglobulin chains can interfere with downstream 
applications.  As a result, myeloma cell lines that do not secrete/produce functional 
immunoglobulins have been constructed to obtain specific hybrid cell lines that 
only produce pure mAbs (Kearney et al., 1979). 
 
DNA sequencing of the cDNA product amplified from the 1E2 and NS0 cell lines, 
using kappa light chain specific primers, demonstrated the presence of an 
aberrant mRNA transcript which is present in all standard fusion partners derived 
from the original MOPC-21 tumour (Carroll et al., 1988).  The expression of this 
non-functional kappa transcript is variable and can be rather high in certain 
hybridomas, exceeding levels of the productive light chain mRNA.  In such cell 
lines the PCR primers for amplification of the variable domain of the kappa chain 
will mainly amplify the aberrant kappa chain transcript (Duan and Pomerantz, 
1994).  The expression of this aberrant transcript can interfere with kappa mRNA 
sequencing by producing ambiguities in the sequencing reactions.  On one or two 
occasions ‘dirty’ unreadable sequence was obtained when analysing the PCR 
derived 1E2 kappa chain products by DNA sequencing.  This would indicate either 
improperly purified PCR products or the amplification of both the functional and 
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aberrant kappa chain cDNA in one reaction.  If the latter were true, cDNA cloning 
would separate the two transcripts.  The majority of the PCR derived 1E2 kappa 
chains that were sequenced were, however, found to be of the aberrant kappa 
chain transcript, suggesting that the aberrant kappa chain mRNA is far in excess 
of the functional kappa chain mRNA in the 1E2 hybridoma cell line. 
 
With the use of our heavy chain specific primers, for the construction of a scFv, we 
consistently obtained two VH cDNA species from the 1E2 hybridoma cell line and a 
single VH cDNA species from the NS0 hybridoma cell line.  Sequence 
determination of the PCR product present in both cell lines was homologous to the 
aberrant heavy chain transcript (AberrG7) reported by Vidarsson and colleagues 
(2001).  Due to the poor quality of the sequencing results obtained for the second, 
smaller cDNA species amplified from the 1E2 cell line (Figure 3.2B), we were 
unable to rule out the possibility that this product was, in fact, the functional heavy 
chain gene. 
 
There has been one report in the literature that describes the construction of an 
anti-insulin scFv (Lake et al., 1994).  The heavy and light chain variable genes 
were amplified from a murine anti-insulin IgG 1-producing hybridoma, HB-125, 
which was generated using the fusion partner Sp2/0-Ag14.  The authors did not 
report the amplification of any aberrant transcripts.  This scFv was shown to bind 
insulin in an insulin ELISA but at a 3.5-fold lower affinity than the parent mAb.  The 
authors attributed this difference to the fact that the parent mAb is bivalent and 
that because the scFv is an engineered molecule its conformation may have been 
altered which in turn affected its ability to bind to insulin. 
 
In the case of mouse hybridomas, special care must be taken when designing the 
synthetic oligonucleotides to avoid the amplification of an aberrant kappa and 
heavy chain mRNA transcript that is inherited from the original MOPC-21 tumour 
from which most myeloma fusion partners are derived (Carroll et al., 1988).  In an 
attempt to eliminate PCR contamination by endogenous aberrant kappa chain 
mRNA, Duan and Pomerantz (1994) designed an aberrant kappa chain CDR-
specific primer set which specifically amplifies the aberrant transcript.  These 
primers are located in the CDR1 and CDR3 regions of the aberrant kappa 
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transcript.  Together with the immunoglobulin degenerate PCR primers, a quick 
and efficient selection of the correct kappa chain variable cDNAs can be achieved.  
Heavy and light chain genes are amplified using the immunoglobulin degenerate 
primers and the PCR products cloned into plasmids.  Recombinant plasmids 
containing the aberrant light chain transcript are identified by further amplification 
with the aberrant kappa chain CDR-specific primer set.  Only recombinant 
plasmids containing the aberrant transcript will show bands representing the 
aberrant light chain insert on an agarose gel.  Lanes which do not contain a band 
either contain the functional kappa chain insert or do not contain any insert.  This 
technique significantly reduces the amount of sequencing required to identify 
plasmids containing the functional kappa chain transcript.  Duan and Pomerantz 
(1994) also constructed a ribozyme-based expression vector which eliminates the 
aberrant kappa transcript by cleaving it in the CDR1 region. 
 
4.1.2.  Problematic techniques 
 
Although we eventually managed to perfect the cloning of the heavy and light 
chains of mAbs, a number of obstacles were encountered en route.  Firstly, with 
the construction of a scFv fragment the presence of aberrant heavy and light chain 
transcripts interfered with the amplification of functional immunoglobulin chains.  
This has been confirmed by a number of researchers (Carroll et al., 1988; Duan 
and Pomerantz, 1994; Vidarsson et al., 2001) and new techniques/methods have 
been designed to overcome this issue. 
 
When constructing the rFabs we encountered a number of difficulties with the 
ligases used and with the restriction enzyme sites used for cloning.  The T4 DNA 
ligase failed to ligate the respective chains to the vector.  This problem was 
overcome by changing the brand of ligase.  The pAK19 expression vector was 
designed such that cloning of the heavy and light chain involved the use of MluI.  
As a result a ‘stuffer’ fragment had to be ligated onto the light chain to introduce a 
new restriction site for cloning.  This, in turn, produced its own set of problems.  
These difficulties were eventually solved by separately subcloning the heavy and 
light chain fragments into the pCXII vector before finally cloning the entire Fab 
fragment into the pAK19 expression vector. 
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4.2.  METHODS FOR THE CONSTRUCTION OF RECOMBINANT FABS 
 
A number of methods exist for the production of rFab and scFv fragments; namely 
hybridoma cell lines, phage display, and ribosome display.  In this study, mAbs 
were produced by the hybridoma technique described by Köhler and Milstein 
(1975).  The genes encoding the heavy and light chains were amplified from the 
respective hybridoma cell lines by RT-PCR, subcloned into the pAK19 expression 
vector and expressed in E. coli 25F2 cells.  Before the introduction of phage 
display, this was the standard method for the construction of scFv or Fab.  The 
only differences would be the choice of expression vector, restriction sites for 
cloning, and the host cell for expression.  The main reason for adopting the 
hybridoma cell line approach is that hybridomas were readily available and the 
method is less complex and involved than phage display, a technique which is 
more commonly used for the production of antibody libraries from immunoglobulin 
expressing cells. 
 
An alternative approach would have been to use the phage display method.  In 
this method, variable genes are amplified from a library of diverse antibodies 
isolated from IgG-secreting plasma cells from animals or individuals immunized 
with a specific antigen.  The scFv/Fab are displayed on the surface of the 
bacteriophage.  scFv/Fab with high affinity and specificity to the target antigen 
(e.g. insulin) are selected by panning.  The advantage of phage display systems is 
that it provides a faster and more efficient selection method than traditional 
bacterial screening.  In addition, with the hybridoma approach, a single rFab to a 
specific antigen is constructed whereas with the phage display method a number 
of rFab with differing affinities/specificities can be selected. 
 
Some of the limitations encountered with cell-based display systems are overcome 
by ribosome display which is carried out in vitro.  Protein-ribosome-mRNA 
complexes are formed which allows for the simultaneous isolation of protein and 
mRNA by affinity selection.  The mRNA can then be amplified by RT-PCR and 
additionally PCRed, mutated, or cloned (Hanes and Plückthun, 1997). 
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4.2.1. Characterisation of rFab 
 
The cDNA encoding the anti-insulin and anti-GAD65 rFab were cloned.  The 
predicted amino acid sequences were aligned (Figure 3.22 and 3.23, respectively).  
rFab 126 and rFab 123 share the same classes for CDR1 and 2 but differ in their 
CDR3 class; the heavy chain CDRs showed 46% homology.  The highest 
homology in the anti-insulin rFab light chains was found between rFab 126 and the 
1E2 light chain sequence (53% homology).  A comparison of the overlapping 
amino acid sequence in the CDR regions of the GAD65 rFab heavy chains 
showed that amino acid sequences derived from human rFab DP-D and DP-A 
were closely related to each other (60% homology).  While these two rFab share 
the same CDR 1 and 2 classes, they differ in their CDR3 class.  Comparison of the 
overlapping amino acid sequence in the CDRs of the light chain showed the 
highest homology when comparing b96.11 with DP-A and 221-442 with DP-D (67 
and 61% homology, respectively).  While b96.11 and DP-A share the same 
classes for CDRs 1 and 2, they differ in the CDR3 class.  DP-A binds to the 
carboxyl-terminal of GAD65 whereas DP-D and b96.11 bind to the middle or 
amino-terminal end of the molecule.  It is, therefore, not surprising that differences 
exist in CDR3 as this is where the greatest sequence diversity occurs. 
 
4.3.  AUTOANTIBODIES IN THE SERA OF DIABETIC PATIENTS 
 
4.3.1.  GAD65 autoantibodies 
 
Autoantibodies to the 65kDa isoform of glutamate decarboxylase (GAD65Abs) are 
accepted markers for type 1 diabetes and, together with autoantibodies to insulin 
(IAA) and a protein tyrosine phosphatase-like islet cell antigen (IA-2), predict the 
disease (Vandewalle et al., 1995).  Moreover, GAD65Abs have recently been 
implicated in GAD65 presentation to T cells (Jaume et al., 2002; Reijonen et al., 
2000) and may, therefore, play a role in the pathogenesis of type 1 diabetes.  
Characterization of type 1 diabetes-specific GAD65 and insulin autoantibody 
epitopes will provide important information to further our understanding of the 
immunopathologic mechanisms leading to type 1 diabetes. 
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The identification of disease-specific GAD65Ab epitopes in type 1 diabetes has 
been hampered by the fact that the epitopes are conformational (Tuomi et al., 
1994; Schwartz et al., 1999).  Epitope identification has been attempted using 
GAD65/67 fusion proteins.  Using these fusion proteins it has been shown that 
sera of type 1 diabetes patients recognize conformational epitopes located in the 
middle (amino acid 240-435 = epitope 1) and the carboxy-terminal end (amino acid 
451-570 = epitope 2) of GAD65 (Daw and Powers, 1995; Hampe et al., 2000; 
Padoa et al., 2003).  This reactivity pattern differs significantly from that of 
GAD65Abs in stiff-man syndrome patients (Björk et al., 1994; Daw et al., 1996), 
autoimmune polyendocrine syndrome type 1 patients (Björk et al., 1994), first 
degree relatives of type 1 diabetes patients (Hampe et al., 2000), the general 
population (Hampe et al., 2000), and type 1.5 diabetes patients (Falorni et al., 
2000; Hampe et al., 2000). 
 
While the analysis of antibody binding patterns using GAD65/67 fusion proteins 
provided valuable information about GAD65Ab binding patterns (Falorni et al., 
2000; Hampe et al., 2000), information about conformational disease-specific 
GAD65Abs and their epitopes was limited (Ziegler et al., 1996).  Changes of 
GAD65Ab epitopes were observed in prediabetic children (Bonifacio et al., 2000), 
indicating that the humoral response to GAD65 changes as an individual 
progresses to type 1 diabetes.  To identify disease-associated GAD65Abs and 
their epitopes Padoa and colleagues (2003) cloned rFab of well characterized 
GAD65-specific mAbs.  The use of rFab rather than intact immunoglobulins 
prevents potential steric hindrance.  The six GAD65-specific rFab were cloned 
from human mAbs b96.11, DP-C, DP-A, and DP-D (derived from autoimmune 
disease patients), and from murine mAbs 144 and 221-442.  The epitope regions 
recognized by the six mAbs were spread over the length of the GAD65 molecule 
ensuring that different epitope specificities were represented.  Our observation that 
the rFabs bound most GAD65/67 fusion proteins more weakly than GAD65 
confirmed earlier findings that the epitopes’ conformations are changed in the 
fusion proteins. 
 
Although the patients’ sera present a polyclonal mixture of GAD65Abs with 
different epitope specificities, we were able to obtain a significant reduction in 
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GAD65 binding using the rFabs as competitors.  rFab b96.11 and DP-C, derived 
from human mAbs, significantly inhibited the binding of the majority of type 1 
diabetic sera to GAD65.  Also, rFab DP-D and DP-A, derived from mAbs isolated 
from a type 1 diabetic patient (Madec et al., 1996), and 221-442, derived from a 
murine mAb (Ziegler et al., 1996), inhibited the GAD65Ab binding, but to a lesser 
extent.  These findings are in agreement with previous reports that major 
GAD65Ab epitopes in type 1 diabetes are located in the middle region and the 
carboxy-terminus of the molecule (Daw and Powers, 1995; Schwartz et al., 1999). 
 
The binding of GAD65Ab in type 1 diabetes patients to GAD65 was analyzed by 
competitive radioimmunoassay with the six rFab to ascertain disease-specific 
GAD65Ab binding specificities.  The competition pattern in type 1 diabetes 
patients was different from that in GAD65Ab-positive type 1.5 diabetes patients 
(n=44), first degree relatives (n=38), and healthy individuals (n=14).  While 87% 
and 72% of the type 1 diabetes sera were competed by rFab b96.11 and DP-C, 
respectively, only 34 % and 26% of type 1.5 diabetes patients, 18% and 25% of 
first degree relatives, and 7% and 28% of healthy individuals showed competition 
(p<0.0001).  These novel findings (Padoa et al., 2003) with GAD65-specific rFab 
support the view that type 1 diabetes is associated with disease- and epitope-
specific GAD65Ab and supports the notion that the middle epitope is disease-
specific.  These GAD65-specific rFab should prove useful in predicting type 1 
diabetes. 
 
Previous data has shown that GAD65Abs can modulate GAD65 processing and 
presentation to MHC class II-restricted T cells and thus have a pathogenic role in 
the development of type 1 diabetes (Jaume et al., 2002; Reijonen et al., 2000).  
DP-D, DP-C, and DP-A were shown to promote the presentation of GAD65 
epitopes outside their own binding sites, while inhibiting the presentation of their 
specific epitope to T cells (Jaume et al., 2002).  This is in conjunction with the 
observation that antibodies can suppress the presentation of certain epitopes due 
to their high affinity binding (Simitsek et al., 1995; reviewed by Watts, 1997) and 
underlines the possible involvement of GAD65Abs in the modulation of T cell 
responses to GAD65.  rFab b96.11, DP-C, and other type 1 diabetes-specific rFab 
may represent a novel tool to modulate this processing and will be of importance 
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in elucidating the mechanisms by which GAD65Abs may influence disease-
progression.  Future experiments will be needed to investigate whether rFab 
b96.11 or DP-C can block the action of pathogenic serum antibodies in order to 
reveal whether these disease-specific GAD65Abs in type 1 diabetes patients' sera 
are pathogenic or the result of epitope spreading induced by the disease 
progression. 
 
Epitope spreading is the phenomenon whereby there is a shift in the position of 
the epitopes from one domain of the antigen to another as an autoimmune disease 
progresses.  For example, antibodies to GAD65 are initially produced against the 
middle and C-terminal regions of the antigen in type 1 diabetes.  The autoimmune 
response may then undergo intramolecular epitope spreading towards epitopes on 
the N-terminus and further epitopes located in the middle in genetically 
predisposed individuals which leads to onset of the disease (Schlosser et al., 
2005). 
 
In conclusion, rFab fragments b96.11, DP-C, DP-D, DP-A, and 221-442 recognize 
shared epitopes with GAD65Abs in type 1 diabetes patient sera, and thus can 
serve as tools for epitope mapping and detection of epitope shifts in different 
stages of the disease. 
 
4.3.2.  Insulin autoantibodies 
 
IAA are among the first autoantibodies to appear in individuals prior to the clinical 
onset of type 1 diabetes (Ziegler et al., 1999).  Their appearance is inversely 
correlated with age (Graham et al., 2002).  This makes them especially important 
as markers for type 1 diabetes in children (Karjalainen et al., 1989).  While 
antibody epitopes for other autoantigens in type 1 diabetes have been extensively 
studied, little is known about IAA epitopes.  In the past, researchers have utilised 
naturally occurring isoforms of insulin for the analysis of IAA epitopes.  In two 
studies, human, bovine, and porcine insulin were used to reveal differences in the 
binding characteristics of IAA and antibodies to exogenous administered insulin 
(IA), locating the major binding site of IA to the A-chain, while type 1 diabetes-
associated IAA recognise a conformational epitope requiring both the A and B 
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chain (Diaz and Wilkin, 1987; Wilkin et al., 1988).  Differences in epitope 
specificities of IAA and IA were also detected using random peptide phage display 
(Devandra et al., 2003).  Monoclonal antibodies and their rFab are being 
successfully used in the epitope analysis of other autoantibodies in type 1 diabetes 
(Schlosser et al., 1997; Schwartz et al., 1999; Kolm-Litty et al., 2000; Padoa et al., 
2003).  This method is particularly useful in the study of conformational epitopes 
since the structure of the antigen remains intact (Binder et al., 2004). 
 
The development of a PAS-based IAA radiobinding assay greatly reduced the 
required amount of serum and allowed for a more comprehensive analysis of the 
antibodies (Williams et al., 1997).  In this study we developed a new reagent to 
perform antibody epitope mapping of IAA.  Monoclonal antibody 126 binds to a 
wide range of different isoforms of insulin and proinsulin (Schroer et al., 1983).  
We were able to localise the epitope of 126 to the A chain loop of insulin (A8-A10).  
We cloned and sequenced the Fab portion of mAb 126 and analysed the amino 
acid sequence, deduced from the nucleotide sequence, by comparing it to the 
closest related germline sequence available in GenBank.  The heavy chain 
underwent somatic mutations resulting in seven amino acid residue substitutions, 
located in CDR1 and CDR2, while the light chain remained identical to the 
germline sequence. 
 
The expressed rFab 126 binds specifically to insulin.  The antigen binding site of 
the rFab fragment was identical to that of the intact mAb since the binding of rFab 
126 to insulin was inhibited by the presence of the intact mAb 126.  Significant 
competition was observed when IAA present in the sera of type 1 and type 1.5 
diabetes patients was incubated with insulin and rFab 126.  A wide range of 
competition was observed within the serum samples that competed with rFab 126 
for binding to insulin.  No correlation was found between the degree of competition 
with IAA titre, presence of other autoantibodies, or age of onset.  Similarly, no 
difference was found between the degree of competition observed in the type 1 
and type 1.5 diabetic patients groups.  This finding differs to those observed when 
analysing GAD65Abs in the sera of diabetic patients.  Here the competition pattern 
differed in the type 1 patients as compared to the type 1.5 patients.  This 
discrepancy may be due to the small number of patients analysed for the IAAs or 
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the fact that the major IAA epitopes in type 1 diabetes are located at a different 
position on the insulin molecule i.e. not on the A chain loop where mAb 126 binds. 
 
The lack of observed competition between rFab 126 and some of the patient sera 
could be due to an excess of high affinity autoantibodies in the sera of these 
patients which prevents the rfab from binding.  The consequence of diluted 
patients’ sera on the competitive effects of the rFab were, however, not analysed 
because the study by Padoa et al. (2003) showed that dilution of GAD65Ab 
positive patient sera had no influence on the degree of inhibition. 
 
To our knowledge this is the first study describing epitope analysis of IAA using 
rFab.  This kind of analysis should prove to be of great value in the epitope 
analysis of IAA and IA.  While GAD65Ab and IA-2Ab radiobinding assays have 
been standardised and a WHO standard is available (Mire-Sluis et al., 2000), the 
IAA radiobinding assay is plagued by large inter laboratory variations (Bingley et 
al., 2003).  IAA have also been isolated from healthy individuals and from patients 
with autoimmune diseases other than type 1 diabetes (Wilkin, 1991).  Epitope 
mapping of IAA may improve our understanding of the underlying autoimmune 
response and aid in the accurate prediction of type 1 diabetes. 
 
A study carried out on IAA positive first degree relatives of type 1 diabetes patients 
showed that their binding sites for insulin were similar.  The epitope that these 
insulin autoantibodies bind to on insulin was mapped, by comparative studies 
using insulin from different species, to amino acids B1-B3 and A8-A13 (Castano et 
al., 1993).  This study supports our finding that the binding of rFab 126 is directed 
to the A chain loop (A8-A10) of insulin.  Although the sera studied may have 
antibodies recognising multiple epitopes on insulin, there was an overall inhibition 
of binding in the presence of rFab 126 which would suggest that a percentage of 
these autoantibodies recognise the same epitope as rFab 126 i.e. on the A chain 
loop. 
 
The identification of disease specific epitopes may also provide new methods for 
the treatment/prevention of type 1 diabetes.  If a disease specific epitope is 
identified, patients can be treated with a peptide that binds to this epitope, 
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effectively blocking the autoantibody from binding to the antigen.  A study 
performed by Daniel and Wegmann (1996) showed that when NOD mice were 
administered with the B-(9-23) insulin fragment, either subcutaneously or 
intranasally, a delay in the onset and the incidence of diabetes decreased in 
relation to mice given a control peptide. 
 
4.4.  OTHER USES OF RECOMBINANT FAB 
 
Type 2 diabetes is a heterogeneous and polygenic disorder resulting from the 
interaction of genetic and environmental factors.  The disease is characterised by 
a failure of the pancreatic β cells to secrete sufficient quantities of insulin in the 
presence of reduced insulin sensitivity.  Type 2 diabetes accounts for about 90% 
of all cases of the disease, affecting 150 million people worldwide (King et al., 
1998). 
 
The prevalence of type 2 diabetes is increasing in South Africa, especially in the 
black population.  A sensitive method is required to detect those individuals who 
could develop the disease.  Studies have shown that high levels of proinsulin and 
32,33 split proinsulin indicate future progression to type 2 diabetes (Nijpels et al., 
1996; Wareham et al., 1999).  Assays that are currently used cannot accurately 
distinguish between the intermediates in the insulin pathway due to the similarity in 
their tertiary structure.  An assay specific for 32,33 split proinsulin has not yet been 
produced.  Nor has it been possible to detect with confidence the levels of 65,66 
split proinsulin because of the low concentration of this peptide in the circulation. 
 
Genetic engineering will help improve the performance of immunoassays and 
provide better reagents for clinical diagnosis.  The production and genetic 
manipulation of novel mAbs that only contain the antigen binding domains of 
immunoglobulins will help reduce non-specific binding (Warren et al., 2005).  In 
addition, the production of antibodies against novel epitopes may be possible and 
this will be extremely useful in developing assays for 32,33- and 65,66- split 
proinsulin since no monoclonal antibodies that specifically bind to this protein 
exist.  The ability to accurately measure these molecules may provide important 
information on β-cell dysfunction in type 2 diabetic patients. 
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We have amplified, cloned, and expressed the hypervariable domains of the heavy 
and light chain of an insulin specific mAb 126.  This rFab can be fused to an 
enzyme, for example alkaline phosphatase, to produce a reagent that can be used 
in immunoassays.  Site-directed mutagenesis can also be used to alter the binding 
affinity and specificity of the rFab.  These novel antibodies could be used in 
assays designed to measure insulin and its precursors and screen populations 
who have a high risk of developing type 2 diabetes.  Furthermore, the 
methodology can be used in any assay that uses mAbs and it will, therefore, be 
possible to improve both the sensitivity and specificity of diagnostic assays.  A 
study by Warren et al. (2005) showed that non-specific interference was 
considerably reduced with the use of a scFv as opposed to the parent mAb.  
ScFvs lack the constant domain of an antibody and, therefore, interference is 
essentially eliminated. 
 
Insulin autoantibody assays have posed major problems in terms of reproducibility, 
sensitivity, and specificity.  With the advent of antibody engineering it is envisioned 
that rFab specific to insulin and its precursors can be constructed and used to 
standardise and improve the insulin autoantibody assay.  Also, the construction of 
rFab which could recognise disease specific IAAs, would greatly enhance the 
usefulness of insulin RBAs. 
 
Engineered antibodies also have other clinical uses.  For instance they can be 
used in cancer therapy as magic bullets for targeting and destroying tumour cells 
(reviewed by Merluzzi et al., 2000; Linenberger et al., 2002; Stevenson et al., 
2002).  Many antibodies raised against tumour cell surface markers are made in 
non-humans and are therefore not able to be used for the treatment of human 
cancers.  However, this problem has been addressed by the production of 
chimeric (murine variable regions combined with human IgG constant domain) or 
humanised mAbs in which the hypervariable regions are isolated and placed within 
a human antibody framework, thus reducing the risk of immune reaction against 
the antibody, as in Herceptin (Morrison et al., 1984; Jones et al., 1986; McNeil, 
1998). 
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Other applications of recombinant antibodies include their use in epitope mapping 
(Padoa et al., 2005), disease specific epitope mapping (Padoa et al., 2003) and 
high-resolution X-ray crystallographic studies of antigen binding sites.  The smaller 
Fab, or scFvs, are more advantageous for epitope studies as they eliminate the 
possibility of steric hindrance.  Similarly, the large size of immunoglobulins and the 
flexibility of the hinge connecting Fab arms and the Fc domain have prompted 
crystallographers to turn to Fab (Saul and Poljak, 1992) and Fv fragments (Boulot 
et al., 1990) for determining the 3-dimensional structure of antigen-antibody 
complexes. 
 
4.5.  PROTEIN MODELLING 
 
The 3-dimensional structures of protein complexes, determined by X-ray 
crystallisation methods, provide a number of insights into protein-protein 
interactions.  These interactions play an important role when developing new 
drugs and treatments for disease.  Although the number of proteins with defined 3-
dimensional structures is increasing, the majority have not yet been crystallised.  
As a result, various computer software programmes have been designed to 
overcome this problem.  The 3-dimensional models that were generated for rFabs 
123, 126, and DP-D fit the desired structure of an antibody molecule as the heavy 
and light chain CDRs are brought together to form a neat antigen binding pocket. 
 
Once the 3-dimensional structures of proteins have been computationally 
determined, protein docking experiments can be performed.  The structure of a 
complex between two proteins is predicted based on the independently 
crystallized structures of the components.  We used the freely available 
PatchDock software in an attempt to refine the epitope that rFab 126 binds to on 
insulin.  Using this software together with Swiss PdbViewer it was possible to 
determine which residues on insulin are bound by the rFab 126 and vice versa.  Of 
the three models generated, only model three supported our findings that rFab 126 
binds to the A chain loop of insulin.  This model was also the only model which 
showed involvement of amino acid residues in the CDRs of the rFab 126.  X-ray 
crystallography and mutagenesis studies would be able to further optimise the 
models generated. 
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The major limitation of PatchDock is that the docking is based purely on shape 
complementarity; intermolecular forces are not taken into account when the 
models are generated.  A further limitation of this method is that of the hundred or 
more models generated (results are ranked according to a geometric 
complementarity score which is supposed to measure the fit of the shape) the final 
model chosen is at the discretion of the user. 
 
4.6.  LIMITATIONS OF THE CURRENT STUDY 
 
In this study we had a total of five mAbs and of these, we were only able to 
construct two functional rFab that showed dose dependent binding to insulin and 
GAD65, respectively: rFab 126 and rFab DP-D.  We were unable to construct a 
rFab for mAb 127 and mAb 1E2 as the heavy chain gene could not be amplified 
for mAb 127 and we were only able to amplify the non-functional heavy chain 
transcript for mAb 1E2.  We were able to clone and express a rFab for mAb 123 
but this Fab did not exhibit binding to the insulin molecule in a RBA.  This may be 
due to a lower yield of expressed rFab 123 and hence a lower concentration of the 
purified rFab, incorrect folding of the heavy and light chain in the periplasm of E. 
coli, lack of association of the two chains in the periplasm, or a decreased affinity 
for insulin.  The latter explanation is, however, unlikely as a number of studies 
have shown that rFab generally have similar, or slightly lower, affinities for the 
antigen molecule than the parent mAb (Eriksson et al., 2000; Itoh et al., 2003).  
Itoh et al. (2001) reported a three fold lower affinity in the rFab which they 
attributed to a difference in valency between the rFab and intact mAb. 
 
Although we were able to map part of the epitope that rFab 126 binds to on insulin 
to the A chain loop, we cannot rule out the involvement of the insulin B chain if it is 
a conformational epitope. 
 
The sample size used to determine disease specific IAA epitopes in type 1 and 
type 1.5 diabetic subjects was relatively small which limits the conclusions that can 
be drawn. 
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4.7.  FUTURE STUDIES 
 
The clinical manifestation of type 1 diabetes is the endpoint of a long lasting 
immune-mediated destruction of the β-cells.  Autoantibodies originating from this 
process can be applied in the diagnosis and clinical discrimination of autoimmune 
diabetes as well as in the prediction of the disease.  At clinical diagnosis, between 
80-90% of patients with type 1 diabetes are positive for antibodies to β-cell 
antigens.  These antibodies can also be detected in the presymptomatic period 
(before onset of the disease), and can, therefore, be used to predict the disease 
(reviewed by Atkinson and Eisenbarth, 2001).  It is important to determine the 
prevalence of autoantibodies in diabetic patients as this will provide valuable 
information on the autoimmune response in type I diabetics.  Little is known about 
the autoimmune role in the pathology of disease in African populations.  One study 
has shown a lower prevalence of GAD autoantibodies in Black South Africans 
compared to data from Caucasian type I diabetic patients (Rheeder et al., 2001).  
There is, thus, some evidence for ethnic differences in the autoimmune response.  
This needs to be researched using not only the measurement of GAD antibodies 
but also IA-2, and insulin autoantibodies.  The latter two autoantibodies have 
never been investigated in the South African black population.  The insulin 
epitopes will also be of interest because we can look at ethnic differences in the 
prevalence of insulin autoantibodies and ethnic differences in epitopes bound by 
such antibodies.  These types of investigations have never been performed before 
and are important in giving clues to possible differences in autoimmune response 
to autoantigens in different populations.  It must also be remembered that the 
prevalence of type I diabetes is thought to be lower in Africans than Europeans 
(Rewers et al., 1990; Karvonen et al., 1993; Karvonen et al., 2000) and there may, 
therefore, also be significant ethnic differences in both the aetiology and pathology 
of the disease. 
 
This information will help us to characterise diabetes in the different population 
groups in South Africa.  We believe this will provide important information on the 
role of the immune system in the disease aetiology, particularly in black South 
Africans for whom there is little such data. 
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The epitope to which the monoclonal antibody that we are using in this study binds 
to on insulin, has not been completely mapped.  Initial studies suggest that the A 
chain loop (A8-A10) is involved in the binding of insulin to rFab 126.  With the use 
of computer modelling and X-ray crystallography (performed on the antibody-
antigen complex) we hope to be able to define which residues within the binding 
site of the antibody are important for determining binding affinity and specificity.  
Random or directed mutagenesis of the CDRs can be performed to alter the 
specificity of the rFab or improve the affinity of rFab 126 for insulin. 
 
We would also like to produce a bifunctional fusion protein consisting of the rFab 
126 fused to the N-terminus of alkaline phosphatase (rFab-AP).  This rFab-AP can 
then be used in an insulin ELISA.  The design of an insulin ELISA using 
genetically engineered Fabs (raised against insulin) may help to overcome the 
difficulties of standardisation of conventional insulin autoantibody assays.  The 
production and genetic manipulation of novel monoclonal antibodies that only 
contain the antigen binding domains of immunoglobulins will help reduce non-
specific binding.  In addition, the production of antibodies against novel epitopes 
may be possible and this will be extremely useful in developing assays for 32,33- 
and 65,66- split proinsulin since no monoclonal antibodies that specifically bind 
these proteins exist. 
 
4.8.  CONCLUSION 
 
The methodology of genetic engineering has made it possible to produce tailor-
made antibodies which do not depend on animal vehicles.  The increasing number 
of crystal structures of antibody combining sites, especially complexes with 
antigens, allow for a clearer picture of structural conservation and variability.  The 
technology to produce mAbs led to the determination of an enormous number of 
antibody sequences, mostly from cloned DNA sequences.  This led to the defining 
of consensus sequences, which allowed for rapid cloning of antibody genes by the 
polymerase chain reaction (PCR), thereby generating even more sequence 
information (Devlin et al., 1990).  Using bacterial expression technology, different 
types of fragments were made in fully functional form in E. coli (Buchner et al., 
1991).  This expression system allowed for the rapid analysis of the effect of 
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designed mutations and the consequence of random changes.  The applications of 
these rFab are widespread.  The information that we are obtaining from our 
research on the type 1 diabetic patients using genetically engineered Fabs is 
extremely important in obtaining a better understanding of the disease process 
and how best to treat type 1 diabetes patients. 
 
Approximately 17 million people worldwide have type 1 diabetes and this number 
is increasing.  Type 1 diabetes is a serious, debilitating disease with life 
threatening complications.  The financial burden associated with the management 
of this disease is enormous.  Early diagnosis and intervention can improve the 
morbidity and mortality.  The identification of type 1 diabetes-associated insulin 
and GAD65 autoantibody epitopes is important as this will provide us with a better 
understanding of the pathogenic involvement of these autoantibodies in the 
disease progression and also, how best to block insulin and GAD65 autoantibody 
binding as a possible treatment method. 
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APPENDIX 1 
 
1.1.  LIST OF REAGENTS AND SUPPLIERS 
 
REAGENT SUPPLIER 
30 % (w/v) acrylamide/bis solution (19:1) Biorad 
Agarose FMC BioProducts 
Ammonium chloride Saarchem 
Ammonium heptamolybdate tetrahydrate Merck 
Ammonium persulphate USB 
Bacto agar Difco 
BioMax X-ray film Kodak 
Boric acid Merck 
Bovine serum albumin Sigma 
Bromophenol blue sodium salt BDH 
Calcium chloride uniVAR 
Carbenicillin USB 
Carbon Dioxide Affrox 
Cobalt(II) chloride Merck 
Coomassie Brilliant Blue R250 Merck 
Copper sulphate Merck 
p-Coumaric acid Sigma 
DMEM Gibco 
DMSO Sigma 
dNTPs AEC Amersham 
DTT AEC Amersham 
EDTA Saarchem 
Ethanol BDH 
Ethidium bromide USB 
Fetal Calf Serum Sigma 
Filter paper Millipore/BIO-RAD 
Glacial acetic acid BDH 
Glucose Synthon 
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REAGENT SUPPLIER 
Glutamine Gibco 
Glycerol Merck 
Glycine Merck 
Hydrochloric acid 32 % BDH 
Hydrogen peroxide 30 % BDH 
Imidazole Saarchem 
Immobilin-P membrane Millipore 
Iodine-125 AEC Amersham 
Iron(II) sulphate Merck 
Kaleidoscope Prestained Standards BIORAD 
LN2 Affrox 
Luminol Sigma 
Lysozyme Fluka 
Methanol BDH 
Magnesium chloride Sigma 
Magnesium sulphate Sigma 
Manganese (II) chloride Merck 
β-mercaptoethanol Sigma 
Molecular weight marker Gibco 
MOPS Sigma 
M-MuLV reverse transcriptase Invitrogen 
Ni-NTA agarose Qiagen 
Penicillin-streptomycin Gibco 
Penta-His HRP conjugate Qiagen 
Plasmid miniprep kit Qiagen 
Polyethylene glycol Merck 
Polyoxyethylenesorbitan monolaurate (Tween 20) Sigma 
Potassium chloride Merck 
Potassium dihydrogen phosphate Merck 
di-Potassium hydrogen phosphate Merck 
Potassium hydroxide Merck 
Potassium sulphate Saarchem 
  
240
REAGENT SUPPLIER 
Protein A sepharose Zymed 
Protein G sepharose Zymed 
Rat anti mouse kappa:HRP Serotec 
Restriction enzymes and supplied buffers: 
• BsrGI (10 000 U/mL) 
• EcoRI (20 000 U/mL) 
• HindIII (20 000 U/mL) 
• MluI (10 000 U/mL) 
• SphI (5 000 U/mL) 
New England Biolabs 
Ribonuclease inhibitor AEC Amersham 
SDS Sigma 
Shrimp Alkaline Phosphatase USB 
Sodium chloride Sky chem 
di-Sodium hydrogen phosphate Merck 
Sodium dihydrogen phosphate Merck 
Sodium hydrogen carbonate Merck 
Sodium hydroxide AAR 
Sodium Pyruvate Gibco 
Sterivex-GS 0.22 µm filter unit Millipore 
Sucrose Merck 
T4 DNA ligase NEB 
Taq DNA polymerase Qiagen 
Temed USB 
Tetracycline Sigma 
Thiamine-HCl Calbiochem 
Tricine Sigma 
Tris Merck 
Trypan blue solution Sigma 
Tryptone Difco 
XL10-Gold Ultracompetent Cells Stratagene 
Yeast extract Difco 
Zinc sulphate Sigma 
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1.2.  SOLUTIONS 
 
Agarose gels 
Weigh out agarose and dissolve in 1 x TBE buffer.  Boil until clear.  Add 5 µl of 
ethidium bromide (10 mg/ml) per 100 ml of gel 
 
10 % Ammonium persulphate (APS) 
Dissolve 1 g APS in 10 ml of dH2O.  Store at 4°C. 
 
Blocking solution 
Dissolve 1 % BSA in 1 x TBST. 
 
Carbenicillin 
Dissolve 50 mg/ml stock in dH2O.  Sterilise by filtration through a 0.22 µm filter.  
Aliquot and store at -20°C. 
 
Coating buffer (IAA) 
150 mM NaCl 
20 mM Tris 
Make up to a final volume of 500 ml and store at 4°C.  Before coating the plates, 
add 0.5 % BSA. 
 
Destaining solution 
Mix 600 ml methanol, 300 ml water, 100 ml glacial acetic acid. 
Immerse the gel in at least 5 volumes of staining solution and place on a slowly 
rotating platform for a minimum of 4 hours at room temperature.  Remove the stain 
and save it for future use.  Destain the gel by soaking it in the methanol/acetic acid 
solution (described above) on a slowly rocking platform for 4 to 8 hours at room 
temperature, changing the destaining solution three or four times. 
 
DMEM stock solution 
13.38 g DMEM 
3.7 g  NaHCO3 
10 ml  L-glutamine (200 mM) 
  
242
10 ml  Sodium pyruvate (100 mM) 
10 ml  Penicillin-streptomycin (5 000 U/ml and 5 000 µg/ml, respectively) 
Make up to 950 ml with dH2O and pH to 7.0.  Make up to 1 000 ml and filter 
sterilize through a 0.22 µm filter.  Store at 4°C until necessary.  Prior to use, 
measure out the volume required and supplement with FCS to a final 
concentration of 10 %. 
 
ECL detection solution 
250 mM luminol (5-amino-2,3-dihydro-1,4-pthalaginedione) in DMSO. 
Make 1 ml aliquots and store at -20°C. 
90 mM p-coumaric acid in DMSO. 
Make 500 µl aliquots and store at –20°C. 
 
a.  Solution A 
1 ml  luminol 
440 µl  p-coumaric acid 
10 ml  1 M Tris-HCl pH 8.5 
Make up to 100 ml with dH2O. 
 
b.  Solution B 
62 µl  30 % H2O2 
10 ml  1 M Tris-HCl pH 8.5 
Make up to 100 ml with dH2O 
 
0.5 M EDTA pH 8.0 
93.1 g  EDTA 
Make up to 500 ml with dH2O.  Adjust to pH 8.0 with NaOH pellets.  Autoclave. 
 
Elution buffer 
50 mM NaH2PO4 
300 mM NaCl 
300 mM Imidazole 
Make up to 1 000 ml with dH2O.  Adjust the pH to 8.0 using NaOH. 
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Ficoll loading dye 
50 %  Sucrose 
50 mM EDTA (pH 7.0) 
0.1 %  Bromophenol blue dye 
10 %  Ficoll 
Make up to volume with dH2O.  Store at 4°C. 
 
1 M Glucose 
Dissolve 9 g Glucose in 50 ml dH2O.  Filter sterilise. 
 
1 M Glycine buffer pH 2.5 
Dissolve 15 g Glycine in 200 ml dH2O.  pH to 2.5. 
 
250 mM KCl 
Dissolve 1.86 g KCl in 100 ml dH2O. 
 
Luria agar (pH 7.0) 
10 g  Bacto-Tryptone 
5 g  Bacto-Yeast extract 
10 g  NaCl 
Make up to 1 000 ml with dH2O.  Adjust the pH to 7.0 with approximately 1 ml of 
NaOH.  Add 15 g agar and autoclave.  Allow to cool to about 50°C to 60°C before 
adding 1 ml of carbenicillin (50 mg/ml).  Plates can be poured directly from the 
flask; allow about 10 ml of medium per sterile petri dish.  When the medium has 
hardened completely, invert the plates and store them at 4°C until needed.  The 
plates should be removed from storage 1 to 2 hours before they are used.  If the 
plates are fresh, they will ‘sweat’ when incubated at 37°C.  This allows bacterial 
colonies or bacteriophage plaques to spread across the surfaces of the plates and 
increases the chances of cross contamination.  This problem can be avoided by 
wiping off any condensation from the lids of the plates and incubating the plates 
for several hours at 37°C in an inverted position before they are used. 
 
Luria-Bertani medium (pH 7.0) 
10 g  Bacto-Tryptone 
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5 g  Bacto-Yeast extract 
10 g  NaCl 
Make up to 1 000 ml with dH2O.  Adjust the pH to 7.0 with approximately 1 ml of 
NaOH.  Autoclave. 
 
Lysis buffer 
50 mM NaH2PO4 
300 mM NaCl 
10 mM Imidazole 
Make up to 1 000 ml with dH2O.  Adjust the pH to 8.0 using NaOH. 
 
2 M MgCl2 
Dissolve 19 g of MgCl2 in 90 ml dH2O.  Adjust the volume to 100 ml with dH2O and 
sterilise by autoclaving. 
 
Micronutrients 
3 nM  (NH4)6(MoO7)24 
400 nM H3BO3 
30 nM  CoCl2 
10 nM  CuSO4 
80 nM  MnCl2 
10 nM  ZnSO4 
Make up to 1 000 ml with dH2O. 
 
Molecular weight marker (100bp) 
250 µl  Ladder (250 µg) 
2.1 ml  1 x TE 
125 µl  Ficoll loading dye 
Store at 4°C. 
 
10 x MOPS buffer 
400 mM MOPS 
40 mM Tricine 
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Dissolve these two reagents and adjust the pH to 7.4 with KOH.  Then add the 
following ingredients sequentially. 
100 µM FeSO4 
95 mM NH4Cl 
2.76 mM K2SO4 
5 µM  CaCl2 
5.28 mM MgCl2 
500 mM NaCl 
2.5 ml  Micronutrients 
Finally, bring the total volume to 250 ml with dH2O. 
 
MOPS assembly 
450 ml autoclaved H2O 
50 ml  10 x MOPS 
5 ml  20 % glucose 
1 ml  tetracycline (5 mg/ml in 50 % ethanol) 
500 µl  15 mM Thiamine HCl 
500 µl  1 M K2HPO4 
For the second round of growth (i.e., expression of the Fab) do not add the 
K2HPO4. 
 
PBS (pH 7.4) 
1.81 g  Na2HPO4 
0.24 g  KH2PO4 
8 g  NaCl 
0.2 g  KCl 
Adjust the pH to 7.4 and make up to a final volume of 1 000 ml.  Store at 4°C. 
 
Polyacrylamide gel solution 
 
a.  15 % Resolving gel 
2.3 ml  dH2O 
2.5 ml  1 M Tris pH 8.8 (lower tris) 
  
246
5 ml  30 % acrylamide mix 
0.1 ml  10 % APS 
4 µl  temed 
 
b.  Stacking gel 
2.85 ml dH2O 
1.25 ml 1 M Tris pH 6.8 (upper tris) 
0.82 ml 30 % acrylamide mix 
25 µl  10 % APS 
2 µl  temed 
 
c.  Lower SDS gel buffer 
18.17 g Tris base (1.5 M) 
4 ml  10 % SDS 
pH 8.8 with HCl.  Make up to 100 ml with dH2O. 
 
d.  Upper SDS gel buffer 
6.06 g  Tris base 
4 ml  10 % SDS 
pH 6.8 with HCl.  Make up to 100 ml with dH2O. 
 
25% Polyethylene glycol 6000 
Dissolve 25 g of PEG in 100 ml of 0.9% saline. 
 
RF1 
3 g  RbCl 
2.35 g  MnCl2.4H2O 
7.5 ml  1 M KAc (pH 7.5) 
0.375 g CaCl2.2H2O 
37.5 g  Glycerin 
pH to 5.8 with 0.2 M acetic acid.  Make up to 250 ml with dH2O and filter sterilize. 
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RF2 
5 ml  0.5 M MOPS 
0.3 g  RbCl 
2.75 g  CaCl2.2H2O 
37.5 g  Glycerin 
pH to 6.8 with NaOH.  Make up to 250 ml with dH2O and filter sterilize. 
 
10 % SDS 
10 g/100 ml 
Weigh out SDS in a fume hood.  Autoclave the dH2O before adding the SDS 
powder. 
 
2 x SDS gel loading buffer 
0.125 M Tris base pH 6.8 
4 %  SDS (0.4 g/10 ml) (electrophoresis grade) 
1 mg/10 ml bromophenol blue 
20 %  glycerol 
Dissolve SDS in Tris.  Then add glycerol and dissolve by heating.  Add 
bromophenol blue.  Make up to 10 ml with dH2O. 
 
SOC medium 
20 g  bacto-tryptone 
5 g  bacto-yeast 
0.5 g  NaCl 
Dissolve in 950 ml dH2O.  Add 10 ml of 250 mM KCl that has been sterile filtered. 
Adjust the pH to 7.0.  Make up to 1 000 ml with dH2O and autoclave.  Add 5 ml of 
sterile 2 M MgCl2 and 20 ml 1 M glucose that has been sterile filtered.  Aliquot into 
sterile 15 ml Falcon tubes. 
 
Staining solution 
Dissolve 0.25 g of Coomassie Brilliant Blue R250 in 90 ml of methanol:H2O (1:1 
v/v) and 10 ml of glacial acetic acid.  Filter the solution through a Whatman No. 1 
filter to remove any particulate matter. 
 
  
248
10 x TBE buffer 
108 g  Tris base 
55 g  Boric acid 
7.4 g  EDTA 
Make up to 1 000 ml with dH2O.  Autoclave. 
 
10 x TBST buffer (pH 7.5) 
3.03 g  Tris base (50 mM) 
4.38 g  NaCl (150 mM) 
Adjust the pH to 7.5.  Make up to 500 ml with dH2O.  Before use add 0.05 % 
Tween 20. 
 
1 x TE buffer (pH 8.0) 
10 mM Tris 
1 mM  EDTA 
Make up to 1 000 ml with dH2O.  If necessary, pH to 8.0 with HCl. 
 
Tetracycline 
Dissolve 50 mg/ml stock in ethanol.  Aliquot and store at -20°C. 
 
Tris-glycine PAGE buffer 
3.03 g  Tris base 
14.4 g  Glycine 
10 ml   10 % SDS 
Make up to 1 000 ml with dH2O. 
 
Tris-glycine transfer buffer 
6.06 g  Tris base 
28.8 g  Glycine 
Make up to 1 800 ml in dH2O.  Once all the reagents are completely dissolved add 
200 ml methanol. 
 
1 M Tris pH 8.0 
Dissolve 24.22 g Tris in 200 ml dH2O.  pH to 8.0. 
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Wash buffer (IAA) 
50 mM Tris 
1 %  Tween 20 
Make up to 1 000 ml with dH2O.  pH to 8.0. 
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APPENDIX 2 
 
Blast results for the alignment of the sequences obtained for the 1E2 and NS0 
heavy chain genes. 
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APPENDIX 3 
 
Blast results for the alignment of the aberrant kappa chain transcript with the 
sequence obtained for the 1E2/NS0 light chain. 
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APPENDIX 4 
 
Blast results for the alignment of the aberrant heavy chain transcript and the 
sequence obtained for the 1E2 heavy chain. 
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APPENDIX 5 
 
Blast results for the alignment of the aberrant heavy chain transcript and the 
sequence obtained for the NS0 heavy chain. 
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APPENDIX 6 
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APPENDIX 7 
 
Published papers: 
 
1. Recombinant Fabs of human monoclonal antibodies specific to the middle 
epitope of GAD65 inhibit type 1 diabetes-specific GAD65Abs (DIABETES, 
VOL 52, NOVEMBER 2003) 
2. Epitope analysis of insulin autoantibodies using recombinant Fab 
(CLINICAL AND EXPERIMENTAL IMMUNOLOGY, VOL 140, JUNE 2005) 
